Consumul de statine și reducerea mortalității legate de cancer

Abstract

Context: O reducere a disponibilității colesterolului poate limita proliferarea celulară necesară pentru creșterea cancerului și metastaze. Am testat ipoteza că utilizarea statinelor a început înainte de diagnosticarea cancerului este asociată cu o mortalitate redusă legată de cancer.

Metode: Am evaluat mortalitatea în rândul pacienților din întreaga populație daneză care au primit un diagnostic de cancer între 1995 și 2007, cu urmărire până la 31 decembrie 2009. În rândul pacienților cu vârsta de 40 de ani sau peste, 18.721 folosiseră statine în mod regulat înainte de diagnosticul de cancer și 277.204 nu au folosit niciodată statine.

Rezultate: Raporturile de pericol ajustate multivariabil pentru utilizatorii de statine, comparativ cu pacienții care nu au folosit niciodată statine, au fost de 0,85 (interval de încredere 95% [IC], 0,83-0,87) pentru deces din orice cauză și 0,85 (IC 95%, 0,82-0,87) pentru moartea de cancer. Raporturile de pericol ajustate pentru deces din orice cauză în funcție de doza zilnică definită de statină (doza medie de întreținere presupusă pe zi) au fost de 0,82 (IÎ 95%, 0,81 până la 0,85) pentru o doză de 0,01 până la 0,75 doză zilnică definită pe zi, 0,87 ( IÎ 95%, 0,83 – 0,89) pentru doza zilnică definită de 0,76 până la 1,50 pe zi și 0,87 (IÎ 95%, 0,81 până la 0,91) pentru doza zilnică mai mare de 1,50 definită pe zi; raporturile de pericol corespunzătoare pentru deces prin cancer au fost 0,83 (95% CI, 0,81-0,86), 0,87 (95% CI, 0,83-0,91) și 0,87 (95% CI, 0,81-0,92).Reducerea mortalității legate de cancer în rândul consumatorilor de statine în comparație cu cei care nu au folosit niciodată statine a fost observată pentru fiecare dintre cele 13 tipuri de cancer.

Concluzii: utilizarea statinei la pacienții cu cancer este asociată cu o mortalitate redusă prin cancer. Acest lucru sugerează necesitatea studiilor de statine la pacienții cu cancer.

N Engl J Med

 . 8 noiembrie 2012; 367 (19): 1792-802. doi: 10.1056 / NEJMoa1201735.

Consumul de statine și reducerea mortalității legate de cancer

Sune F Nielsen 1,  Børge G Nordestgaard ,  Stig E BojesenAfilieri extinde

Colesterolul este o componentă structurală fundamentală a membranelor celulare ale mamiferelor și este esențial pentru proliferarea celulară. 1,2  Statinele inhibă producția de colesterol endogen 3  și blochează prenilarea proteinelor și, prin urmare, utilizarea statinelor poate influența proliferarea și migrația celulară. 4,5

Proliferarea celulelor canceroase este văzută clinic ca o creștere a cancerului și metastază și, în cele din urmă, duce la moartea pacientului. O reducere a disponibilității colesterolului ar putea duce la scăderea proliferării și migrării celulelor canceroase. 6,7 De  asemenea, o reducere a produselor din aval în calea mevalonate datorită utilizării statina a fost asociat cu mai multe potentiale proprietati anticancerigene 8-12  si un risc redus de recurenta a cancerului. 13,14  La nivel celular, statinele au fost legate de oprirea progresiei ciclului celular și de creșterea radiosensibilizării în celulele canceroase. 10,15,16 Astfel, utilizarea regulată a statinelor înainte și după un diagnostic de cancer ar putea reduce teoretic mortalitatea legată de cancer. În studiile la scară largă cu statine pentru a reduce riscul bolilor cardiovasculare în rândul persoanelor fără cancer, utilizarea statinelor nu a influențat incidența cancerului sau a mortalității asociate. 17,18

Am emis ipoteza că utilizarea statinelor începută înainte de diagnosticarea cancerului ar fi asociată cu o mortalitate redusă legată de cancer. Pentru a testa această ipoteză, am analizat datele privind pacienții cu cancer din întreaga populație daneză pentru perioada 1995 până în 2009, comparând mortalitatea în rândul pacienților care au utilizat statine înainte de diagnostic cu mortalitatea în rândul celor care nu au folosit niciodată statine.

Metode

POPULAȚIA DE STUDIU ȘI COLECTAREA DE DATE

Sistemul danez de înregistrare civilă înregistrează toate nașterile, imigrațiile, emigrațiile și decesele din Danemarca prin intermediul numerelor de înregistrare civilă, care identifică în mod unic toți locuitorii Danemarcei și includ informații cu privire la vârstă și sex. Sistemul danez de înregistrare civilă este 100% complet, astfel încât, în scopuri practice, nu se pierd persoane în urma monitorizării. 19

Persoanele cu cancer diagnosticate între 1 ianuarie 1995 și 31 decembrie 2007 au fost identificate cu utilizarea Registrului danez al cancerului, care urmărește datele privind 98% din toate cazurile de cancer incident din Danemarca 20,21  și este orbit de înregistrarea statinei utilizare. Prin includerea numai a pacienților care au primit un diagnostic de cancer până în 2007, am permis cel puțin 2 ani de urmărire pentru toți pacienții. Toate diagnosticele din registru sunt atribuite pe baza examenului histologic de către un patolog complet instruit. Diagnosticarea cancerului a fost clasificată în conformitate cu   codurile C00.0 – C43.0, C45.0 – C96.0, D00.0 – D03.0 și D05.0 – D09 din clasificarea internațională a bolilor, a 10-a revizuire (ICD-10). .0. 22,23

Sistemul de stadializare tumora-nod-metastază (TNM) 24 a  fost adoptat de Registrul danez al cancerului la 1 ianuarie 2004, astfel încât informațiile referitoare la dimensiunea tumorii primare, răspândite în sistemul limfatic și metastazele la distanță în momentul diagnosticului au fost disponibil în perioada 2004-2007. Dimensiunea tumorii a fost clasificată ca fiind mică (T0, T1 sau T2) sau mare (T3 sau T4), cancerul răspândindu-se în sistemul limfatic ca fiind nici unul (N0) sau oricare (N1, N2 sau N3) și metastaze îndepărtate ca niciuna (M0) sau oricare (M1).

Din 1995 până în 2003, Registrul danez al cancerului a înregistrat informațiile de tratament în mod dihotomic (niciunul vs. niciunul), atât pentru radioterapie, cât și pentru chimioterapie, începute în decurs de 4 luni după un diagnostic de cancer. Cu toate acestea, nu au fost disponibile detalii cu privire la tipul specific de tratament administrat.

UTILIZARE STATINELOR

Registrul statistic al produselor medicamentoase din Danemarca a înregistrat informații despre toate medicamentele prescrise eliberate în farmaciile daneze începând cu 1995 și este orbit de înregistrarea diagnosticelor de cancer. Statinele au fost clasificate drept cod chimic terapeutic anatomic C10AA; codurile pentru alte medicamente care scad colesterolul au fost C10AB, C10AC, C10AD, C10AX și C10BA (Tabelul S1 din  apendicele suplimentar , disponibil împreună cu textul integral al acestui articol la NEJM.org). Pentru fiecare rețetă completată pentru fiecare participant la studiu, am înregistrat numele medicamentului, data eliberării și cantitatea totală a dozei zilnice recomandate definite (adică, doza medie de întreținere presupusă pe zi). Tabelul S1 din  apendicele suplimentar enumeră distribuțiile diferitelor tipuri de medicamente cu statine și alte medicamente care scad colesterolul prescrise.

Doza zilnică pentru utilizatorii de statine a fost estimată ca doză 2  împărțită la | t 1 − t 2 |, unde doza 2  este penultima prescripție a unei statine înainte de diagnosticul de cancer, măsurată în doze zilnice definite totale (adică, totalul de miligrame eliberate, împărțit la doza zilnică definită pentru statina specifică) (Tabelul S1 din  apendicele suplimentar ). Valoarea | t 1 −t 2 | este intervalul dintre datele ultimei prescripții a statinei (t 1 ) și penultima prescripție a statinei (t 2 ) înainte de diagnosticarea cancerului (Fig. S4 din  apendicele suplimentar). Dozele de statine au fost analizate în următoarele categorii de doze zilnice definite pe zi: 0,00 (referință), 0,01 până la 0,75, 0,76 până la 1,50 și mai mult de 1,50.

Pentru a exclude cauzalitatea inversă, utilizarea statinelor a fost măsurată numai înainte de data diagnosticării cancerului și a fost utilizată pentru a indica utilizarea statinelor înainte și după diagnosticul cancerului. Am analizat, de asemenea, dacă pacienții au folosit vreodată statine, într-o analiză în care toți pacienții cu cancer care au primit vreodată o statină înainte de diagnosticul de cancer au fost comparați cu cei care nu au folosit niciodată statine.

Pacienții cărora li s-au completat prescripțiile cu statine în termen de 6 luni înainte de data diagnosticului de cancer și în termen de 2 ani înainte de data diagnosticului au fost clasificați drept consumatori obișnuiți de statine (a se vedea figurile S1 și S4 din  apendicele suplimentar ). Fig. S2 din  apendicele suplimentar  arată că modelul prescripțiilor completate pentru statine a fost aproximativ simetric înainte și după diagnosticul de cancer. Toți pacienții care au folosit statine înainte de diagnosticul de cancer, dar a căror utilizare a fost în afara intervalelor de timp specificate, au fost clasificați drept utilizatori neregulați de statine.

Deoarece utilizarea statinelor a crescut și informațiile privind clasificarea și tratamentul TNM pentru fiecare pacient cu cancer s-au modificat în timpul perioadei de observație, am efectuat, de asemenea, un studiu cuibărit 1: 3 (adică, un studiu care a adaptat fiecare utilizator de statine cu trei pacienți care nu folosiseră niciodată statine), cu potrivire pentru sex, vârstă la diagnosticarea cancerului, anul diagnosticului și tipul de cancer (Fig. S3, S11 și S14 în  anexa suplimentară ). 23  Pentru a aborda tiparele necunoscute și alte potențiale prejudecăți între utilizatorii de statine și pacienții care nu folosiseră niciodată statine, s-a efectuat o analiză a scorului de înclinație și ajustarea pentru codul de zonă în care a fost localizat furnizorul (a se vedea  apendicele suplimentar ).

BOALĂ CARDIOVASCULARĂ ȘI DIABET MELLITUS

Diagnosticele bolilor cardiovasculare și ale diabetului zaharat înainte de diagnosticul de cancer au fost identificate cu utilizarea Registrului național al pacienților, 20  care înregistrează toate internările spitalicești din Danemarca. Diagnosticele pentru bolile cardiovasculare și diabetul zaharat au fost clasificate în conformitate cu codurile ICD-10 I00 – I99 și, respectiv, E10 – E14.

CAUZELE MORȚII

Sistemul danez de înregistrare civilă înregistrează data decesului pentru toate persoanele din Danemarca. Pentru toate decesele din Danemarca, Registrul danez al cauzelor de deces 25  înregistrează până la trei cauze de deces clasificate, după cum a raportat medicul curant în practica generală sau la un spital sau de către un medic dintr-un departament de criminalistică sau patologie. Diagnosticele enumerate drept cauze de deces sunt clasificate cu utilizarea ICD-10. Pentru acest studiu, cauza decesului a fost definită ca fiind prima dintre cele trei cauze de deces clasificate, astfel cum a fost evaluată de oricare dintre medicii enumerați mai sus ca fiind cauza principală a decesului. În analizele de sensibilitate, au fost examinate și alte categorizări ale morții cauzale specifice.

ALTE COVARIATE

Din 1980, Statistics Danemarca a adunat informații referitoare la toate persoanele care locuiesc în Danemarca. Pentru acest studiu, am obținut date despre rasă și descendență etnică, cel mai înalt nivel de educație și dimensiunea zonei rezidențiale.

ANALIZE STATISTICE

Am exclus din analize pacienții cu cancer care aveau vârsta mai mică de 40 de ani, deoarece este puțin probabil ca acești pacienți să primească statine. Metoda indicatorului lipsă a fost utilizată pentru a ține cont de informațiile lipsă. 26

Curbele de incidență cumulative au fost estimate prin metoda Fine și Grey 27  și au fost comparate cu utilizarea testelor log-rank. Modele de regresie Cox cu timpul (în ani) după un diagnostic de cancer, ca scară de timp, au fost utilizate pentru a calcula rapoartele de pericol cu ​​intervale de încredere de 95%. Modelele Cox multivariabile au fost ajustate în funcție de vârstă la diagnostic; stadiul cancerului (dimensiunea tumorii, prezența sau absența răspândirii în sistemul limfatic și prezența sau absența metastazelor la distanță); starea în ceea ce privește chimioterapia, radioterapia, diagnosticul bolilor cardiovasculare înainte de cancer și diagnosticul diabetului zaharat înainte de cancer; anul nașterii; sex; rasă și origine etnică (97% dintre pacienți erau persoane albe de origine daneză); cel mai înalt nivel de educație; și dimensiunea zonei rezidențiale.

Toți 295.925 de pacienți au fost urmăriți de la data diagnosticării cancerului; datele au fost cenzurate la data decesului (195.594 pacienți) sau emigrare (635) sau la 31 decembrie 2009 (99.696), oricare ar fi fost primul. Astfel, riscul concurent de deces a fost luat în considerare în analiză prin intermediul cenzurii la data decesului (informații care sunt 100% complete în registrele daneze). Efectul evenimentelor concurente a fost, de asemenea, modelat prin calcularea raporturilor de pericol, ca o măsură a riscului relativ, luând în considerare moartea, cu utilizarea metodei Fine și Grey. 27 Pentru analizele de regresie a riscurilor proporționale Cox, nu am detectat nicio încălcare majoră a presupunerii riscurilor proporționale grafic după trasarea jurnalului pericolului cumulativ pentru diferite categorii de doze de statine, în funcție de jurnalul duratei de urmărire după cancer diagnostic.

Subgrupurile au fost pre-specificate și au cuprins 27 de tipuri de cancer (fig. S14 în  apendicele suplimentar ) și nouă caracteristici ale pacienților. Am efectuat toate calculele cu ajutorul software-ului Stata, versiunea 12.0MP (StataCorp).

Rezultate

PACIENTI DE STUDIU

Tabelul 1. Caracteristicile de bază ale pacienților, în funcție de utilizarea statinei, în studiile la nivel național și corelate.

Am inclus pacienți din întreaga populație daneză care au primit un diagnostic de cancer între 1995 și 2007 și i-au urmat până la 31 decembrie 2009 (mediană, 2,6 ani; interval, 0-15). Dintre pacienții cu vârsta de 40 de ani sau peste, 18.721 au folosit statine în mod regulat până la diagnosticul de cancer, în timp ce 277.204 nu au folosit niciodată statine sau alte medicamente care scad colesterolul înainte de diagnosticul de cancer (Fig. S1 în  apendicele suplimentar ). Caracteristicile inițiale ale pacienților sunt prezentate în  Tabelul 1 . Pe parcursul a 1.072.503 ani-persoană de urmărire, 195.594 de pacienți au murit: 162.067 din cauza cancerului, 14.489 din cauze cardiovasculare și 19.038 din alte cauze.

UTILIZARE ȘI MORTALITATE A STATINULUI

Figura 1. Utilizarea regulată a statinelor și incidența cumulativă a decesului din orice cauză și decesul cauzat de cancer, în funcție de timpul de după diagnosticarea cancerului.

Incidența cumulativă a decesului din orice cauză în funcție de timpul de urmărire de la data diagnosticului de cancer a fost mai mică în rândul consumatorilor de statine decât în ​​rândul pacienților care nu au folosit niciodată statine (P <0,001 prin testul log-rank) ( Figura 1A ). Cele două curbe de incidență cumulative converg după 5 ani de urmărire, probabil din cauza mortalității cardiovasculare crescute în rândul consumatorilor de statine, în comparație cu pacienții care nu au folosit niciodată statine (Fig. S5 în  Anexa suplimentară ). Raportul de risc ajustat multivariabil pentru deces din orice cauză în rândul consumatorilor de statine, comparativ cu pacienții care nu au folosit niciodată statine, a fost de 0,85 (interval de încredere 95% [IC], 0,83-0,87). Rezultatele studiului asociat 1: 3 au fost similare ( Figura 1B ).

Incidența cumulativă a morții cauzate de cancer în funcție de timpul de urmărire de la data diagnosticului de cancer a fost, de asemenea, mai mică în rândul consumatorilor de statine decât în ​​rândul pacienților care nu au folosit niciodată statine (P <0,001 prin testul log-rank) ( Figura 1A ). Raportul de risc ajustat multivariabil pentru decesul cauzat de cancer în rândul consumatorilor de statine, comparativ cu pacienții care nu au folosit niciodată statine, a fost de 0,85 (IÎ 95%, 0,82 – 0,87), cu rezultate similare în studiul asociat 1: 3 ( Figura 1B ).

DOZA STATINĂ ȘI MORTALITATEA

Figura 2. Riscul de deces din diverse cauze, în conformitate cu doza zilnică definită de statină.

Raporturile de pericol ajustate multivariabil pentru deces din orice cauză în funcție de doza zilnică de statină definită, comparativ cu utilizarea fără statine, au fost de 0,82 (IÎ 95%, 0,81 până la 0,85) pentru o doză de 0,01 până la 0,75 doză zilnică definită, 0,87 ( IC 95%, 0,83-0,89) pentru doza zilnică definită de 0,76 până la 1,50 și 0,87 (IC 95%, 0,81-0,91) pentru doza zilnică mai mare de 1,50 ( Figura 2A). Raporturile de risc corespunzătoare pentru decesul cauzat de cancer au fost de 0,83 (95% CI, 0,81-0,86), 0,87 (95% CI, 0,83-0,91) și 0,87 (95% CI, 0,81-0,92). Raporturile de risc corespunzătoare pentru deces din cauze cardiovasculare au fost 1,08 (95% CI, 0,99 la 1,19), 1,25 (95% CI, 1,12 la 1,41) și 1,24 (95% CI, 1,03 la 1,48). În cele din urmă, raporturile de risc corespunzătoare pentru deces din alte cauze au fost de 0,70 (95% CI, 0,64-0,77), 0,76 (95% CI, 0,68-0,86) și 0,77 (95% CI, 0,66-0,92). Studiul imbricat 1: 3 a avut rezultate similare ( Figura 2B ).

ANALIZE DE SENSIBILITATE

Rezultatele pentru mortalitatea cauzată de cancer au rămas similare atunci când am luat în considerare riscul concurent de deces din alte cauze cu utilizarea regresiei subhazardului fin și gri (Fig. S6 în  apendicele suplimentar ). O analiză care a fost limitată la pacienții care au avut cancer mic fără metastaze și o analiză care a inclus pacienți care au folosit vreodată statine au avut rezultate similare. În plus, rezultatele au fost similare atunci când am clasificat decesul în funcție de toate cauzele clasificate de deces din Registrul danez de cauze ale decesului, mortalitatea legată de cancer limitată la același cancer ca și cancerul incident, a exclus ajustarea pentru covariabile cu informații lipsă pentru mai multe mai mult de 0,1% din toți pacienții și ajustat pentru codul de zonă al furnizorului (fig. S7 până la S13 în  apendicele suplimentar).

Reducerea mortalității legate de cancer în rândul consumatorilor de statine în comparație cu pacienții care nu au folosit niciodată statine a fost observată pentru 13 tipuri de cancer: raporturile de risc ajustate multivariabil pentru decesul cauzate de cancer în rândul consumatorilor de statine au fost cuprinse între 0,64 (IC 95%, 0,46 până la 0,88) pentru cancerul de col uterin până la 0,89 (IC 95%, 0,81 până la 0,98) pentru cancerul pancreatic (Fig. S14 în  anexa suplimentară ). Pentru cele 14 tipuri de cancer rămase, raporturile de risc ajustate multivariabil au fost în mare măsură similare, dar cu intervale de încredere care s-au suprapus peste 1,0. Rezultatele studiului imbricat 1: 3 au fost, de asemenea, în mare măsură similare (Fig. S14, panoul din dreapta, în  apendicele suplimentar ). Figura 3. Orice utilizare a statinelor și riscul de deces cauzat de cancer.

În analize stratificate în funcție de caracteristicile asociate cu un risc crescut de deces din orice cauză sau din cauza cancerului (de exemplu, sex, vârstă, tratament cu chimioterapie, tratament cu radioterapie, dimensiune mai mare a tumorii, prezența metastazelor la diagnostic, diagnosticarea bolilor cardiovasculare înainte de cancer și diagnosticul de diabet zaharat înainte de cancer), mortalitatea legată de cancer a fost redusă în rândul consumatorilor de statine, comparativ cu pacienții care nu au folosit niciodată statine, în toate straturile, cu excepția pacienților cu cancer care primeau chimioterapie ( Figura 3 ). Un istoric de diabet sau boli cardiovasculare înainte sau după diagnosticul de cancer nu a influențat în mod substanțial rezultatele (fig. S15 și S16 și tabelul S2 din  apendicele suplimentar ).

Încercând să ne adaptăm pentru diferențele din istoricul medical al pacienților cu cancer, pentru a evita o „părtinire a utilizatorului sănătos”, am repetat studiul asociat 1: 3 cu potrivirea scorului de înclinație (Fig. S17 în  anexa suplimentară ). Rezultatele au fost similare cu cele prezentate în  Figura 2 , cu excepția faptului că utilizarea statinelor nu mai este asociată cu creșterea mortalității cardiovasculare.

Discuţie

În acest studiu la nivel național, am observat că utilizarea statinelor la pacienții cu cancer a fost asociată cu o mortalitate redusă legată de cancer. Descoperirile noastre sunt plauzibile, deoarece statinele inhibă sinteza colesterolului în celule prin inhibarea 3-hidroxi-3-metilglutaril coenzimei A (HMG-CoA) reductază, enzima care limitează rata în calea mevalonatului și a sintezei colesterolului. 28  Multe dintre aceste produse în aval sunt utilizate în proliferarea celulară , deoarece acestea sunt necesare pentru funcțiile celulare esențiale , cum ar fi menținerea integrității membranei, semnalizare, sinteza proteinelor si progresia ciclului celular. 15,28  Întreruperile acestor procese în celulele maligne duc la inhibarea creșterii cancerului și a metastazei. 15,29-31 În special, calea mevalonatului este reglată în sus de p53 (proteina supresoare tumorale) mutantă 32 ,  care este frecventă în cancer. 33 În  consecință, inhibarea acestei căi cu statine întoarce fenotipul malign al celulelor canceroase mutate p53. 32  Scăderea produselor din aval ale căii mevalonate a fost legată de apoptoză și de producția redusă de matrice-metaloproteinază și angiogeneză, precum și de o reducere a invazivității cancerelor in situ. 8-12  statine au fost legate de oprirea progresiei ciclului celular în celulele canceroase cu efecte antiproliferative rezultate, de inhibarea funcțiilor celulare cheie în celulele canceroase și de radiosensibilizarea crescută. 10,15,16

Deoarece statinele sunt localizate selectiv la ficat, mai puțin de 5% dintr-o doză dată ajunge în sistemul circulator. 6,34  Pentru tipurile de cancer, altele decât cancerul hepatic și biliar, 35  un mecanism plauzibil din spatele riscului redus de deces observat de cancer ar putea fi reducerea nivelurilor plasmatice de colesterol. Într-adevăr, cancerele cu creștere rapidă necesită o absorbție ridicată a colesterolului extracelular, iar pacienții cu cancer au niveluri reduse de colesterol în plasmă. 36,37  Prin urmare, o reducere indusă de statină a nivelurilor de colesterol sintetizat sau circulant local ar putea inhiba creșterea cancerului și metastazele și reduce mortalitatea.

Descoperirile noastre sunt, de asemenea, susținute de observarea mortalității reduse legate de cancer la pacienții cu cancer de prostată avansat care iau statine 38  și o recurență redusă corespunzător în rândul pacienților cu cancer de prostată 39  sau de sân 13,14  . Cu toate acestea, utilizarea statinelor la persoanele fără cancer, cu scopul de a reduce riscul bolilor cardiovasculare, nu influențează incidența cancerului sau mortalitatea cauzată de cancer. 17,18  Cu toate acestea, observația noastră că mortalitatea prin toate cauzele la pacienții cu cancer care luau statine a fost redusă cu 15% (IC 95%, 13-17) este similară cu reducerea observată a mortalității prin toate cauzele de 10% (95 % CI, 7-13) la pacienții cu risc de deces din cauze cardiovasculare. 40 Absența unei relații doză-răspuns pentru statine și mortalitatea legată de cancer sugerează că orice doză de statină va fi suficientă pentru reducerea mortalității la pacienții cu cancer.

Teoretic posibilele limitări ale acestui studiu includ părtinirea selecției; cu toate acestea, aceasta nu este o problemă, deoarece am urmărit toți pacienții cu cancer din întreaga populație daneză care au avut vârsta de 40 de ani sau mai mult și au fost eligibili pentru consumul de statine, fără pierderi de urmărire. O limitare potențială aferentă se referă la disponibilitatea și completitudinea informațiilor de diagnostic; cu toate acestea, Registrul danez al cancerului captează date privind 98% din toate diagnosticele de cancer din Danemarca, Registrul național al prescripțiilor daneze înregistrează 100% din toate prescripțiile eliberate de statine, precum și sistemul danez de înregistrare civilă și Registrul danez al datelor de captură a cauzelor morții 100% din toate decesele. Datele privind caracteristicile cancerelor (dimensiunea și prezența sau absența metastazelor în momentul diagnosticului) lipseau pentru mulți pacienți care nu folosiseră niciodată statine;cu toate acestea, această limitare nu pare să fi denaturat constatările noastre, deoarece rezultatele studiului la nivel național au fost similare cu cele ale studiului cuibărit 1: 3, în care informațiile lipsă erau echilibrate între utilizatorii de statine și pacienții care nu folosiseră niciodată statine.

O altă limitare este posibilitatea ca utilizarea statinelor să fie un marker al creșterii gradului de conștientizare a sănătății, afectând teoretic rezultatele noastre. Așa cum ne-am așteptat, utilizatorii de statine au fost mai predispuși să fie bărbați și să aibă boli cardiovasculare sau diabet, astfel încât datele ar putea fi predispuse la o părtinire sănătoasă a utilizatorului, ceea ce ar putea indica prezența unei părtiniri prin indicație (de exemplu, pacienții din acest studiu pot avea a avut mai multe motive pentru a primi medicamentul de către medic). Cu toate acestea, atât studiul imbricat 1: 3, care a avut un număr egal de bărbați și femei și a exclus pacienții cu boli cardiovasculare sau diabet, cât și analiza scorului de înclinație, care s-a potrivit pentru probabilitatea ca pacientul să primească statine pe baza modelelor în istoria medicală, au avut rezultate similare cu cele ale studiului la nivel național.Similitudinea rezultatelor dintre aceste trei analize argumentează împotriva unei influențe a sexului masculin, a bolilor cardiovasculare sau a diabetului zaharat sau a unei conștientizări sporite a sănătății în rândul consumatorilor de statine.

În cele din urmă, deoarece 97% dintre pacienți erau persoane albe de origine daneză, rezultatele noastre s-ar putea să nu se aplice neapărat altor grupuri etnice.

În concluzie, în rândul pacienților cu cancer, am observat o asociere între utilizarea statinelor în momentul diagnosticului și un risc redus de mortalitate legată de cancer, cu o reducere de până la 15%. Este necesară evaluarea prospectivă a ipotezei că utilizarea statinelor prelungește supraviețuirea pacienților cu cancer.

Formularele de divulgare  furnizate de autori sunt disponibile împreună cu textul integral al acestui articol la NEJM.org.

Mulțumim personalului din Registrul danez al cancerului pentru că a oferit acces la înregistrările sale de date.

Afilierile Autorului

De la Departamentul de Biochimie Clinică, Spitalul Herlev, Spitalul Universitar din Copenhaga, Herlev și Facultatea de Științe ale Sănătății, Universitatea din Copenhaga, Copenhaga – ambele în Danemarca.

Adresați solicitări de reimprimare către Dr. Bojesen la Departamentul de Biochimie Clinică, 54M1, Spitalul Herlev, Spitalul Universitar din Copenhaga, Herlev Ringvej 75, DK-2730 Herlev, Danemarca sau la adresa  stig.egil.bojesen@regionh.dk .

Material suplimentar

Anexă suplimentarăPDF375 KB
Formulare de divulgarePDF103KB
  1. Baserga R. Molecular biology of the cell cycle. Int J Radiat Biol 1986;49:219-226
  2. 2.Lamond AI. Review of: Molecular biology of the cell, 4th edition. Nature 2002;417:383-383
  3. 3.Lamb E. Top 200 drugs of 2008. Pharmacy Times. May 15, 2009.
    • 4.Fenton RG, Kung HF, Longo DL, Smith M. Regulation of intracellular actin polymerization by prenylated cellular proteins. J Cell Biol 1992;117:347-356
    • 5.Herold G, Jungwirth R, Rogler G, Geerling I, Stange EF. Influence of cholesterol supply on cell growth and differentiation in cultured enterocytes (CaCo-2). Digestion 1995;56:57-66
    • 6.Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 2010;9:603-621
    • 7.DeBerardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008;18:54-61
    • 8.Fritz G. HMG-CoA reductase inhibitors (statins) as anticancer drugs. Int J Oncol 2005;27:1401-1409
    • 9.Fritz G. Targeting the mevalonate pathway for improved anticancer therapy. Curr Cancer Drug Targets 2009;9:626-638
    • 10.Jakobisiak M, Golab J. Potential antitumor effects of statins. Int J Oncol 2003;23:1055-1069
    • 11.Mannello F, Tonti GA. Statins and breast cancer: may matrix metalloproteinase be the missing link. Cancer Invest 2009;27:466-470
    • 12.Solomon KR, Freeman MR. Do the cholesterol-lowering properties of statins affect cancer risk? Trends Endocrinol Metab 2008;19:113-121
    • 13.Ahern TP, Pedersen L, Tarp M, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst 2011;103:1461-1468
    • 14.Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 2008;109:573-579
    • 15.Chan KKW, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003;9:10-19
    • 16.Gauthaman K, Fong CY, Bongso A. Statins, stem cells, and cancer. J Cell Biochem 2009;106:975-983
    • 17.Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012 May 16 (Epub ahead of print).
      • 18.Emberson JR, Kearney PM, Blackwell L, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012;7:e29849-e29849
      • 19.Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System: a cohort of eight million persons. Dan Med Bull 2006;53:441-449
      • 20.Andersen TF, Madsen M, Jorgensen J, Mellemkjaer L, Olsen JH. The Danish National Hospital Register: a valuable source of data for modern health sciences. Dan Med Bull 1999;46:263-268
      • 21.Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry – history, content, quality and use. Dan Med Bull 1997;44:535-539
      • 22.Nielsen SF, Bojesen SE, Birgens HS, Nordestgaard BG. Risk of thyroid cancer, brain cancer, and non-Hodgkin lymphoma after adult leukemia: a nationwide study. Blood 2011;118:4062-4069
      • 23.Nielsen SF, Nordestgaard BG, Bojesen SE. Associations between first and second primary cancers: a population-based study. CMAJ 2012;184:E57-E69
      • 24.Sobin L, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. 7th ed. Hoboken, NJ: Wiley, 2009.
        • 25.Helweg-Larsen K. The Danish register of causes of death. Scand J Public Health 2011;39:Suppl:26-29
        • 26.Donders AR, Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006;59:1087-1091
        • 27.Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509
        • 28.Wong WWL, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002;16:508-519
        • 29.Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-942
        • 30.Denoyelle C, Vasse M, Korner M, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001;22:1139-1148
        • 31.Kusama T, Mukai M, Iwasaki T, et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Cancer Res 2001;61:4885-4891
        • 32.Freed-Pastor WA, Mizuno H, Zhao X, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012;148:244-258
        • 33.Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-629
        • 34.Garcia MJ, Reinoso RF, Sanchez Navarro A, Prous JR. Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 2003;25:457-481
        • 35.Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma: a randomized controlled trial. Br J Cancer 2001;84:886-891
        • 36.Benn M, Tybjaerg-Hansen A, Stender S, Frikke-Schmidt R, Nordestgaard BG. Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study. J Natl Cancer Inst 2011;103:508-519
        • 37.Fiorenza AM, Branchi A, Sommariva D. Serum lipoprotein profile in patients with cancer: a comparison with non-cancer subjects. Int J Clin Lab Res 2000;30:141-145
        • 38.Platz EA, Leitzmann MF, Visvanathan K, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006;98:1819-1825
        • 39.Hamilton RJ, Banez LL, Aronson WJ, et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2010;116:3389-3398
        • 40.Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-1681

        Citing Articles (582)

        1. Wen-Yen Huang, Chia-Hsiang Li, Cheng-Li Lin, Ji-An Liang. (2106) Long-term statin use in patients with lung cancer and dyslipidemia reduces the risk of death. Oncotarget 7:27, 42208-42215.
        2. Fang Yu, Babu Gajendran, Ning Wang, Klarke M. Sample, Wuling Liu, Chunlin Wang, Anling Hu, Eldad Zacksenhaus, Xiaojiang Hao, Yaacov Ben-David. (2021) ERK activation via A1542/3 limonoids attenuates erythroleukemia through transcriptional stimulation of cholesterol biosynthesis genes. BMC Cancer 21:1.
        3. Wen Jiang, Jin-Wei Hu, Xu-Ran He, Wei-Lin Jin, Xin-Yang He. (2021) Statins: a repurposed drug to fight cancer. Journal of Experimental & Clinical Cancer Research 40:1.
        4. Liusheng Li, Ning Cui, Tengteng Hao, Jianhua Zou, Wu Jiao, Kangjun Yi, Wu Yu. (2021) Statins use and the prognosis of colorectal cancer: a meta-analysis. Clinics and Research in Hepatology and Gastroenterology 45:5, 101588.
        5. Jetta Sandeep Kumar, Gangireddy Sujeevan Reddy, Raghavender Medishetti, Aramita Ray, Shilpak Dilip Bele, Kazi Amirul Hossain, B. Thirupataiah, Rebecca Kristina Edwin, Parameswar Behera, Alex Joseph, Gautham G. Shenoy, C. Mallikarjuna Rao, Manojit Pal. (2021) Sonochemical synthesis of rosuvastatin based novel 3-methyleneisoindolin-1-one derivatives as potential anticancer agents. Journal of Molecular Structure 1240, 130574.
        6. Shinya Matsuzaki, Heather Miller, Tsuyoshi Takiuchi, Maximilian Klar, Koji Matsuo. (2021) Effects of aspirin and statin use on venous thromboembolism prophylaxis and survival in patients with endometrial cancer. Expert Opinion on Drug Safety.
        7. Qing-Wen Ren, Si-Yeung Yu, Tiew-Hwa Katherine Teng, Xue Li, Ka-Shing Cheung, Mei-Zhen Wu, Hang-Long Li, Pui-Fai Wong, Hung-Fat Tse, Carolyn S P Lam, Kai-Hang Yiu. (2021) Statin associated lower cancer risk and related mortality in patients with heart failure. European Heart Journal 42:32, 3049-3059.
        8. Sanjay Divakaran, Anju Nohria. (2021) Decoding the link between heart failure and incident cancer. European Heart Journal 42:32, 3060-3062.
        9. Maria M. Rubinstein, Kristy A. Brown, Neil M. Iyengar. (2021) Targeting obesity-related dysfunction in hormonally driven cancers. British Journal of Cancer 125:4, 495-509.
        10. Carmen Garcia-Ruiz, Laura Conde de la Rosa, Vicent Ribas, Jose C. Fernandez-Checa. (2021) MITOCHONDRIAL CHOLESTEROL AND CANCER. Seminars in Cancer Biology 73, 76-85.
        11. Amir R. Afshari, Hamid Mollazadeh, Neil C. Henney, Tannaz Jamialahmad, Amirhossein Sahebkar. (2021) Effects of statins on brain tumors: a review. Seminars in Cancer Biology 73, 116-133.
        12. Diego Gómez-Coronado, Miguel A. Lasunción, Javier Martínez-Botas, María E. Fernández-Suárez. (2021) Role of cholesterol metabolism in the anticancer pharmacology of selective estrogen receptor modulators. Seminars in Cancer Biology 73, 101-115.
        13. Giovanna Revilla, Lídia Cedó, Mireia Tondo, Antonio Moral, José Ignacio Pérez, Rosa Corcoy, Enrique Lerma, Victoria Fuste, Srivinasa T. Reddy, Francisco Blanco-Vaca, Eugènia Mato, Joan Carles Escolà-Gil. (2021) LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies. Seminars in Cancer Biology 73, 134-157.
        14. Khadijeh Mahboobnia, Matteo Pirro, Ettore Marini, Francesco Grignani, Evgeny E. Bezsonov, Tannaz Jamialahmadi, Amirhossein Sahebkar. (2021) PCSK9 and cancer: Rethinking the link. Biomedicine & Pharmacotherapy 140, 111758.
        15. Dafne Jacome Sanz, Juuli Raivola, Hanna Karvonen, Mariliina Arjama, Harlan Barker, Astrid Murumägi, Daniela Ungureanu. (2021) Evaluating Targeted Therapies in Ovarian Cancer Metabolism: Novel Role for PCSK9 and Second Generation mTOR Inhibitors. Cancers 13:15, 3727.
        16. Andry Van de Louw, Austin Cohrs, Douglas Leslie. (2021) Effects of Statins on the Incidence and Mortality of Sepsis in Patients with New Cancer Diagnosis. Journal of Clinical Medicine 10:15, 3427.
        17. Elsa Brånvall, Sara Ekberg, Sandra Eloranta, Tove Wästerlid, Brenda M. Birmann, Karin E. Smedby. (2021) Statin use and survival in 16 098 patients with non‐Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era. British Journal of Haematology 177.
        18. Sujeong Shin, Dong Wook Shin, In Young Cho, Su-Min Jeong, Hyein Jung. (2021) Status of dyslipidemia management and statin undertreatment in Korean cancer survivors: A Korean National Health and Nutrition Examination Survey study. European Journal of Preventive Cardiology 28:8, 864-872.
        19. William A. Stokes, Elizabeth Molina, Jessica D. McDermott, Rustain L. Morgan, Thomas Bickett, Kareem R. Fakhoury, Arya Amini, Sana D. Karam. (2021) Survival impact of a ngiotensin‐converting enzyme inhibitors and angiotensin II receptor antagonists in head and neck cancer. Head & Neck 7.
        20. Jiaojiao Zheng, Giola Santoni, Shao-Hua Xie, Jesper Lagergren. (2021) Improved prognosis in gastric adenocarcinoma among metformin users in a population-based study. British Journal of Cancer 125:2, 277-283.
        21. Young Yun Jung, Jeong‐Hyeon Ko, Jae‐Young Um, Arunachalam Chinnathambi, Sulaiman Ali Alharbi, Gautam Sethi, Kwang Seok Ahn. (2021) LDL cholesterol promotes the proliferation of prostate and pancreatic cancer cells by activating the STAT3 pathway. Journal of Cellular Physiology 236:7, 5253-5264.
        22. Noha M. Mounier, Sara A. Wahdan, Amany M. Gad, Samar S. Azab. (2021) Role of inflammatory, oxidative, and ER stress signaling in the neuroprotective effect of atorvastatin against doxorubicin-induced cognitive impairment in rats. Naunyn-Schmiedeberg’s Archives of Pharmacology 394:7, 1537-1551.
        23. Qiang Pan, Shanshan Zhong, Hanling Wang, Xuege Wang, Ni Li, Yaqi Li, Guoying Zhang, Huairui Yuan, Yannan Lian, Qilong Chen, Ying Han, Jiacheng Guo, Qiuli Liu, Tong Qiu, Jun Jiang, Qintong Li, Minjia Tan, Huiyong Yin, Junjie Peng, Yichuan Xiao, Jun Qin. (2021) The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability. Molecular Cell 81:13, 2736-2751.e8.
        24. Gi-Hoon Nam, Minsu Kwon, Hanul Jung, Eunbyeol Ko, Seong A Kim, Yoonjeong Choi, Su Jeong Song, Seohyun Kim, Yeji Lee, Gi Beom Kim, Jihoon Han, Jiwan Woo, Yakdol Cho, Cherlhyun Jeong, Seung-Yoon Park, Thomas M. Roberts, Yong Beom Cho, In-San Kim. (2021) Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer. Journal for ImmunoTherapy of Cancer 9:7, e002474.
        25. Kyu-Tae Han, Seungju Kim. (2021) Post-Diagnostic Statin Use Reduces Mortality in South Korean Patients with Dyslipidemia and Gastrointestinal Cancer. Journal of Clinical Medicine 10:11, 2361.
        26. Khouloud Sassi, Thomas Nury, Mohammad Samadi, Fatma Ben-Aissa Fennira, Anne Vejux, Gérard Lizard. 2021. Cholesterol Derivatives as Promising Anticancer Agents in Glioblastoma Metabolic Therapy. Gliomas, 97-120.
        27. Liqian Ma, Wonhwa Cho, Erik R. Nelson. (2021) Our evolving understanding of how 27-hydroxycholesterol influences cancer. Biochemical Pharmacology 7, 114621.
        28. Miguel A. Lasunción, Javier Martínez-Botas, Covadonga Martín-Sánchez, Rebeca Busto, Diego Gómez-Coronado. (2021) Cell cycle dependence on the mevalonate pathway: Role of cholesterol and non-sterol isoprenoids. Biochemical Pharmacology 343, 114623.
        29. Hanan Goldberg, Faizan K. Mohsin, Refik Saskin, Girish S. Kulkarni, Alejandro Berlin, Miran Kenk, Christopher J.D. Wallis, Zachary Klaassen, Thenappan Chandrasekar, Ardalan E. Ahmad, Rashid K. Sayyid, Olli Saarela, Linda Penn, Shabbir M.H. Alibhai, Neil Fleshner. (2021) The Suggested Unique Association Between the Various Statin Subgroups and Prostate Cancer. European Urology Focus 7:3, 537-545.
        30. Wen Ni, Hui Mo, Yuanyuan Liu, Yuanyuan Xu, Chao Qin, Yunxia Zhou, Yuhui Li, Yuqing Li, Aijun Zhou, Su Yao, Rong Zhou, Jianping Huo, Liheng Che, Jianming Li. (2021) Targeting cholesterol biosynthesis promotes anti-tumor immunity by inhibiting long noncoding RNA SNHG29-mediated YAP activation. Molecular Therapy 394.
        31. Mark Gormley, James Yarmolinsky, Tom Dudding, Kimberley Burrows, Richard M. Martin, Steven Thomas, Jessica Tyrrell, Paul Brennan, Miranda Pring, Stefania Boccia, Andrew F. Olshan, Brenda Diergaarde, Rayjean J. Hung, Geoffrey Liu, Danny Legge, Eloiza H. Tajara, Patricia Severino, Martin Lacko, Andrew R. Ness, George Davey Smith, Emma E. Vincent, Rebecca C. Richmond, Thilo Dörk. (2021) Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization study. PLOS Genetics 17:4, e1009525.
        32. Chen Huang, Chuqi Lei, Boyu Pan, Senbiao Fang, Yubao Chen, Wenfeng Cao, Liren Liu. (2021) Potential Prospective Biomarkers for Non-small Cell Lung Cancer: Mini-Chromosome Maintenance Proteins. Frontiers in Genetics 12.
        33. Robert J. Hamilton, Keyue Ding, Juanita M. Crook, Christopher J. O’Callaghan, Celestia S. Higano, David P. Dearnaley, Eric M. Horwitz, S. Larry Goldenberg, Mary K. Gospodarowicz, Laurence Klotz. (2021) The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. European Urology 79:4, 446-452.
        34. Azam Majidi, Renhua Na, Susan J. Jordan, Anna De Fazio, Penelope M. Webb, . (2021) Statin use and survival following a diagnosis of ovarian cancer: A prospective observational study. International Journal of Cancer 148:7, 1608-1615.
        35. Shreetama Bandyopadhayaya, Mikhail G. Akimov, Ranjeet Verma, Ankit Sharma, Divya Sharma, Gopal C. Kundu, Natalia M. Gretskaya, Vladimir V. Bezuglov, Chandi C. Mandal. (2021) N ‐arachidonoyl dopamine inhibits epithelial–mesenchymal transition of breast cancer cells through ERK signaling and decreasing the cellular cholesterol. Journal of Biochemical and Molecular Toxicology 35:4.
        36. Jia‐Li Feng, Xiwen Qin. (2021) Does adherence to lipid‐lowering medications improve cancer survival? A nationwide study of breast and colorectal cancer, and melanoma. British Journal of Clinical Pharmacology 87:4, 1847-1858.
        37. Haiyan Chen, Siqi Dai, Yimin Fang, Liubo Chen, Kai Jiang, Qichun Wei, Kefeng Ding. (2021) Hepatic Steatosis Predicts Higher Incidence of Recurrence in Colorectal Cancer Liver Metastasis Patients. Frontiers in Oncology 11.
        38. Hanan Goldberg, Faizan K. Mohsin, Alejandro Berlin, Thenappan Chandrasekar, Christopher J.D. Wallis, Zachary Klaassen, Ardalan E. Ahmad, Refik Saskin, Miran Kenk, Olli Saarela, Girish S. Kulkarni, Shabbir M.H. Alibhai, Neil Fleshner. (2021) The suggested chemopreventive association of metformin with prostate cancer in diabetic patients. Urologic Oncology: Seminars and Original Investigations 39:3, 191.e17-191.e24.
        39. Peng-Cheng Zhong, Rong Shu, Hui-Wen Wu, Zhi-Wen Liu, Xiao-Ling Shen, Ying-Jie Hu. (2021) Altered gene expression in glycolysis–cholesterol synthesis axis correlates with outcome of triple-negative breast cancer. Experimental Biology and Medicine 246:5, 560-571.
        40. Sadanori Okada, Takeshi Morimoto, Hisao Ogawa, Hirofumi Soejima, Chisa Matsumoto, Mio Sakuma, Masafumi Nakayama, Naofumi Doi, Hideaki Jinnouchi, Masako Waki, Izuru Masuda, Yoshihiko Saito. (2021) Association Between Statins and Cancer Incidence in Diabetes: a Cohort Study of Japanese Patients with Type 2 Diabetes. Journal of General Internal Medicine 36:3, 632-639.
        41. Yan Fu, Tiantian Zou, Xiaotian Shen, Peter J. Nelson, Jiahui Li, Chao Wu, Jimeng Yang, Yan Zheng, Christiane Bruns, Yue Zhao, Lunxiu Qin, Qiongzhu Dong. (2021) Lipid metabolism in cancer progression and therapeutic strategies. MedComm 2:1, 27-59.
        42. Maria P. Ikonomopoulou, Yaiza Lopez-Mancheño, Marta G. Novelle, Maite Martinez-Uña, Lahiru Gangoda, Martin Pal, Luis Filipe Costa-Machado, Pablo Jose Fernandez-Marcos, Grant A. Ramm, Manuel Alejandro Fernandez-Rojo. (2021) LXR stimulates a metabolic switch and reveals cholesterol homeostasis as a statin target in Tasmanian devil facial tumor disease. Cell Reports 34:11, 108851.
        43. Ke Chen, Jianrong Guo, Tao Zhang, Jian Gu, Huili Li, Jiliang Wang, Dan Zhao. (2021) The Role of Dyslipidemia in Colitis-Associated Colorectal Cancer. Journal of Oncology 2021, 1-13.
        44. Tiffany Scully, Abora Ettela, Derek LeRoith, Emily Jane Gallagher. (2021) Obesity, Type 2 Diabetes, and Cancer Risk. Frontiers in Oncology 10.
        45. Roger J. Bedimo, Lesley S. Park, Fatima M. Shebl, Keith Sigel, Christopher T. Rentsch, Kristina Crothers, Maria C. Rodriguez-Barradas, Matthew Bidwell Goetz, Adeel A. Butt, Sheldon T. Brown, Cynthia Gibert, Amy C. Justice, Janet P. Tate. (2021) Statin exposure and risk of cancer in people with and without HIV infection. AIDS 35:2, 325-334.
        46. Yin-Che Lu, Da-Wei Huang, Pin-Tzu Chen, Ching-Fang Tsai, Mei-Chen Lin, Che-Chen Lin, Shi-Heng Wang, Yi-Jiun Pan. (2021) Association between statin use and second cancer risk in breast cancer patients: a nationwide population-based cohort study. Breast Cancer Research and Treatment 185:3, 773-783.
        47. Prema S. Rao, U. Subrahmanyeswara Rao. (2021) Statins decrease the expression of c-Myc protein in cancer cell lines. Molecular and Cellular Biochemistry 476:2, 743-755.
        48. In Young Cho, Kyungdo Han, Dong Wook Shin, Sang Hyun Park, Dong Woog Yoon, Sujeong Shin, Su-Min Jeong, Jong Ho Cho. (2021) Cardiovascular risk and undertreatment of dyslipidemia in lung cancer survivors: A nationwide population-based study. Current Problems in Cancer 45:1, 100615.
        49. Nicole Prabhu, Navina Kapur, William Catalona, Robin Leikin, Irene Helenowski, Borko Jovanovich, Michael Gurley, Tochi M. Okwuosa, Timothy M. Kuzel. (2021) Statin use and risk of prostate cancer biochemical recurrence after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations 39:2, 130.e9-130.e15.
        50. Niloufar Khojandi, Lindsey M. Kuehm, Alexander Piening, Maureen J. Donlin, Eddy C. Hsueh, Theresa L. Schwartz, Kaitlin Farrell, John M. Richart, Elizabeth Geerling, Amelia K. Pinto, Sarah L. George, Carolyn J. Albert, David A. Ford, Xiufen Chen, Justin Kline, Ryan M. Teague. (2021) Oxidized Lipoproteins Promote Resistance to Cancer Immunotherapy Independent of Patient Obesity. Cancer Immunology Research 9:2, 214-226.
        51. Yuki Matsushita, Hayato Nakagawa, Kazuhiko Koike. (2021) Lipid Metabolism in Oncology: Why It Matters, How to Research, and How to Treat. Cancers 13:3, 474.
        52. Moumita Nath, Kasturi Bhattacharjee, Yashmin Choudhury. (2021) Vildagliptin, a dipeptidyl peptidase-4 inhibitor, reduces betel-nut induced carcinogenesis in female mice. Life Sciences 266, 118870.
        53. Linda My Huynh, Emily Keit, Aviva Atri Schuller, Raymond Ceja Carrillo, Erica Huang, Thomas E. Ahlering, Shawna Boyle, Charles Enke, Michael J. Baine. (2021) Impact of statin use on overall and time to biochemical failure following radical prostatectomy or radiation therapy. World Journal of Urology 42.
        54. Ai‐Ho Liao, Wan‐Ting Lin, Hang‐Kang Chen, Cheng‐Ping Shih, Chih‐Hung Wang, Yueng‐Hsiang Chu. (2021) Synergistic effects of combined treatment with ultrasound‐mediated cisplatin‐loaded microbubbles and atorvastatin on head and neck cancer. Head & Neck 43:1, 15-26.
        55. Hussein Hammoud, Zahraa Saker, Hayat Harati, Youssef Fares, Hisham F. Bahmad, Sanaa Nabha. (2021) Drug Repurposing in Medulloblastoma: Challenges and Recommendations. Current Treatment Options in Oncology 22:1.
        56. Pin-Yao Chen, Meng-Ju Hsieh, Ying-Hsiu Liao, Yu-Che Lin, Yung-Te Hou. (2021) Liver-on-a-chip platform to study anticancer effect of statin and its metabolites. Biochemical Engineering Journal 165, 107831.
        57. Katelyn M. Atkins, Danielle S. Bitterman, Tafadzwa L. Chaunzwa, Christopher L. Williams, Rifaquat Rahman, David E. Kozono, Elizabeth H. Baldini, Hugo J.W.L. Aerts, Balaji K. Tamarappoo, Udo Hoffmann, Anju Nohria, Raymond H. Mak. (2021) Statin Use, Heart Radiation Dose, and Survival in Locally Advanced Lung Cancer. Practical Radiation Oncology 374.
        58. Mi Hee Cho, Tae Gon Yoo, Su-Min Jeong, Dong Wook Shin. (2021) Association of Aspirin, Metformin, and Statin Use with Gastric Cancer Incidence and Mortality: A Nationwide Cohort Study. Cancer Prevention Research 14:1, 95-104.
        59. Elsi Ferro, Carla Bosia, Carlo C. Campa. (2021) RAB11-Mediated Trafficking and Human Cancers: An Updated Review. Biology 10:1, 26.
        60. Renya Zeng, Jixin Dong. (2021) The Hippo Signaling Pathway in Drug Resistance in Cancer. Cancers 13:2, 318.
        61. Umesh Goneppanavar, Jasvinder Kaur. 2021. Anesthesia and Cancer Recurrence. Textbook of Onco-Anesthesiology, 13-41.
        62. Joshua K. Park, Nathan J. Coffey, Aaron Limoges, Anne Le. 2021. The Heterogeneity of Lipid Metabolism in Cancer. The Heterogeneity of Cancer Metabolism, 39-56.
        63. Gregor Brandstetter, Sebastian Blatt, Jutta Goldschmitt, Louise Taylor, Paul Heymann, Bilal Al-Nawas, Thomas Ziebart. (2021) Targeted sensitization of tumor cells for radiation through monocarboxylate transporters 1 and 4 inhibition in vitro. Clinical Oral Investigations 25:1, 295-310.
        64. Tomas Koltai, Stephan J. Reshkin, Fátima Baltazar, Larry Fliegel. 2021. Cholesterol metabolism in prostate cancer. Prostate Cancer Metabolism, 211-240.
        65. Md Amir Hossain, Guilai Liu, Beiying Dai, Yaxuan Si, Qitao Yang, Junaid Wazir, Lutz Birnbaumer, Yong Yang. (2021) Reinvigorating exhausted CD8 + cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. Medicinal Research Reviews 41:1, 156-201.
        66. Sanjay Kumar Dey, Sabyasachi Senapati. 2021. Insulin and Insulin-Like Growth Factor-1 Associated Cancers. Obesity and Cancer, 25-48.
        67. Jonny Alejandro Garcia Luna, Eduardo López-Medina, Norman Danilo Maldonado-Vargas, Adrian D. Smith. (2021) Opportunities for the use of routinely collected data for the generation of large randomized evidence in Colombia. Wellcome Open Research 6, 182.
        68. Lara Paula Fernández, María Merino, Gonzalo Colmenarejo, Juan Moreno‐Rubio, Ruth Sánchez‐Martínez, Adriana Quijada‐Freire, Marta Gómez de Cedrón, Guillermo Reglero, Enrique Casado, María Sereno, Ana Ramírez de Molina. (2020) Metabolic enzyme ACSL3 is a prognostic biomarker and correlates with anticancer effectiveness of statins in non‐small cell lung cancer. Molecular Oncology 14:12, 3135-3152.
        69. Mazaher Ahmadi, Shayan Amiri, Stevan Pecic, Filip Machaj, Jakub Rosik, Marek J. Łos, Javad Alizadeh, Reza Mahdian, Simone C. da Silva Rosa, Dedmer Schaafsma, Shahla Shojaei, Tayyebeh Madrakian, Amir A. Zeki, Saeid Ghavami. (2020) Pleiotropic effects of statins: A focus on cancer. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease 1866:12, 165968.
        70. Olöf Bjarnadottir, Maria Feldt, Maria Inasu, Pär-Ola Bendahl, Karin Elebro, Siker Kimbung, Signe Borgquist. (2020) Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study. Scientific Reports 10:1.
        71. Yinfei Tan, Eleonora Sementino, Zemin Liu, Kathy Q. Cai, Joseph R. Testa. (2020) Wnt signaling mediates oncogenic synergy between Akt and Dlx5 in T-cell lymphomagenesis by enhancing cholesterol synthesis. Scientific Reports 10:1.
        72. L.A. Schuckmann, K. Khosrotehrani, R. Ghiasvand, M.C.B. Hughes, J.C. Pols, M. Malt, B.M. Smithers, A.C. Green. (2020) Statins may reduce disease recurrence in patients with ulcerated primary melanoma. British Journal of Dermatology 183:6, 1049-1055.
        73. Siker Kimbung, Maria Inasu, Tor Stålhammar, Björn Nodin, Karin Elebro, Helga Tryggvadottir, Maria Ygland Rödström, Karin Jirström, Karolin Isaksson, Helena Jernström, Signe Borgquist. (2020) CYP27A1 expression is associated with risk of late lethal estrogen receptor-positive breast cancer in postmenopausal patients. Breast Cancer Research 22:1.
        74. Maria Feldt, Julien Menard, Ann H. Rosendahl, Barbara Lettiero, Pär-Ola Bendahl, Mattias Belting, Signe Borgquist. (2020) The effect of statin treatment on intratumoral cholesterol levels and LDL receptor expression: a window-of-opportunity breast cancer trial. Cancer & Metabolism 8:1.
        75. Martin Boegemann, Katrin Schlack, Michael Rink, Stephan Bernhardt, Michael Moran, Marcus Hubbe, Lothar Bergmann, Marianne Schmid, Arne Strauss. (2020) Effect of comorbidities/comedications on sunitinib outcomes for metastatic renal cell carcinoma: the STAR-TOR registry. Future Oncology 16:35, 2939-2948.
        76. Nicolas Germain, Mélanie Dhayer, Marie Boileau, Quentin Fovez, Jerome Kluza, Philippe Marchetti. (2020) Lipid Metabolism and Resistance to Anticancer Treatment. Biology 9:12, 474.
        77. Nathan G. Kase, Elissa Gretz Friedman, Michael Brodman, Chifei Kang, Emily J. Gallagher, Derek LeRoith. (2020) The midlife transition and the risk of cardiovascular disease and cancer Part I: magnitude and mechanisms. American Journal of Obstetrics and Gynecology 223:6, 820-833.
        78. Hanan Goldberg, Faizan K. Mohsin, Refik Saskin, Girish S. Kulkarni, Alejandro Berlin, Miran Kenk, Christopher J. D. Wallis, Thenappan Chandrasekar, Zachary Klaassen, Olli Saarela, Linda Penn, Shabbir M. H. Alibhai, Neil Fleshner. (2020) The deleterious association between proton pump inhibitors and prostate cancer-specific mortality – a population-based cohort study. Prostate Cancer and Prostatic Diseases 23:4, 622-629.
        79. Elizabeth Theusch, Yii-Der I. Chen, Jerome I. Rotter, Ronald M. Krauss, Marisa W. Medina. (2020) Genetic variants modulate gene expression statin response in human lymphoblastoid cell lines. BMC Genomics 21:1.
        80. Joseph Longo, Jenna E. van Leeuwen, Mohamad Elbaz, Emily Branchard, Linda Z. Penn. (2020) Statins as Anticancer Agents in the Era of Precision Medicine. Clinical Cancer Research 26:22, 5791-5800.
        81. Laurence Pellerin, Lorry Carrié, Carine Dufau, Laurence Nieto, Bruno Ségui, Thierry Levade, Joëlle Riond, Nathalie Andrieu-Abadie. (2020) Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives. Cancers 12:11, 3147.
        82. Sanaz Dastghaib, Shahla Shojaei, Zohreh Mostafavi-Pour, Pawan Sharma, John B. Patterson, Afshin Samali, Pooneh Mokarram, Saeid Ghavami. (2020) Simvastatin Induces Unfolded Protein Response and Enhances Temozolomide-Induced Cell Death in Glioblastoma Cells. Cells 9:11, 2339.
        83. Huixia Lu, Jordi Martí. (2020) Influence of Cholesterol on the Orientation of the Farnesylated GTP-Bound KRas-4B Binding with Anionic Model Membranes. Membranes 10:11, 364.
        84. A. Carretero-González, D. Lora, R. Manneh, D. Lorente, D. Castellano, G. de Velasco. (2020) Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials. Clinical and Translational Oncology 22:11, 2126-2129.
        85. Hui Lv, Ding Shi, Min Fei, Yu Chen, Fei Xie, Zhuoyan Wang, Ying Wang, Peiying Hu. (2020) Association Between Statin Use and Prognosis of Breast Cancer: A Meta-Analysis of Cohort Studies. Frontiers in Oncology 10.
        86. I. I. Shaposhnik, V. V. Genkel. (2020) Antitumor effects of cardiovascular drugs. Meditsinskiy sovet = Medical Council:14, 56-62.
        87. Andrea Bisso, Marco Filipuzzi, Gianni Paolo Gamarra Figueroa, Giulia Brumana, Francesca Biagioni, Mirko Doni, Giorgia Ceccotti, Nina Tanaskovic, Marco Jacopo Morelli, Vera Pendino, Fulvio Chiacchiera, Diego Pasini, Daniela Olivero, Stefano Campaner, Arianna Sabò, Bruno Amati. (2020) Cooperation Between MYC and β‐Catenin in Liver Tumorigenesis Requires Yap/Taz. Hepatology 72:4, 1430-1443.
        88. Mariana Nunes, Miguel Henriques Abreu, Carla Bartosch, Sara Ricardo. (2020) Recycling the Purpose of Old Drugs to Treat Ovarian Cancer. International Journal of Molecular Sciences 21:20, 7768.
        89. Ghazal Alipour Talesh, Véronique Trézéguet, Aksam Merched. (2020) Hepatocellular Carcinoma and Statins. Biochemistry 59:37, 3393-3400.
        90. Audrey A Tran, Vinay Prasad. (2020) Drug repurposing for cancer treatments: a well-intentioned, but misguided strategy. The Lancet Oncology 21:9, 1134-1136.
        91. Jetta Sandeep Kumar, B. Thirupataiah, Raghavender Medishetti, Aramita Ray, Shilpak Dilip Bele, Kazi Amirul Hossain, Gangireddy Sujeevan Reddy, Rebecca Kristina Edwin, Alex Joseph, Nitesh Kumar, Gautham G. Shenoy, C. Mallikarjuna Rao, Manojit Pal. (2020) Rosuvastatin based novel 3-substituted isocoumarins / 3-alkylidenephthalides: Ultrasound assisted synthesis and identification of new anticancer agents. European Journal of Medicinal Chemistry 201, 112335.
        92. Erik J Snider, Andrew M Kaz, John M Inadomi, William M Grady. (2020) Chemoprevention of esophageal adenocarcinoma. Gastroenterology Report 8:4, 253-260.
        93. Augusto Bleve, Barbara Durante, Antonio Sica, Francesca Maria Consonni. (2020) Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad. International Journal of Molecular Sciences 21:16, 5845.
        94. Sabine Galland, Patricia Martin, Giulia Fregni, Igor Letovanec, Ivan Stamenkovic. (2020) Attenuation of the pro-inflammatory signature of lung cancer-derived mesenchymal stromal cells by statins. Cancer Letters 484, 50-64.
        95. Sixten Harborg, Uffe Heide-Jørgensen, Thomas P. Ahern, Marianne Ewertz, Deirdre Cronin-Fenton, Signe Borgquist. (2020) Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study. Breast Cancer Research and Treatment 183:1, 153-160.
        96. Arvand Asghari, Michihisa Umetani. (2020) Obesity and Cancer: 27-Hydroxycholesterol, the Missing Link. International Journal of Molecular Sciences 21:14, 4822.
        97. Elsa Brånvall, Sara Ekberg, Sandra Eloranta, Tove Wästerlid, Brenda M. Birmann, Karin E. Smedby. (2020) Statin use is associated with improved survival in multiple myeloma: A Swedish population‐based study of 4315 patients. American Journal of Hematology 95:6, 652-661.
        98. Wei Deng, Hongliang Liu, Sheng Luo, Jeffrey Clarke, Carolyn Glass, Li Su, Lijuan Lin, David C. Christiani, Qingyi Wei. (2020) APOB Genotypes and CDH13 Haplotypes in the Cholesterol-Related Pathway Genes Predict Non–Small Cell Lung Cancer Survival. Cancer Epidemiology Biomarkers & Prevention 29:6, 1204-1213.
        99. Maryam Zamanian-Daryoush, Daniel J. Lindner, Jennifer Buffa, Banu Gopalan, Jie Na, Stanley L. Hazen, Joseph A. DiDonato. (2020) Apolipoprotein A-I anti-tumor activity targets cancer cell metabolism. Oncotarget 11:19, 1777-1796.
        100. Ehsan Samiei, Amir Seyfoori, Brian Toyota, Saeid Ghavami, Mohsen Akbari. (2020) Investigating Programmed Cell Death and Tumor Invasion in a Three-Dimensional (3D) Microfluidic Model of Glioblastoma. International Journal of Molecular Sciences 21:9, 3162.
        101. Sandrine B. Lavenus, Sara M. Tudor, Maria F. Ullo, Karl W. Vosatka, Jeremy S. Logue. (2020) A flexible network of vimentin intermediate filaments promotes migration of amoeboid cancer cells through confined environments. Journal of Biological Chemistry 295:19, 6700-6709.
        102. Faustino Mollinedo, Consuelo Gajate. (2020) Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy. Journal of Lipid Research 61:5, 611-635.
        103. Domenico Tamburrino, Stefano Crippa, Stefano Partelli, Livia Archibugi, Paolo Giorgio Arcidiacono, Massimo Falconi, Gabriele Capurso. (2020) Statin use improves survival in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Digestive and Liver Disease 52:4, 392-399.
        104. Esraa Al Dujaily, Juvenal Baena, Madhumita Das, Marco Sereno, Claire Smith, Tamihiro Kamata, Leah Officer, Catrin Pritchard, John Le Quesne. (2020) Reduced Protumorigenic Tumor-Associated Macrophages With Statin Use in Premalignant Human Lung Adenocarcinoma. JNCI Cancer Spectrum 4:2.
        105. Karis Tutuska, Laura Parrilla-Monge, Erica Di Cesare, Alice Nemajerova, Ute M. Moll. (2020) Statin as anti-cancer therapy in autochthonous T-lymphomas expressing stabilized gain-of-function mutant p53 proteins. Cell Death & Disease 11:4.
        106. Afsane Bahrami, Simona Bo, Tannaz Jamialahmadi, Amirhossein Sahebkar. (2020) Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms. Ageing Research Reviews 58, 101024.
        107. Joungyoun Kim, Eun-A. Choi, Ye-Eun Han, Jae-woo Lee, Ye-seul Kim, Yonghwan Kim, Hyo-Sun You, Hyeong-Jin Hyun, Hee-Taik Kang. (2020) Association between statin use and all-cause mortality in cancer survivors, based on the Korean health insurance service between 2002 and 2015. Nutrition, Metabolism and Cardiovascular Diseases 30:3, 434-440.
        108. Shahla Shojaei, Navid Koleini, Ehsan Samiei, Mahmoud Aghaei, Laura K. Cole, Javad Alizadeh, Md Imamul Islam, Amir‐reza Vosoughi, Mohammed Albokashy, Yaron Butterfield, Hassan Marzban, Fred Xu, James Thliveris, Elissavet Kardami, Grant M. Hatch, Eftekhar Eftekharpour, Mohsen Akbari, Sabine Hombach‐Klonisch, Thomas Klonisch, Saeid Ghavami. (2020) Simvastatin increases temozolomide‐induced cell death by targeting the fusion of autophagosomes and lysosomes. The FEBS Journal 287:5, 1005-1034.
        109. Emma H. Allott, Ericka M. Ebot, Konrad H. Stopsack, Amparo G. Gonzalez-Feliciano, Sarah C. Markt, Kathryn M. Wilson, Thomas U. Ahearn, Travis A. Gerke, Mary K. Downer, Jennifer R. Rider, Stephen J. Freedland, Tamara L. Lotan, Philip W. Kantoff, Elizabeth A. Platz, Massimo Loda, Meir J. Stampfer, Edward Giovannucci, Christopher J. Sweeney, Stephen P. Finn, Lorelei A. Mucci. (2020) Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clinical Cancer Research 26:5, 1086-1093.
        110. Collins Rory, Bowman Louise, Landray Martin, Peto Richard. (2020) The Magic of Randomization versus the Myth of Real-World Evidence. N Engl J Med 382:7, 674-678.
          • Binlu Huang, Bao-liang Song, Chenqi Xu. (2020) Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nature Metabolism 2:2, 132-141.
          • Lixia Ji, Chaolong Liu, Yanting Yuan, Hui Gao, Zhen‐xue Tang, Zhihong Yang, Zhan‐tao Liu, Guo‐hui Jiang. (2020) Key roles of Rho GTPases, YAP, and Mutant P53 in anti‐neoplastic effects of statins. Fundamental & Clinical Pharmacology 34:1, 4-10.
          • Lei Zhang, Yifang Huang, Xuedong Gan, Siying He, Xiaohuan Cheng, Na Yang, Siwei Li, Zuhua Li, Fang Zheng. (2020) The Pharmacogenomics “Side-effect” of TP53/EGFR in Non-small Cell Lung Cancer Accompanied with Atorvastatin Therapy: A Functional Network Analysis. Anti-Cancer Agents in Medicinal Chemistry 19:17, 2060-2071.
          • Maria Isabel Camara Planek, Adam J. Silver, Annabelle Santos Volgman, Tochukwu M. Okwuosa. (2020) Exploratory Review of the Role of Statins, Colchicine, and Aspirin for the Prevention of Radiation‐Associated Cardiovascular Disease and Mortality. Journal of the American Heart Association 9:2.
          • Elizabeth G. Ratcliffe, Mohamed Shibeika, Andrew D. Higham, Janusz A. Jankowski. 2020. Chemoprevention of Esophageal Cancer. Esophageal Cancer, 113-125.
          • Khevin Itoua-Gassaye, Anne Coubret, Ghislaine Bari, Roxanne Desquines, Estelle Montanard. (2020) Iatrogénie médicamenteuse et troubles de la prostate. Actualités Pharmaceutiques 59:592, 34-37.
          • Lisa M. Butler, Ylenia Perone, Jonas Dehairs, Leslie E. Lupien, Vincent de Laat, Ali Talebi, Massimo Loda, William B. Kinlaw, Johannes V. Swinnen. (2020) Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Advanced Drug Delivery Reviews 159, 245-293.
          • Andy Göbel, Martina Rauner, Lorenz C. Hofbauer, Tilman D. Rachner. (2020) Cholesterol and beyond – The role of the mevalonate pathway in cancer biology. Biochimica et Biophysica Acta (BBA) – Reviews on Cancer, 188351.
          • Keitaro Hayashi, Yoshimasa Nakazato, Noriaki Morito, Mizuki Sagi, Tomoe Fujita, Naohiko Anzai, Masayuki Chida. (2020) Fluvastatin is effective against thymic carcinoma. Life Sciences 240, 117110.
          • Albert Boretti. (2020) Nutrition, lipidic parameters, and cancer risk and progress. Nutrition 69, 110538.
          • Nikos Koundouros, George Poulogiannis. (2020) Reprogramming of fatty acid metabolism in cancer. British Journal of Cancer 122:1, 4-22.
          • Xin Zhou, Qing Yang. (2020) From hemorrhagic stroke to lipid paradox: a double-hit hypothesis underlying low low-density lipoprotein cholesterol related cardiovascular risk—a narrative review. Journal of Bio-X Research 3:3, 97-103.
          • Joanna M. Karasinska, James T. Topham, Steve E. Kalloger, Gun Ho Jang, Robert E. Denroche, Luka Culibrk, Laura M. Williamson, Hui-Li Wong, Michael K.C. Lee, Grainne M. O’Kane, Richard A. Moore, Andrew J. Mungall, Malcolm J. Moore, Cassia Warren, Andrew Metcalfe, Faiyaz Notta, Jennifer J. Knox, Steven Gallinger, Janessa Laskin, Marco A. Marra, Steven J.M. Jones, Daniel J. Renouf, David F. Schaeffer. (2020) Altered Gene Expression along the Glycolysis–Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer. Clinical Cancer Research 26:1, 135-146.
          • Jing Yang, Chunyu Li, Ying Shen, Hong Zhou, Yueqin Shao, Wei Zhu, Yan Chen. (2020) Impact of statin use on cancer-specific mortality and recurrence. Medicine 99:14, e19596.
          • Yonglin Xie, Qin Lu, Cameron Lenahan, Shuxu Yang, Daoyang Zhou, Xuchen Qi. (2020) Whether statin use improves the survival of patients with glioblastoma?. Medicine 99:9, e18997.
          • Francisco Blanco-Vaca, Lídia Cedó, Josep Julve. (2019) Phytosterols in Cancer: From Molecular Mechanisms to Preventive and Therapeutic Potentials. Current Medicinal Chemistry 26:37, 6735-6749.
          • Yonglong Zhang, Yanfeng Liu, Jinlin Duan, Hui Wang, Yuchen Zhang, Ke Qiao, Jian Wang. (2019) Cholesterol depletion sensitizes gallbladder cancer to cisplatin by impairing DNA damage response. Cell Cycle 18:23, 3337-3350.
          • Farooq Ahmad, Xiaoyan Wang, Wanwan Li. (2019) Toxico‐Metabolomics of Engineered Nanomaterials: Progress and Challenges. Advanced Functional Materials 29:51, 1904268.
          • Chris Plummer, Richard M. Steingart, Wojcech Jurczak, Zaza Iakobishvili, Alex R. Lyon, John P. Plastaras, Giorgio Minotti. (2019) Treatment specific toxicities: Hormones, antihormones, radiation therapy. Seminars in Oncology 46:6, 414-420.
          • Tianshun Zhang, Ruihua Bai, Qiushi Wang, Keke Wang, Xiang Li, Kangdong Liu, Joohyun Ryu, Ting Wang, Xiaoyu Chang, Weiya Ma, Ann M. Bode, Qingxin Xia, Yongping Song, Zigang Dong. (2019) Fluvastatin Inhibits HMG-CoA Reductase and Prevents Non–Small Cell Lung Carcinogenesis. Cancer Prevention Research 12:12, 837-848.
          • Signe Borgquist, Per Broberg, Jasaman Tojjar, Håkan Olsson. (2019) Statin use and breast cancer survival – a Swedish nationwide study. BMC Cancer 19:1.
          • Peipei Liu, Úna C. McMenamin, Andrew D. Spence, Brian T. Johnston, Helen G. Coleman, Chris R. Cardwell. (2019) Furosemide use and survival in patients with esophageal or gastric cancer: a population-based cohort study. BMC Cancer 19:1.
          • Michael B. Jameson, Kirsten Gormly, David Espinoza, Wendy Hague, Gholamreza Asghari, Grahame Mark Jeffery, Timothy Jay Price, Christos Stelios Karapetis, Michael Arendse, James Armstrong, John Childs, Frank A. Frizelle, Sam Ngan, Andrew Stevenson, Martinus Oostendorp, Stephen P. Ackland. (2019) SPAR – a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial. BMC Cancer 19:1.
          • Yusuke Kobayashi, Kouji Banno, Haruko Kunitomi, Shimpei Nagai, Takayuki Takahashi, Mayuka Anko, Moito Iijima, Takashi Takeda, Yusuke Matoba, Kanako Nakamura, Kosuke Tsuji, Eiichiro Tominaga, Daisuke Aoki. (2019) Is antidyslipidemic statin use for cancer prevention a promising drug repositioning approach?. European Journal of Cancer Prevention 28:6, 562-567.
          • Yonghui Wu, Jeremy L. Warner, Liwei Wang, Min Jiang, Jun Xu, Qingxia Chen, Hui Nian, Qi Dai, Xianglin Du, Ping Yang, Joshua C. Denny, Hongfang Liu, Hua Xu. (2019) Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients With Cancer: A New Paradigm for Drug Repurposing. JCO Clinical Cancer Informatics:3, 1-9.
          • Takuya Oikawa, Yasuhiko Sakata, Kotaro Nochioka, Masanobu Miura, Ruri Abe, Shintaro Kasahara, Masayuki Sato, Hajime Aoyanagi, Chiharu Saga, Yasuko Ikeno, Takashi Shiroto, Koichiro Sugimura, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa. (2019) Association between temporal changes in C-reactive protein levels and prognosis in patients with previous myocardial infarction – A report from the CHART-2 Study. International Journal of Cardiology 293, 17-24.
          • Romain Riscal, Nicolas Skuli, M. Celeste Simon. (2019) Even Cancer Cells Watch Their Cholesterol!. Molecular Cell 76:2, 220-231.
          • Geon-Hee Kim, Sang-Yeon Kan, Hyeji Kang, Sujin Lee, Hyun Myung Ko, Ji Hyung Kim, Ji-Hong Lim. (2019) Ursolic Acid Suppresses Cholesterol Biosynthesis and Exerts Anti-Cancer Effects in Hepatocellular Carcinoma Cells. International Journal of Molecular Sciences 20:19, 4767.
          • Romana-Rea Begicevic, Frank Arfuso, Marco Falasca. (2019) Bioactive lipids in cancer stem cells. World Journal of Stem Cells 11:9, 693-704.
          • Zhiyuan Zhu, Pingde Zhang, Ning Li, Karrie Mei Yee Kiang, Stephen Yin Cheng, Vincent Kam-Wai Wong, Gilberto Ka-Kit Leung. (2019) Lovastatin Enhances Cytotoxicity of Temozolomide via Impairing Autophagic Flux in Glioblastoma Cells. BioMed Research International 2019, 1-12.
          • Takuya Oikawa, Yasuhiko Sakata, Kotaro Nochioka, Masanobu Miura, Ruri Abe, Shintaro Kasahara, Masayuki Sato, Hajime Aoyanagi, Takashi Shiroto, Koichiro Sugimura, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa. (2019) Increased risk of cancer death in patients with chronic heart failure with a special reference to inflammation-A report from the CHART-2 Study. International Journal of Cardiology 290, 106-112.
          • Hyeji Kang, Taerim Oh, Young Yil Bahk, Geon-Hee Kim, Sang-Yeon Kan, Dong Hoon Shin, Ji Hyung Kim, Ji-Hong Lim. (2019) HSF1 Regulates Mevalonate and Cholesterol Biosynthesis Pathways. Cancers 11:9, 1363.
          • Yun Rose Li, Vicky Ro, Laura Steel, Elena Carrigan, Jenny Nguyen, Austin Williams, Alycia So, Julia Tchou. (2019) Impact of long-term lipid-lowering therapy on clinical outcomes in breast cancer. Breast Cancer Research and Treatment 176:3, 669-677.
          • Yong Cui, Wanqing Wen, Tao Zheng, Honglan Li, Yu-Tang Gao, Hui Cai, Mingrong You, Jing Gao, Gong Yang, Wei Zheng, Yong-Bing Xiang, Xiao-Ou Shu. (2019) Use of Antihypertensive Medications and Survival Rates for Breast, Colorectal, Lung, or Stomach Cancer. American Journal of Epidemiology 188:8, 1512-1528.
          • Takuji Hayashi, Kazutoshi Fujita, Makoto Matsushita, Norio Nonomura. (2019) Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer. Cancers 11:8, 1153.
          • Eva Neumann, Peter Klaiber, Kathleen Freitag, Matthias Schwab, Elke Schaeffeler, Jörg Hennenlotter, Falko Fend, Stephan Kruck, Marcus Scharpf, Arnulf Stenzl, Jens Bedke, Steffen Rausch. (2019) Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation. Journal of Cancer Research and Clinical Oncology 145:7, 1835-1843.
          • Xingzhe Ma, Enguang Bi, Yong Lu, Pan Su, Chunjian Huang, Lintao Liu, Qiang Wang, Maojie Yang, Matthew F. Kalady, Jianfei Qian, Aijun Zhang, Anisha A. Gupte, Dale J. Hamilton, Chengyun Zheng, Qing Yi. (2019) Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment. Cell Metabolism 30:1, 143-156.e5.
          • Kimia Sheikholeslami, Annan Ali Sher, Sandhini Lockman, Daniel Kroft, Meysam Ganjibakhsh, Kazem Nejati-Koshki, Shahla Shojaei, Saeid Ghavami, Mojgan Rastegar. (2019) Simvastatin Induces Apoptosis in Medulloblastoma Brain Tumor Cells via Mevalonate Cascade Prenylation Substrates. Cancers 11:7, 994.
          • Yue Li, Xingkang He, Yu’e Ding, Hongyang Chen, Leimin Sun. (2019) Statin uses and mortality in colorectal cancer patients: An updated systematic review and meta‐analysis. Cancer Medicine 8:6, 3305-3313.
          • Logan Vincent, Douglas Leedy, Sofia Carolina Masri, Richard K. Cheng. (2019) Cardiovascular Disease and Cancer: Is There Increasing Overlap?. Current Oncology Reports 21:6.
          • Sidse Ehmsen, Martin H. Pedersen, Guisong Wang, Mikkel G. Terp, Amina Arslanagic, Brian L. Hood, Thomas P. Conrads, Rikke Leth-Larsen, Henrik J. Ditzel. (2019) Increased Cholesterol Biosynthesis Is a Key Characteristic of Breast Cancer Stem Cells Influencing Patient Outcome. Cell Reports 27:13, 3927-3938.e6.
          • Shifei Wang, Jiancheng Xiu, Wangjun Liao, Yulin Liao, Jianping Bin. (2019) Relative Effect of Current Intensive Lipid-Lowering Drugs on Cardiovascular Outcomes in Secondary Prevention ― A Meta-Analysis of 12 Randomized Trials ―. Circulation Journal 83:6, 1356-1367.
          • Meysam Gachpazan, Hoda Kashani, Majid Khazaei, Seyed Mahdi Hassanian, Majid Rezayi, Fereshteh Asgharzadeh, Majid Ghayour-Mobarhan, Gordon A. Ferns, Amir Avan. (2019) The Impact of Statin Therapy on the Survival of Patients with Gastrointestinal Cancer. Current Drug Targets 20:7, 738-747.
          • Li‐Ting Kao, Shih‐Han Hung, Pai‐Feng Kao, Ju‐Chi Liu, Herng‐Ching Lin. (2019) Inverse association between statin use and head and neck cancer: Population‐based case‐control study in Han population. Head & Neck 41:5, 1193-1198.
          • Anders H. Riis, Rune Erichsen, Eva B. Ostenfeld, Carsten S. Højskov, Ole Thorlacius‐Ussing, Mogens Tornby Stender, Timothy L. Lash, Holger Jon Møller. (2019) Validating registry data on statins prescriptions by blood measurements. Pharmacoepidemiology and Drug Safety 28:5, 609-615.
          • Jui-Ming Liu, Tien-Hsing Chen, Heng-Chang Chuang, Chun-Te Wu, Ren-Jun Hsu. (2019) Statin reduces the risk of dementia in diabetic patients receiving androgen deprivation therapy for prostate cancer. Prostate Cancer and Prostatic Diseases 22:2, 276-283.
          • Andrew D. Spence, John Busby, Carmel M. Hughes, Brian T. Johnston, Helen G. Coleman, Chris R. Cardwell. (2019) Statin use and survival in patients with gastric cancer in two independent population‐based cohorts. Pharmacoepidemiology and Drug Safety 28:4, 460-470.
          • Olivia Lacroix, Alexandra Couttenier, Evelien Vaes, Chris R. Cardwell, Harlinde De Schutter, Annie Robert. (2019) Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study. Cancer Causes & Control 30:4, 385-393.
          • Raewyn J Hopkins, Robert P Young. (2019) Mevalonate signaling, COPD and cancer: the statins and beyond. Journal of Investigative Medicine 67:4, 711-714.
          • Leila Pirmoradi, Nayer Seyfizadeh, Saeid Ghavami, Amir A Zeki, Shahla Shojaei. (2019) Targeting cholesterol metabolism in glioblastoma: a new therapeutic approach in cancer therapy. Journal of Investigative Medicine 67:4, 715-719.
          • Qing Ma, Yang Gao, Pei Xu, Kai Li, Xiaolong Xu, Jingbo Gao, Yuwen Qi, Jingjing Xu, Yan Yang, Wenjing Song, Xin He, Shuting Liu, Xiaoning Yuan, Weinan Yin, Yanqi He, Wenting Pan, Lei Wei, Jingwei Zhang. (2019) Atorvastatin Inhibits Breast Cancer Cells by Downregulating PTEN/AKT Pathway via Promoting Ras Homolog Family Member B (RhoB). BioMed Research International 2019, 1-15.
          • Michael Fattouh, Gina Y. Chang, Thomas J. Ow, Keivan Shifteh, Gregory Rosenblatt, Viraj M. Patel, Richard V. Smith, Michael B. Prystowsky, Nicolas F. Schlecht. (2019) Association between pretreatment obesity, sarcopenia, and survival in patients with head and neck cancer. Head & Neck 41:3, 707-714.
          • Marcia A. Ciccone, Stephanie A. Whitman, Charlotte L. Conturie, Niquelle Brown, Christina E. Dancz, Begum Özel, Koji Matsuo. (2019) Effectiveness of progestin-based therapy for morbidly obese women with complex atypical hyperplasia. Archives of Gynecology and Obstetrics 299:3, 801-808.
          • Yu-Jin Kwon, Na-Young You, Jae-Woo Lee, Joungyoun Kim, Hee-Taik Kang. (2019) High Receipt of Statins Reduces the Risk of Lung Cancer in Current Smokers With Hypercholesterolemia: The National Health Insurance Service–Health Screening Cohort. Clinical Lung Cancer 20:2, e177-e185.
          • Abhinav Gupta, William Stokes, Megan Eguchi, Mohammad Hararah, Arya Amini, Adam Mueller, Rustain Morgan, Cathy Bradley, David Raben, Jessica McDermott, Sana D Karam. (2019) Statin use associated with improved overall and cancer specific survival in patients with head and neck cancer. Oral Oncology 90, 54-66.
          • Yafei Chen, Xiaoli Li, Rui Zhang, Yuhong Xia, Zhuo Shao, Zubing Mei. (2019) Effects of statin exposure and lung cancer survival: A meta-analysis of observational studies. Pharmacological Research 141, 357-365.
          • Nicholas Theodosakis, Casey G. Langdon, Goran Micevic, Irina Krykbaeva, Robert E. Means, David F. Stern, Marcus W. Bosenberg. (2019) Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment‐resistant melanoma, colorectal, and lung cancer. Pigment Cell & Melanoma Research 32:2, 292-302.
          • Pilar Hoyos, Vittorio Pace, Andrés Alcántara. (2019) Biocatalyzed Synthesis of Statins: A Sustainable Strategy for the Preparation of Valuable Drugs. Catalysts 9:3, 260.
          • Francesca Cortese. (2019) Statins: Are they really all the same?. Current Vascular Pharmacology 17:3, 211-212.
          • Amira Saleh, Hassan M. ElFayoumi, Mahmoud Youns, Waleed Barakat. (2019) Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions. Naunyn-Schmiedeberg’s Archives of Pharmacology 392:2, 165-175.
          • Oscar Calvillo-Argüelles, Husam Abdel-Qadir, Maria Michalowska, Filio Billia, Sivisan Suntheralingam, Eitan Amir, Paaladinesh Thavendiranathan. (2019) Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy. Canadian Journal of Cardiology 35:2, 153-159.
          • Anika Dutta, Neelam Sharma-Walia. (2019) Curbing Lipids: Impacts ON Cancer and Viral Infection. International Journal of Molecular Sciences 20:3, 644.
          • India Anderson-Carter, Natasza Posielski, Jinn-ing Liou, Tariq A. Khemees, Tracy M. Downs, E. Jason Abel, David F. Jarrard, Kyle A. Richards. (2019) The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study. Urologic Oncology: Seminars and Original Investigations 37:2, 130-137.
          • Connie B. Newman, David Preiss, Jonathan A. Tobert, Terry A. Jacobson, Robert L. Page, Larry B. Goldstein, Clifford Chin, Lisa R. Tannock, Michael Miller, Geetha Raghuveer, P. Barton Duell, Eliot A. Brinton, Amy Pollak, Lynne T. Braun, Francine K. Welty, . (2019) Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 39:2.
          • Kyohei Marume, Seiji Takashio, Toshiyuki Nagai, Kenichi Tsujita, Yoshihiko Saito, Tsutomu Yoshikawa, Toshihisa Anzai. (2019) Effect of Statins on Mortality in Heart Failure With Preserved Ejection Fraction Without Coronary Artery Disease ― Report From the JASPER Study ―. Circulation Journal 83:2, 357-367.
          • Daniel D. Waller, Jaeok Park, Youla S. Tsantrizos. (2019) Inhibition of farnesyl pyrophosphate (FPP) and/or geranylgeranyl pyrophosphate (GGPP) biosynthesis and its implication in the treatment of cancers. Critical Reviews in Biochemistry and Molecular Biology 54:1, 41-60.
          • E. Andrew Ochroch, Gavin Michael Wright, Bernhard J. C. J. Riedel. 2019. Anesthesia for Open Pulmonary Resection: A Systems Approach. Principles and Practice of Anesthesia for Thoracic Surgery, 389-412.
          • Hans Carl Hasselbalch, Morten Orebo Holmström. (2019) Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?. Seminars in Immunopathology 41:1, 5-19.
          • Woo-Young Kim. (2019) Therapeutic targeting of lipid synthesis metabolism for selective elimination of cancer stem cells. Archives of Pharmacal Research 42:1, 25-39.
          • Sung-Hwan Moon, Chun-Hao Huang, Shauna L. Houlihan, Kausik Regunath, William A. Freed-Pastor, John P. Morris, Darjus F. Tschaharganeh, Edward R. Kastenhuber, Anthony M. Barsotti, Rachel Culp-Hill, Wen Xue, Yu-Jui Ho, Timour Baslan, Xiang Li, Allison Mayle, Elisa de Stanchina, Lars Zender, David R. Tong, Angelo D’Alessandro, Scott W. Lowe, Carol Prives. (2019) p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression. Cell 176:3, 564-580.e19.
          • Chau L.B. Ho, Enayet K. Chowdhury, Monique Breslin, Jenny Doust, Christopher M. Reid, Lindon M.H. Wing, Mark R. Nelson, Lawrence J. Beilin, Garry L. Jennings, Collin I. Johnston, Graham J. Macdonald, John E. Marley, John J. McNeil, Trefor O. Morgan, Christopher M. Reid, Philip Ryan, Malcolm J. West, Lindon M.H. Wing. (2019) Short- and long-term association of lipid-lowering drug treatment and cardiovascular disease by estimated absolute risk in the Second Australian National Blood Pressure study. Journal of Clinical Lipidology 13:1, 148-155.
          • Angeliki Kotti, Annica Holmqvist, Maria Albertsson, Xiao-Feng Sun. (2019) Survival benefit of statins in older patients with rectal cancer: A Swedish population-based cohort study. Journal of Geriatric Oncology.
          • Amel B. Ibrahim, Hala F. Zaki, Walaa W. Ibrahim, Mervat M. Omran, Samia A. Shouman. (2019) Evaluation of tamoxifen and simvastatin as the combination therapy for the treatment of hormonal dependent breast cancer cells. Toxicology Reports 6, 1114-1126.
          • Stephanie S. Faubion, Ekta Kapoor, Ann M. Moyer, Howard N. Hodis, Virginia M. Miller. (2019) Statin therapy: does sex matter?. Menopause 26:12, 1425-1435.
          • Yusuke Kobayashi, Kouji Banno, Haruko Kunitomi, Eiichiro Tominaga, Daisuke Aoki. (2019) Current state and outlook for drug repositioning anticipated in the field of ovarian cancer. Journal of Gynecologic Oncology 30:1.
          • Tae-Wook Kong, Hee-Sug Ryu, Seung Cheol Kim, Takayuki Enomoto, Jin Li, Kenneth H. Kim, Seung-Hyuk Shim, Peng-Hui Wang, Suwanit Therasakvichya, Yusuke Kobayashi, Maria Lee, Tingyan Shi, Shin-Wha Lee, Mikio Mikami, Satoru Nagase, Myong Cheol Lim, Jianliu Wang, Sarikapan Wilailak, Sang Wun Kim, Sook-Hee Hong, David SP Tan, Masaki Mandai, Suk-Joon Chang, Ruby Yun-Ju Huang, Kimio Ushijima, Jung-Yun Lee, Xiaojun Chen, Kazunori Ochiai, Taek Sang Lee, Bingyi Yang, Farhana Kalam, Qiaoying Lv, Mohd Faizal Ahmad, Muhammad Rizki Yaznil, Kanika Batra Modi, Manatsawee Manopunya, Dae Hoon Jeong, Arb-aroon Lertkhachonsuk, Hyun Hoon Chung, Hidemichi Watari, Seob Jeon. (2019) Asian Society of Gynecologic Oncology International Workshop 2018. Journal of Gynecologic Oncology 30:2.
          • E. S. Luboyatnikova, A. R. Kiselev, M. V. Komarova, V. A. Rodionova, E. V. Kapp, D. V. Duplyakov. (2018) ST-Elevation Myocardial Infarction in Patients With Malignancies. Kardiologiia 58:12, 5-12.
          • Mohammed A. M. Farooqi, Nikita Malhotra, Som D. Mukherjee, Stephanie Sanger, Sukhbinder K. Dhesy-Thind, Peter Ellis, Darryl P. Leong, Robert M. Lafrenie. (2018) Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials. PLOS ONE 13:12, e0209486.
          • Corinna Seliger, Julia Schaertl, Michael Gerken, Christian Luber, Martin Proescholdt, Markus J. Riemenschneider, Michael F. Leitzmann, Peter Hau, Monika Klinkhammer-Schalke, Helen Fillmore. (2018) Use of statins or NSAIDs and survival of patients with high-grade glioma. PLOS ONE 13:12, e0207858.
          • Cecilie D. Sperling, Freija Verdoodt, Merete Kjaer Hansen, Christian Dehlendorff, Søren Friis, Susanne K. Kjaer. (2018) Statin use and mortality among endometrial cancer patients: a Danish nationwide cohort study. International Journal of Cancer 143:11, 2668-2676.
          • Barbara Lettiero, Maria Inasu, Siker Kimbung, Signe Borgquist. (2018) Insensitivity to atorvastatin is associated with increased accumulation of intracellular lipid droplets and fatty acid metabolism in breast cancer cells. Scientific Reports 8:1.
          • Christine Wasinger, Alexandra Hofer, Oliver Spadiut, Martin Hohenegger. (2018) Amino Acid Signature in Human Melanoma Cell Lines from Different Disease Stages. Scientific Reports 8:1.
          • Manal Mehibel, Fernando Ortiz-Martinez, Nadine Voelxen, Amy Boyers, Amy Chadwick, Brian A. Telfer, Wolfgang Mueller-Klieser, Catharine M. West, Susan E. Critchlow, Kaye J. Williams, Ian J. Stratford. (2018) Statin-induced metabolic reprogramming in head and neck cancer: a biomarker for targeting monocarboxylate transporters. Scientific Reports 8:1.
          • Claire H. Pernar, Ericka M. Ebot, Kathryn M. Wilson, Lorelei A. Mucci. (2018) The Epidemiology of Prostate Cancer. Cold Spring Harbor Perspectives in Medicine 8:12, a030361.
          • Shahla Shojaei, Javad Alizadeh, James Thliveris, Navid Koleini, Elissavet Kardami, Grant M Hatch, Fred Xu, Sabine Hombach-Klonisch, Thomas Klonisch, Saeid Ghavami. (2018) Statins: a new approach to combat temozolomide chemoresistance in glioblastoma. Journal of Investigative Medicine 66:8, 1083-1087.
          • Elina Urpilainen, Mikko Marttila, Ari Hautakoski, Martti Arffman, Reijo Sund, Pirjo Ilanne-Parikka, Reetta Arima, Jenni Kangaskokko, Ulla Puistola, Marianne Hinkula, Esa Läärä. (2018) Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study. BMC Cancer 18:1.
          • Zhaojun Shen, Saisai Li, Bo Sheng, Qi Shen, Lu-Zhe Sun, Haiyan Zhu, Xueqiong Zhu. (2018) The role of atorvastatin in suppressing tumor growth of uterine fibroids. Journal of Translational Medicine 16:1.
          • Colin H. Beckwitt, Adam Brufsky, Zoltán N. Oltvai, Alan Wells. (2018) Statin drugs to reduce breast cancer recurrence and mortality. Breast Cancer Research 20:1.
          • Anjana Bhardwaj, Harpreet Singh, Celestine Marie Trinidad, Constance T. Albarracin, Kelly K. Hunt, Isabelle Bedrosian. (2018) The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer. Breast Cancer Research 20:1.
          • Helena Bergström, Elsa Brånvall, Maria Helde-Frankling, Linda Björkhem-Bergman. (2018) Differences in discontinuation of statin treatment in women and men with advanced cancer disease. Biology of Sex Differences 9:1.
          • Matthew H. Ung, Todd A. MacKenzie, Tracy L. Onega, Christopher I. Amos, Chao Cheng. (2018) Statins associate with improved mortality among patients with certain histological subtypes of lung cancer. Lung Cancer 126, 89-96.
          • Miwako Omori, Yusuke Okuma, Taiki Hakozaki, Yukio Hosomi. (2018) Statins improve survival in patients previously treated with nivolumab for advanced non‑small cell lung cancer: An observational study. Molecular and Clinical Oncology.
          • Nick A. Iarrobino, Beant Gill, Mark E. Bernard, Mark V. Mishra, Colin E. Champ. (2018) Targeting Tumor Metabolism With Statins During Treatment for Advanced-stage Pancreatic Cancer. American Journal of Clinical Oncology 41:11, 1125-1131.
          • Chifei Kang, Derek LeRoith, Emily J Gallagher. (2018) Diabetes, Obesity, and Breast Cancer. Endocrinology 159:11, 3801-3812.
          • Jia Li, Ruijuan Liu, Zhengdi Sun, Shifeng Tang, Lu Wang, Cun Liu, Wenge Zhao, Yan Yao, Changgang Sun. (2018) The association between statin use and endometrial cancer survival outcome. Medicine 97:47, e13264.
          • Yazhou He, Xue Li, Danijela Gasevic, Eleanor Brunt, Fiona McLachlan, Marisa Millenson, Maria Timofeeva, John P.A. Ioannidis, Harry Campbell, Evropi Theodoratou. (2018) Statins and Multiple Noncardiovascular Outcomes. Annals of Internal Medicine 169:8, 543.
          • Helga Tryggvadottir, Louise Huzell, Emma Gustbée, Maria Simonsson, Andrea Markkula, Karin Jirström, Carsten Rose, Christian Ingvar, Signe Borgquist, Helena Jernström. (2018) Interactions Between ABCB1 Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients. Frontiers in Oncology 8.
          • Omer Shahab, Rakesh Biswas, James Paik, Haley Bush, Pegah Golabi, Zobair M. Younossi. (2018) Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality. Hepatology Communications 2:10, 1227-1234.
          • Won Kyung Cho, Doo Ho Choi, Won Park, Hyejung Cha, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jonghan Yu, Young-Hyuck Im, Jin Seok Ahn, Yeon Hee Park, Ji-Yeon Kim, Soohyun Ahn. (2018) Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment. Clinical Breast Cancer 18:5, e1141-e1147.
          • Maliha T. Munir, Christopher Ponce, Catherine A. Powell, Kaiser Tarafdar, Teruyoshi Yanagita, Mahua Choudhury, Lauren S. Gollahon, Shaikh M. Rahman. (2018) The contribution of cholesterol and epigenetic changes to the pathophysiology of breast cancer. The Journal of Steroid Biochemistry and Molecular Biology 183, 1-9.
          • Colin H. Beckwitt, Amanda M. Clark, Bo Ma, Diana Whaley, Zoltán N. Oltvai, Alan Wells. (2018) Statins attenuate outgrowth of breast cancer metastases. British Journal of Cancer 119:9, 1094-1105.
          • Yoshio Yamauchi, Maximillian A. Rogers. (2018) Sterol Metabolism and Transport in Atherosclerosis and Cancer. Frontiers in Endocrinology 9.
          • Nisi Zhang, Xiaolong Liang, Chuang Gao, Min Chen, Yiming Zhou, Christopher J. Krueger, Gang Bao, Zhuoran Gong, Zhifei Dai. (2018) Loading Lovastatin into Camptothecin–Floxuridine Conjugate Nanocapsules for Enhancing Anti-metastatic Efficacy of Cocktail Chemotherapy on Triple-negative Breast Cancer. ACS Applied Materials & Interfaces 10:35, 29385-29397.
          • Alfredo Erazo-Oliveras, Natividad R. Fuentes, Rachel C. Wright, Robert S. Chapkin. (2018) Functional link between plasma membrane spatiotemporal dynamics, cancer biology, and dietary membrane-altering agents. Cancer and Metastasis Reviews 37:2-3, 519-544.
          • William A. Stokes, Megan Eguchi, Arya Amini, Mohammad K. Hararah, Ding Ding, Jessica D. McDermott, Cathy J. Bradley, Sana D. Karam. (2018) Survival impact and toxicity of metformin in head and neck cancer: An analysis of the SEER-Medicare dataset. Oral Oncology 84, 12-19.
          • Corinna Seliger, Peter Hau. (2018) Drug Repurposing of Metabolic Agents in Malignant Glioma. International Journal of Molecular Sciences 19:9, 2768.
          • (2018) Idiopathic Pulmonary Fibrosis. N Engl J Med 379:8, 795-798.
            • Cyrus M. Lacbay, Daniel D. Waller, Jaeok Park, Mònica Gómez Palou, Félix Vincent, Xian Fang Huang, Viviane Ta, Albert M. Berghuis, Michael Sebag, Youla S. Tsantrizos. (2018) Unraveling the Prenylation–Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors. Journal of Medicinal Chemistry 61:15, 6904-6917.
            • A. Carmona-Bayonas, P. Jimenez-Fonseca, A. Fernández-Somoano, F. Álvarez-Manceñido, E. Castañón, A. Custodio, F. A. de la Peña, R. M. Payo, L. P. Valiente. (2018) Top ten errors of statistical analysis in observational studies for cancer research. Clinical and Translational Oncology 20:8, 954-965.
            • Tsuyoshi Hamada, Natalia Khalaf, Chen Yuan, Vicente Morales-Oyarvide, Ana Babic, Jonathan A. Nowak, Zhi Rong Qian, Kimmie Ng, Douglas A. Rubinson, Peter Kraft, Edward L. Giovannucci, Meir J. Stampfer, Charles S. Fuchs, Shuji Ogino, Brian M. Wolpin. (2018) Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Clinical Gastroenterology and Hepatology 16:8, 1300-1306.e3.
            • Rahul Potluri, Paul R Carter, Deepthi Lavu, Kevin R Bainey. (2018) The interplay between cholesterol and breast cancer: is there a potential role for statin therapy?. Future Oncology 14:19, 1885-1888.
            • Sarah Dallel, Igor Tauveron, Florence Brugnon, Silvère Baron, Jean Lobaccaro, Salwan Maqdasy. (2018) Liver X Receptors: A Possible Link between Lipid Disorders and Female Infertility. International Journal of Molecular Sciences 19:8, 2177.
            • Yuji Okura, Sumika Ishigaki, Satoko Sakakibara, Chika Yumoto, Mitsue Hashitate, Chika Sekine, Tomomi Fujita, Tsugumi Takayama, Kazuyuki Ozaki, Nobuaki Sato, Tohru Minamino. (2018) Prognosis of Cancer Patients with Aortic Stenosis Under Optimal Cancer Therapies and Conservative Cardiac Treatments. International Heart Journal 59:4, 750-758.
            • Min-Chul Kim, Sung-Cheol Yun, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Jun Hee Woo, Sung-Han Kim, James M Wright. (2018) Statins increase the risk of herpes zoster: A propensity score-matched analysis. PLOS ONE 13:6, e0198263.
            • Xia Li, Jing Zhou. (2018) Impact of postdiagnostic statin use on ovarian cancer mortality: A systematic review and meta-analysis of observational studies. British Journal of Clinical Pharmacology 84:6, 1109-1120.
            • Martyna Zaleska, Olga Mozenska, Jacek Bil. (2018) Statins use and cancer: an update. Future Oncology 14:15, 1497-1509.
            • Colin H. Beckwitt, Keisuke Shiraha, Alan Wells, Saeid Ghavami. (2018) Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling. PLOS ONE 13:5, e0197422.
            • Madhur Nayan, David N. Juurlink, Peter C. Austin, Erin M. Macdonald, Antonio Finelli, Girish S. Kulkarni, Robert J. Hamilton, . (2018) Medication use and kidney cancer survival: A population-based study. International Journal of Cancer 142:9, 1776-1785.
            • Erik R. Nelson. (2018) The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer. Molecular and Cellular Endocrinology 466, 73-80.
            • Iago Pinal-Fernandez, Maria Casal-Dominguez, Andrew L. Mammen. (2018) Statins: pros and cons. Medicina Clínica (English Edition) 150:10, 398-402.
            • Iago Pinal-Fernandez, Maria Casal-Dominguez, Andrew L. Mammen. (2018) Statins: pros and cons. Medicina Clínica 150:10, 398-402.
            • Laura Galbraith, Hing Y. Leung, Imran Ahmad. (2018) Lipid pathway deregulation in advanced prostate cancer. Pharmacological Research 131, 177-184.
            • Kathryn P. Trogden, Rachel A. Battaglia, Parijat Kabiraj, Victoria J. Madden, Harald Herrmann, Natasha T. Snider. (2018) An image‐based small‐molecule screen identifies vimentin as a pharmacologically relevant target of simvastatin in cancer cells. The FASEB Journal 32:5, 2841-2854.
            • Franziska K�ssner, Tina Sauer, Melanie Penke, Sandy Richter, Kathrin Landgraf, Antje K�rner, Wieland Kiess, Norman H�ndel, Antje Garten. (2018) Simvastatin induces apoptosis in PTEN‑haploinsufficient lipoma cells. International Journal of Molecular Medicine.
            • Tomoaki Terakawa, Eriko Katsuta, Li Yan, Nitesh Turaga, Kerry-Ann McDonald, Masato Fujisawa, Khurshid A. Guru, Kazuaki Takabe. (2018) High expression of SLCO2B1 is associated with prostate cancer recurrence after radical prostatectomy. Oncotarget 9:18, 14207-14218.
            • Joshua C. Denny, Sara L. Van Driest, Wei-Qi Wei, Dan M. Roden. (2018) The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development. Clinical Pharmacology & Therapeutics 103:3, 409-418.
            • Neda Bayat, Somayeh Ebrahimi-Barough, Abbas Norouzi-Javidan, Hooshang Saberi, Mohammad Mehdi Mokhtari Ardakan, Arman Ai, Mostafa Soleimannejad, Jafar Ai. (2018) Anti-inflammatory Effects of Atorvastatin by Suppressing TRAF3IP2 and IL-17RA in Human Glioblastoma Spheroids Cultured in a Three-dimensional Model: Possible Relevance to Glioblastoma Treatment. Molecular Neurobiology 55:3, 2102-2110.
            • Hongwei Xia, Xinyu Dai, Huangfei Yu, Sheng Zhou, Zhenghai Fan, Guoqing Wei, Qiulin Tang, Qiyong Gong, Feng Bi. (2018) EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy. Cell Death & Disease 9:3.
            • Rosemary Yu, Joseph Longo, Jenna E. van Leeuwen, Peter J. Mullen, Wail Ba-Alawi, Benjamin Haibe-Kains, Linda Z. Penn. (2018) Statin-Induced Cancer Cell Death Can Be Mechanistically Uncoupled from Prenylation of RAS Family Proteins. Cancer Research 78:5, 1347-1357.
            • Hassan Alhazmi, Ahmed Alnami, Mohammed Arishi, Raad Alameer, Mohammed Al Bratty, Zia Rehman, Sadique Javed, Ismail Arbab. (2018) A Fast and Validated Reversed-Phase HPLC Method for Simultaneous Determination of Simvastatin, Atorvastatin, Telmisartan and Irbesartan in Bulk Drugs and Tablet Formulations. Scientia Pharmaceutica 86:1, 1.
            • Tina Fransgaard, Lau Caspar Thygesen, Ismail Gögenur. (2018) Statin use is not associated with improved 30-day survival in patients undergoing surgery for colorectal cancer. International Journal of Colorectal Disease 33:2, 199-207.
            • Bernardo Cacho-Díaz, Nydia A. Lorenzana-Mendoza, Héctor Spínola-Maroño, Gervith Reyes-Soto, Carlos Cantú-Brito. (2018) Comorbidities, Clinical Features, and Prognostic Implications of Cancer Patients with Cerebrovascular Disease. Journal of Stroke and Cerebrovascular Diseases 27:2, 365-371.
            • Jonathan J. Chen, Lorenzo Galluzzi. (2018) Fighting Resilient Cancers with Iron. Trends in Cell Biology 28:2, 77-78.
            • Koji Matsuo, Malcolm S. Ross, Dwight D. Im, Merieme M. Klobocista, Stephen H. Bush, Marian S. Johnson, Tadao Takano, Erin A. Blake, Yuji Ikeda, Masato Nishimura, Yutaka Ueda, Masako Shida, Kosei Hasegawa, Tsukasa Baba, Sosuke Adachi, Takuhei Yokoyama, Shinya Satoh, Hiroko Machida, Shiori Yanai, Keita Iwasaki, Takahito M. Miyake, Satoshi Takeuchi, Munetaka Takekuma, Tadayoshi Nagano, Mayu Yunokawa, Tanja Pejovic, Kohei Omatsu, Mian M.K. Shahzad, Joseph L. Kelley, Frederick R. Ueland, Lynda D. Roman. (2018) Significance of venous thromboembolism in women with uterine carcinosarcoma. Gynecologic Oncology 148:2, 267-274.
            • Maylein Juan-Rivera, Magaly Martínez-Ferrer. (2018) Integrin Inhibitors in Prostate Cancer. Cancers 10:2, 44.
            • Efstathios T. Pavlidis, Theodoros E. Pavlidis. (2018) Current Molecular and Genetic Aspects of Pancreatic Cancer, the Role of Metastasis Associated Proteins (MTA): A Review. Journal of Investigative Surgery 31:1, 54-66.
            • Joshua K. Park, Nathan J. Coffey, Aaron Limoges, Anne Le. 2018. The Heterogeneity of Lipid Metabolism in Cancer. The Heterogeneity of Cancer Metabolism, 33-55.
            • Vineet K. Raghu, Colin H. Beckwitt, Katsuhiko Warita, Alan Wells, Panayiotis V. Benos, Zoltán N. Oltvai. (2018) Biomarker identification for statin sensitivity of cancer cell lines. Biochemical and Biophysical Research Communications 495:1, 659-665.
            • J. Busby, Ú. McMenamin, A. Spence, B. T. Johnston, C. Hughes, C. R. Cardwell. (2018) Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study. Alimentary Pharmacology & Therapeutics 47:2, 279-288.
            • Knut Stokkeland, Christine Takami Lageborn, Anders Ekbom, Jonas Höijer, Matteo Bottai, Per Stål, Karin Söderberg-Löfdal. (2018) Statins and Angiotensin-Converting Enzyme Inhibitors are Associated with Reduced Mortality and Morbidity in Chronic Liver Disease. Basic & Clinical Pharmacology & Toxicology 122:1, 104-110.
            • Moon Kyung Joo, Jong-Jae Park, Hoon Jai Chun. (2018) Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors. Digestive Diseases 36:1, 1-14.
            • Zakaria Almuwaqqat, Olivia Hung, Susmita Parashar. (2018) Statins and cancer survivors: the need for structured guidelines. Future Cardiology 14:1, 5-8.
            • Nick A. Iarrobino, Beant S. Gill, Mark Bernard, Rainer J. Klement, Maria Werner-Wasik, Colin E. Champ. (2018) The Impact of Serum Glucose, Anti-Diabetic Agents, and Statin Usage in Non-small Cell Lung Cancer Patients Treated With Definitive Chemoradiation. Frontiers in Oncology 8.
            • Alexandra Couttenier, Olivia Lacroix, Evelien Vaes, Chris R. Cardwell, Harlinde De Schutter, Annie Robert, Xing Xie. (2017) Statin use is associated with improved survival in ovarian cancer: A retrospective population-based study. PLOS ONE 12:12, e0189233.
            • Jari Haukka, Leo Niskanen, Anssi Auvinen. (2017) Risk of Cause-Specific Death in Individuals with Cancer-Modifying Role Diabetes, Statins and Metformin. International Journal of Cancer 141:12, 2437-2449.
            • Amy E. Baek, Yen-Rei A. Yu, Sisi He, Suzanne E. Wardell, Ching-Yi Chang, Sanghoon Kwon, Ruchita V. Pillai, Hannah B. McDowell, J. Will Thompson, Laura G. Dubois, Patrick M. Sullivan, Jongsook K. Kemper, Michael D. Gunn, Donald P. McDonnell, Erik R. Nelson. (2017) The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nature Communications 8:1.
            • Yan-Rong Li, Sung-Sheng Tsai, Yu-Sheng Lin, Chang-Min Chung, Szu-Tah Chen, Jui-Hung Sun, Miaw-Jene Liou, Tien-Hsing Chen. (2017) Moderate- to high-intensity statins for secondary prevention in patients with type 2 diabetes mellitus on dialysis after acute myocardial infarction. Diabetology & Metabolic Syndrome 9:1.
            • Mo Zhou, Jinkai Zheng, Jinfeng Bi, Xinye Wu, Jian Lyu, Kun Gao. (2017) Synergistic inhibition of colon cancer cell growth by a combination of atorvastatin and phloretin. Oncology Letters.
            • Isobel Okoye, Afshin Namdar, Lai Xu, Nicole Crux, Shokrollah Elahi. (2017) Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling. Oncotarget 8:58, 98215-98232.
            • Sinor Soltanizadeh, Thea H. Degett, Ismail Gögenur. (2017) Outcomes of cancer surgery after inhalational and intravenous anesthesia: A systematic review. Journal of Clinical Anesthesia 42, 19-25.
            • Edyta Idalia Wolny-Rokicka, Andrzej Tukiendorf, Jerzy Wydmański, Agnieszka Zembroń-Łacny. (2017) The Comparison and Estimation of the Prognostic Value of Lipid Profiles in Patients With Prostate Cancer Depends on Cancer Stage Advancement. American Journal of Men’s Health 11:6, 1745-1751.
            • Christina Blücher, Sonja C. Stadler. (2017) Obesity and Breast Cancer: Current Insights on the Role of Fatty Acids and Lipid Metabolism in Promoting Breast Cancer Growth and Progression. Frontiers in Endocrinology 8.
            • Ting-Fang Lee, Yu-Chi Tseng, Wei-Chin Chang, Yi-Chen Chen, Yu-Rung Kao, Teh-Ying Chou, Chao-Chi Ho, Cheng-Wen Wu. (2017) YAP1 is essential for tumor growth and is a potential therapeutic target for EGFR-dependent lung adenocarcinomas. Oncotarget 8:52, 89539-89551.
            • Signe Benzon Larsen, Christian Dehlendorff, Charlotte Skriver, Susanne Oksbjerg Dalton, Christina Gade Jespersen, Michael Borre, Klaus Brasso, Mette Nørgaard, Christoffer Johansen, Henrik Toft Sørensen, Jesper Hallas, Søren Friis. (2017) Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer. Journal of Clinical Oncology 35:29, 3290-3297.
            • Luyuan Li, Josiane E. Eid, Ana C. Paz, Jonathan C. Trent. (2017) Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy. BioDrugs 31:5, 379-392.
            • Gurdeep Marwarha, Shaneabbas Raza, Kimberly Hammer, Othman Ghribi. (2017) 27-hydroxycholesterol: A novel player in molecular carcinogenesis of breast and prostate cancer. Chemistry and Physics of Lipids 207, 108-126.
            • Yusuke Kobayashi, Hiroyasu Kashima, Yohan Suryo Rahmanto, Kouji Banno, Yu Yu, Yusuke Matoba, Keiko Watanabe, Moito Iijima, Takashi Takeda, Haruko Kunitomi, Miho Iida, Masataka Adachi, Kanako Nakamura, Kosuke Tsuji, Kenta Masuda, Hiroyuki Nomura, Eiichiro Tominaga, Daisuke Aoki. (2017) Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer. Oncotarget 8:42, 72147-72156.
            • Timothy L. Lash, Anders H. Riis, Eva B. Ostenfeld, Rune Erichsen, Mogens Vyberg, Thomas P. Ahern, Ole Thorlacius-Ussing. (2017) Associations of Statin Use With Colorectal Cancer Recurrence and Mortality in a Danish Cohort. American Journal of Epidemiology 186:6, 679-687.
            • Graziela Vieira, Juliana Cavalli, Elaine C. D. Gonçalves, Tainara R. Gonçalves, Larissa R. Laurindo, Maíra Cola, Rafael C. Dutra. (2017) Effects of Simvastatin Beyond Dyslipidemia: Exploring Its Antinociceptive Action in an Animal Model of Complex Regional Pain Syndrome-Type I. Frontiers in Pharmacology 8.
            • Moo-Kon Song, Byoung-Sub Shin, Chung-Sik Ha, Won-Young Park. (2017) Would Lipophilic Statin Therapy as a Prognostic Factor Improve Survival in Patients With Uterine Cervical Cancer?. International Journal of Gynecological Cancer 27:7, 1431-1437.
            • Victor M. Lu, Kerrie L. McDonald. (2017) The current evidence of statin use affecting glioblastoma prognosis. Journal of Clinical Neuroscience 42, 196-197.
            • Tilley Jenkins Vogel, Marc T. Goodman, Andrew J. Li, Christie Y. Jeon. (2017) Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer. Gynecologic Oncology 146:2, 340-345.
            • Thomas J. Schnoeller, Florian Jentzmik, Andres J. Schrader, Julie Steinestel. (2017) Influence of serum cholesterol level and statin treatment on prostate cancer aggressiveness. Oncotarget 8:29, 47110-47120.
            • Freija Verdoodt, Merete Kjaer Hansen, Susanne K. Kjaer, Anton Pottegård, Søren Friis, Christian Dehlendorff. (2017) Statin use and mortality among ovarian cancer patients: A population-based cohort study. International Journal of Cancer 141:2, 279-286.
            • Min-Huey Chung, Yi-Wen Wang, Yung-Lung Chang, Shih-Ming Huang, Wei-Shiang Lin. (2017) Risk of cancer in patients with heart failure who use digoxin: a 10-year follow-up study and cell-based verification. Oncotarget 8:27, 44203-44216.
            • Weimin Xie, Li Ning, Yuenan Huang, Yan Liu, Wen Zhang, Yingchao Hu, Jinghe Lang, Jiaxin Yang. (2017) Statin use and survival outcomes in endocrine-related gynecologic cancers: A systematic review and meta-analysis. Oncotarget 8:25, 41508-41517.
            • Konrad H. Stopsack, Alexandra J. Greenberg, Lorelei A. Mucci. (2017) Common medications and prostate cancer mortality: a review. World Journal of Urology 35:6, 875-882.
            • Sarah E. Ackerman, Olivia A. Blackburn, François Marchildon, Paul Cohen. (2017) Insights into the Link Between Obesity and Cancer. Current Obesity Reports 6:2, 195-203.
            • Yangling Li, Miao Xian, Bo Yang, Meidan Ying, Qiaojun He. (2017) Inhibition of KLF4 by Statins Reverses Adriamycin-Induced Metastasis and Cancer Stemness in Osteosarcoma Cells. Stem Cell Reports 8:6, 1617-1629.
            • A. G. Olsson, B. Angelin, G. Assmann, C. J. Binder, I. Björkhem, A. Cedazo-Minguez, J. Cohen, A. von Eckardstein, E. Farinaro, D. Müller-Wieland, K. G. Parhofer, P. Parini, R. S. Rosenson, J. Starup-Linde, M. J. Tikkanen, L. Yvan-Charvet. (2017) Can LDL cholesterol be too low? Possible risks of extremely low levels. Journal of Internal Medicine 281:6, 534-553.
            • Michael J. Seckl, Christian H. Ottensmeier, Michael Cullen, Peter Schmid, Yenting Ngai, Dakshinamoorthy Muthukumar, Joyce Thompson, Susan Harden, Gary Middleton, Kate M. Fife, Barbara Crosse, Paul Taylor, Stephen Nash, Allan Hackshaw. (2017) Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). Journal of Clinical Oncology 35:14, 1506-1514.
            • Hisham Atef. (2017) Statins and Cancer Mortality; Do We Need Randomized, Controlled Trials?. Journal of Cancer Prevention & Current Research 8:1.
            • Zuozhang Yang, Zhenyi Su, Judy Park DeWitt, Lin Xie, Yongbin Chen, Xiaojuan Li, Lei Han, Dongqi Li, Junfeng Xia, Ya Zhang, Yihao Yang, Congguo Jin, Jing Zhang, Su Li, Kun Li, Zhiping Zhang, Xin Qu, Zewei He, Yanjin Chen, Yan Shen, Mingyan Ren, Zhongqin Yuan. (2017) Fluvastatin Prevents Lung Adenocarcinoma Bone Metastasis by Triggering Autophagy. EBioMedicine 19, 49-59.
            • Ran Li, Ye-Hua Gan. (2017) Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-Iβ Expression. International Journal of Molecular Sciences 18:5, 1010.
            • Signe Borgquist, Anita Giobbie-Hurder, Thomas P. Ahern, Judy E. Garber, Marco Colleoni, István Láng, Marc Debled, Bent Ejlertsen, Roger von Moos, Ian Smith, Alan S. Coates, Aron Goldhirsch, Manuela Rabaglio, Karen N. Price, Richard D. Gelber, Meredith M. Regan, Beat Thürlimann. (2017) Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. Journal of Clinical Oncology 35:11, 1179-1188.
            • Teemu J. Murtola, Antti I. Peltomaa, Kirsi Talala, Liisa Määttänen, Kimmo Taari, Teuvo L.J. Tammela, Anssi Auvinen. (2017) Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer. European Urology Focus 3:2-3, 212-220.
            • Anne Blaes, Anna Prizment, Ryan J. Koene, Suma Konety. (2017) Cardio-oncology Related to Heart Failure. Heart Failure Clinics 13:2, 367-380.
            • Michelle J. Mayer, Laurence H. Klotz, Vasundara Venkateswaran. (2017) The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer. Journal of Urology 197:4, 1068-1075.
            • Uffe Ravnskov. (2017) Comment on ‘Statin use and all-cancer survival: prospective results from the Women’s Health Initiative’. British Journal of Cancer 116:8, e9-e9.
            • Helena Gbelcová, Silvie Rimpelová, Tomáš Ruml, Marie Fenclová, Vítek Kosek, Jana Hajšlová, Hynek Strnad, Michal Kolář, Libor Vítek. (2017) Variability in statin-induced changes in gene expression profiles of pancreatic cancer. Scientific Reports 7:1.
            • Javad Alizadeh, Amir A. Zeki, Nima Mirzaei, Sandipan Tewary, Adel Rezaei Moghadam, Aleksandra Glogowska, Pandian Nagakannan, Eftekhar Eftekharpour, Emilia Wiechec, Joseph W. Gordon, Fred. Y. Xu, Jared T. Field, Ken Y. Yoneda, Nicholas J. Kenyon, Mohammad Hashemi, Grant M. Hatch, Sabine Hombach-Klonisch, Thomas Klonisch, Saeid Ghavami. (2017) Mevalonate Cascade Inhibition by Simvastatin Induces the Intrinsic Apoptosis Pathway via Depletion of Isoprenoids in Tumor Cells. Scientific Reports 7:1.
            • Mahmoud A. Alfaqih, Erik R. Nelson, Wen Liu, Rachid Safi, Jeffery S. Jasper, Everardo Macias, Joseph Geradts, J. Will Thompson, Laura G. Dubois, Michael R. Freeman, Ching-yi Chang, Jen-Tsan Chi, Donald P. McDonnell, Stephen J. Freedland. (2017) CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer. Cancer Research 77:7, 1662-1673.
            • Zubing Mei, Mining Liang, Lezhi Li, Yi Zhang, Qingming Wang, Wei Yang. (2017) Effects of statins on cancer mortality and progression: A systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals. International Journal of Cancer 140:5, 1068-1081.
            • Garret Ma, Idris Samad, Kevin Motz, Linda X. Yin, Madhavi V. Duvvuri, Dacheng Ding, Daryan R. Namba, Jennifer H. Elisseeff, Maureen R. Horton, Alexander T. Hillel. (2017) Metabolic variations in normal and fibrotic human laryngotracheal-derived fibroblasts: A Warburg-like effect. The Laryngoscope 127:3, E107-E113.
            • Hiroshi Yokomichi, Akiko Nagai, Makoto Hirata, Akiko Tamakoshi, Yutaka Kiyohara, Yoichiro Kamatani, Kaori Muto, Toshiharu Ninomiya, Koichi Matsuda, Michiaki Kubo, Yusuke Nakamura, Zentaro Yamagata, Kazuo Misumi, Nobuyoshi Higa, Sunao Matsubayashi, Kei Matsuura, Shiro Minami, Hitoshi Sugihara, Naoya Emoto, Hirotoshi Ohmura, Akihiro Inui, Michihiro Ogasawara, Satoshi Asai, Mitsu- hiko Moriyama, Yasuo Takahashi, Tomoaki Fujioka, Wataru Obara, Seijiro Mori, Hideki Ito, Satoshi Nagayama, Yoshio Miki, Akihide Masumoto, Akira Yamada, Yasuko Nishizawa, Ken Kodama, Satoshi Ugi, Hiroshi Maegawa, Yukihiro Koretsune, Hideo Kusuoka, Masako Ueyama. (2017) Statin use and all-cause and cancer mortality: BioBank Japan cohort. Journal of Epidemiology 27:3, S84-S91.
            • Lee Mozessohn, Craig Earle, David Spaner, Stephanie Y. Cheng, Matthew Kumar, Rena Buckstein. (2017) The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based Study. Journal of the National Cancer Institute 109:3, djw226.
            • Rose Gilbert, Ahmed Al-Janabi, Oren Tomkins-Netzer, Sue Lightman. (2017) Statins as anti-inflammatory agents: A potential therapeutic role in sight-threatening non-infectious uveitis. Porto Biomedical Journal 2:2, 33-39.
            • Mahmoud A. Alfaqih, Emma H. Allott, Robert J. Hamilton, Michael R. Freeman, Stephen J. Freedland. (2017) The current evidence on statin use and prostate cancer prevention: are we there yet?. Nature Reviews Urology 14:2, 107-119.
            • Tochi M Okwuosa, Sarah Anzevino, Ruta Rao. (2017) Cardiovascular disease in cancer survivors. Postgraduate Medical Journal 93:1096, 82-90.
            • Ian Fentiman. 2017. Future Directions. Male Breast Cancer, 167-173.
            • Emily J. Gallagher, Brian A. Neel, Irini M. Antoniou, Shoshana Yakar, Derek LeRoith. 2017. The Increased Risk of Cancer in Obesity and Type 2 Diabetes: Potential Mechanisms. Principles of Diabetes Mellitus, 731-753.
            • Emily J. Gallagher, Brian A. Neel, Irini M. Antoniou, Shoshana Yakar, Derek LeRoith. 2017. The Increased Risk of Cancer in Obesity and Type 2 Diabetes: Potential Mechanisms. Principles of Diabetes Mellitus, 1-23.
            • Lorelei A. Mucci, Kathryn M. Wilson, Edward L. Giovannucci. 2017. Epidemiology of Prostate Cancer. Pathology and Epidemiology of Cancer, 107-125.
            • Ryuma Tokunaga, Yasuo Sakamoto, Shigeki Nakagawa, Mayuko Ohuchi, Daisuke Izumi, Keisuke Kosumi, Katsunobu Taki, Takaaki Higashi, Yuji Miyamoto, Naoya Yoshida, Eiji Oki, Masayuki Watanabe, Hideo Baba. (2017) CONUT: a novel independent predictive score for colorectal cancer patients undergoing potentially curative resection. International Journal of Colorectal Disease 32:1, 99-106.
            • Z. Almuwaqqat, O. Hung, S. Parashar. 2017. Statins in Cardio-Oncology. Cardio-Oncology, 209-219.
            • Elizabeth Y. Wang, Jeffrey Dixson, Nelson B. Schiller, Mary A. Whooley. (2017) Causes and Predictors of Death in Patients With Coronary Heart Disease (from the Heart and Soul Study). The American Journal of Cardiology 119:1, 27-34.
            • Madhur Nayan, Nahid Punjani, David N. Juurlink, Antonio Finelli, Peter C. Austin, Girish S. Kulkarni, Elizabeth Uleryk, Robert J. Hamilton. (2017) Statin use and kidney cancer survival outcomes: A systematic review and meta-analysis. Cancer Treatment Reviews 52, 105-116.
            • Ange Wang, Aaron K Aragaki, Jean Y Tang, Allison W Kurian, JoAnn E Manson, Rowan T Chlebowski, Michael Simon, Pinkal Desai, Sylvia Wassertheil-Smoller, Simin Liu, Stephen Kritchevsky, Heather A Wakelee, Marcia L Stefanick. (2017) Reply to Comment on ‘Statin use and all-cancer survival: prospective results from the Women’s Health Initiative’. British Journal of Cancer 116:3, e2-e2.
            • Ubaldo E. Martinez-Outschoorn, Maria Peiris-Pagés, Richard G. Pestell, Federica Sotgia, Michael P. Lisanti. (2017) Cancer metabolism: a therapeutic perspective. Nature Reviews Clinical Oncology 14:1, 11-31.
            • Xiaonan Liu, Jing Li, Steven E. Schild, Michael H. Schild, William Wong, Sujay Vora, Michael G. Herman, Mirek Fatyga. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. Journal of Cancer Therapy 08:02, 73-85.
            • Ask Tybjærg Nordestgaard, Børge Grønne Nordestgaard. (2016) Coffee intake, cardiovascular disease and all-cause mortality: observational and Mendelian randomization analyses in 95 000–223 000 individuals. International Journal of Epidemiology 10, dyw325.
            • Stephen R. Spindler, Patricia L. Mote, James M. Flegal. (2016) Combined statin and angiotensin-converting enzyme (ACE) inhibitor treatment increases the lifespan of long-lived F1 male mice. AGE 38:5-6, 379-391.
            • Ange Wang, Heather A. Wakelee, Aaron K. Aragaki, Jean Y. Tang, Allison W. Kurian, JoAnn E. Manson, Marcia L. Stefanick. (2016) Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?. Current Atherosclerosis Reports 18:12.
            • Mostafa A. Borahay, Xiao Fang, Jacques G. Baillargeon, Gokhan S. Kilic, Darren F. Boehning, Yong-Fang Kuo. (2016) Statin use and uterine fibroid risk in hyperlipidemia patients: a nested case-control study. American Journal of Obstetrics and Gynecology 215:6, 750.e1-750.e8.
            • Ronan T. Gray, Helen G. Coleman, Carmel Hughes, Liam J. Murray, Chris R. Cardwell. (2016) Statin use and survival in colorectal cancer: Results from a population-based cohort study and an updated systematic review and meta-analysis. Cancer Epidemiology 45, 71-81.
            • Daniel Bar, Ofer Lavie, Nili Stein, Ido Feferkorn, Ayelet Shai. (2016) The effect of metabolic comorbidities and commonly used drugs on the prognosis of patients with ovarian cancer. European Journal of Obstetrics & Gynecology and Reproductive Biology 207, 227-231.
            • Úna C. Mc Menamin, Liam J. Murray, Carmel M. Hughes, Chris R. Cardwell. (2016) Statin use and breast cancer survival: a nationwide cohort study in Scotland. BMC Cancer 16:1.
            • Qiaofei Liu, Yuan Li, Zheyu Niu, Yi Zong, Mengyi Wang, Lutian Yao, Zhaohui Lu, Quan Liao, Yupei Zhao. (2016) Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by promoting M2 polarized tumor associated macrophages. Journal of Experimental & Clinical Cancer Research 35:1.
            • Claudia Lanterna, Andrea Musumeci, Laura Raccosta, Gianfranca Corna, Marta Moresco, Daniela Maggioni, Raffaella Fontana, Claudio Doglioni, Claudio Bordignon, Catia Traversari, Vincenzo Russo. (2016) The administration of drugs inhibiting cholesterol/oxysterol synthesis is safe and increases the efficacy of immunotherapeutic regimens in tumor-bearing mice. Cancer Immunology, Immunotherapy 65:11, 1303-1315.
            • Rory Collins, Christina Reith, Jonathan Emberson, Jane Armitage, Colin Baigent, Lisa Blackwell, Roger Blumenthal, John Danesh, George Davey Smith, David DeMets, Stephen Evans, Malcolm Law, Stephen MacMahon, Seth Martin, Bruce Neal, Neil Poulter, David Preiss, Paul Ridker, Ian Roberts, Anthony Rodgers, Peter Sandercock, Kenneth Schulz, Peter Sever, John Simes, Liam Smeeth, Nicholas Wald, Salim Yusuf, Richard Peto. (2016) Interpretation of the evidence for the efficacy and safety of statin therapy. The Lancet 388:10059, 2532-2561.
            • Gregoire F. Le Bras, Muhammad H. Farooq, Gary W. Falk, Claudia D. Andl. (2016) Esophageal cancer: The latest on chemoprevention and state of the art therapies. Pharmacological Research 113, 236-244.
            • Madhur Nayan, Erin M. Macdonald, David N. Juurlink, Peter C. Austin, Antonio Finelli, Girish S. Kulkarni, Robert J. Hamilton. (2016) Medication use and survival in diabetic patients with kidney cancer: A population-based cohort study. Pharmacological Research 113, 468-474.
            • Madhur Nayan, Antonio Finelli, Michael A.S. Jewett, David N. Juurlink, Peter C. Austin, Girish S. Kulkarni, Robert J. Hamilton. (2016) Statin use and kidney cancer outcomes: A propensity score analysis. Urologic Oncology: Seminars and Original Investigations 34:11, 487.e1-487.e6.
            • Peter J. Mullen, Rosemary Yu, Joseph Longo, Michael C. Archer, Linda Z. Penn. (2016) The interplay between cell signalling and the mevalonate pathway in cancer. Nature Reviews Cancer 16:11, 718-731.
            • Willem M. Lijfering, Joseph. S. Biedermann, Marieke J.H.A. Kruip, Frank W.G. Leebeek, Frits R. Rosendaal, Suzanne C. Cannegieter. (2016) Can we prevent venous thrombosis with statins: an epidemiologic review into mechanism and clinical utility. Expert Review of Hematology 9:11, 1023-1030.
            • Karthigayan Shanmugasundaram, Karen Block. (2016) Renal Carcinogenesis, Tumor Heterogeneity, and Reactive Oxygen Species: Tactics Evolved. Antioxidants & Redox Signaling 25:12, 685-701.
            • Alberico L. Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M. John Chapman, Heinz Drexel, Arno W. Hoes, Catriona S. Jennings, Ulf Landmesser, Terje R. Pedersen, Željko Reiner, Gabriele Riccardi, Marja-Riita Taskinen, Lale Tokgozoglu, W. M. Monique Verschuren, Charalambos Vlachopoulos, David A. Wood, Jose Luis Zamorano. (2016) 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal 37:39, 2999-3058.
            • Matias Soncini, Gianfranca Corna, Marta Moresco, Nadia Coltella, Umberto Restuccia, Daniela Maggioni, Laura Raccosta, Chin-Yo Lin, Francesca Invernizzi, Roberto Crocchiolo, Claudio Doglioni, Catia Traversari, Angela Bachi, Rosa Bernardi, Claudio Bordignon, Jan-Åke Gustafsson, Vincenzo Russo. (2016) 24-Hydroxycholesterol participates in pancreatic neuroendocrine tumor development. Proceedings of the National Academy of Sciences 113:41, E6219-E6227.
            • Alberico L. Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M. John Chapman, Heinz Drexel, Arno W. Hoes, Catriona S. Jennings, Ulf Landmesser, Terje R. Pedersen, Željko Reiner, Gabriele Riccardi, Marja-Riita Taskinen, Lale Tokgozoglu, W.M. Monique Verschuren, Charalambos Vlachopoulos, David A. Wood, Jose Luis Zamorano. (2016) 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Atherosclerosis 253, 281-344.
            • Liangcai Wu, Qianqian Xu, Haohai Zhang, Ming Li, Chengpei Zhu, Minjie Jiang, Xinting Sang, Yi Zhao, Qiang Sun, Haitao Zhao. (2016) A new avenue for obtaining insight into the functional characteristics of long noncoding RNAs associated with estrogen receptor signaling. Scientific Reports 6:1.
            • Ju-Yeon Moon, Man Ho Choi, Jayoung Kim. (2016) Metabolic profiling of cholesterol and sex steroid hormones to monitor urological diseases. Endocrine-Related Cancer 23:10, R455-R467.
            • Salim Yusuf. (2016) Why do people not take life-saving medications? The case of statins. The Lancet 388:10048, 943-945.
            • S. Bhavsar, K. Hagan, R. Arunkumar, Y. Potylchansky, R. Grasu, A. Dang, R. Carlson, C. Cowels, B. Arnold, T.F. Rahlfs, I. Lipski, C. Walsh, A.T. Nguyen, L. Feng, J.P. Cata. (2016) Preoperative statin use is not associated with improvement in survival after glioblastoma surgery. Journal of Clinical Neuroscience 31, 176-180.
            • Jenny J. Lin, Nicole Ezer, Keith Sigel, Grace Mhango, Juan P. Wisnivesky. (2016) The effect of statins on survival in patients with stage IV lung cancer. Lung Cancer 99, 137-142.
            • Ange Wang, Jean Y Tang, Marcia L Stefanick. (2016) Relation of statin use with non-melanoma skin cancer: Prospective results from the Women’s Health Initiative. Women’s Health 12:5, 453-455.
            • Michael T. Schweizer, Evan Y. Yu. (2016) Targeting intratumoral androgens: statins and beyond. Therapeutic Advances in Medical Oncology 8:5, 388-395.
            • Koji Matsuo, Aida Moeini, Hiroko Machida, Morgan E. Fullerton, Anastasiya Shabalova, Laurie L. Brunette, Lynda D. Roman. (2016) Significance of venous thromboembolism in women with cervical cancer. Gynecologic Oncology 142:3, 405-412.
            • T. Klotz. (2016) Abnahme der Inzidenz des Prostatakarzinoms – Hypothesen. Der Urologe 55:8, 1053-1055.
            • Amy E. Baek, Erik R. Nelson. (2016) The Contribution of Cholesterol and Its Metabolites to the Pathophysiology of Breast Cancer. Hormones and Cancer 7:4, 219-228.
            • Amelia Smith, Laura Murphy, Linda Sharp, Darran O’Connor, William M Gallagher, Kathleen Bennett, Thomas I Barron. (2016) De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I–III breast cancer. British Journal of Cancer 115:5, 592-598.
            • Zhiqiang Fan, Handong Jiang, Zili Wang, Jieming Qu. (2016) Atorvastatin partially inhibits the epithelial-mesenchymal transition in A549 cells induced by TGF-β1 by attenuating the upregulation of SphK1. Oncology Reports 36:2, 1016-1022.
            • Tatiana Y. Hargrove, Laura Friggeri, Zdzislaw Wawrzak, Suneethi Sivakumaran, Eugenia M. Yazlovitskaya, Scott W. Hiebert, F. Peter Guengerich, Michael R. Waterman, Galina I. Lepesheva. (2016) Human sterol 14α-demethylase as a target for anticancer chemotherapy: towards structure-aided drug design. Journal of Lipid Research 57:8, 1552-1563.
            • Hisataka Sabe, Ari Hashimoto, Shigeru Hashimoto, Tsukasa Oikawa. (2016) Tumor responsiveness to statins requires overexpression of the ARF6 pathway. Molecular & Cellular Oncology 3:4, e1185564.
            • Emmanuel Thomas, Eugene R. Schiff. (2016) Early Detection of Steatohepatitis: Less Teeth NASHing and More Research?. Digestive Diseases and Sciences 61:7, 1788-1789.
            • Chandi C. Mandal, Ankit Sharma, Mahaveer S. Panwar, James A. Radosevich. (2016) Is cholesterol a mediator of cold-induced cancer?. Tumor Biology 37:7, 9635-9648.
            • Chia-Sheng Yen, Jung-Chien Chen, Yi-Fang Chang, Ya-Fen Hsu, Pei-Ting Chiu, Ching Shiue, Yu-Fan Chuang, George Ou, Ming-Jen Hsu. (2016) Lovastatin causes FaDu hypopharyngeal carcinoma cell death via AMPK-p63-survivin signaling cascade. Scientific Reports 6:1.
            • Arief Lalmohamed, Tjeerd P. van Staa, Peter Vestergaard, Hubertus G. M. Leufkens, Anthonius de Boer, Pieter Emans, Cyrus Cooper, Frank de Vries. (2016) Statins and Risk of Lower Limb Revision Surgery: The Influence of Differences in Study Design Using Electronic Health Records From the United Kingdom and Denmark. American Journal of Epidemiology 184:1, 58-66.
            • Emmanuel Bachy, Jane A. Estell, Eric Van de Neste, Réda Bouabdallah, Joan Bargay, Alain Delmer, Bénédicte Gelas-Dore, Maria Gomes da Silva, Olivier Fitoussi, David Belada, Hervé Maisonneuve, Tanin Intragumtornchai, Thierry Lamy, Peggy Dartigues, John Francis Seymour, Gilles Salles. (2016) Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study. American Journal of Hematology 91:4, 410-415.
            • C. Reith, L. Blackwell, J. Emberson, B. Mihaylova, J. Armitage, J. Fulcher, A. Keech, J. Simes, C. Baigent, R. Collins. (2016) Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. American Heart Journal 176, 63-69.
            • Ange Wang, Aaron K Aragaki, Jean Y Tang, Allison W Kurian, JoAnn E Manson, Rowan T Chlebowski, Michael Simon, Pinkal Desai, Sylvia Wassertheil-Smoller, Simin Liu, Stephen Kritchevsky, Heather A Wakelee, Marcia L Stefanick. (2016) Statin use and all-cancer survival: prospective results from the Women’s Health Initiative. British Journal of Cancer 115:1, 129-135.
            • Claire Hardie, Yoonsuh Jung, Michael Jameson. (2016) Effect of statin and aspirin use on toxicity and pathological complete response rate of neo-adjuvant chemoradiation for rectal cancer. Asia-Pacific Journal of Clinical Oncology 12:2, 167-173.
            • Fangrong Zhang, Min Li, Junling Wang, Xi Liang, Yujie Su, Wei Wang. (2016) Finding New Tricks for Old Drugs: Tumoricidal Activity of Non-Traditional Antitumor Drugs. AAPS PharmSciTech 17:3, 539-552.
            • Giridhar Mudduluru, Wolfgang Walther, Dennis Kobelt, Mathias Dahlmann, Christoph Treese, Yehuda G. Assaraf, Ulrike Stein. (2016) Repositioning of drugs for intervention in tumor progression and metastasis: Old drugs for new targets. Drug Resistance Updates 26, 10-27.
            • Daniel A. Galvão, Dennis R. Taaffe, Nigel Spry, Robert A. Gardiner, Renea Taylor, Gail P. Risbridger, Mark Frydenberg, Michelle Hill, Suzanne K. Chambers, Phillip Stricker, Tom Shannon, Dickon Hayne, Eva Zopf, Robert U. Newton. (2016) Enhancing active surveillance of prostate cancer: the potential of exercise medicine. Nature Reviews Urology 13:5, 258-265.
            • Hee Seung Lee, Sang Hoon Lee, Hyun Jik Lee, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Si Young Song, Seungmin Bang. (2016) Statin Use and Its Impact on Survival in Pancreatic Cancer Patients. Medicine 95:19, e3607.
            • Omer F. Kuzu, Mohammad A. Noory, Gavin P. Robertson. (2016) The Role of Cholesterol in Cancer. Cancer Research 76:8, 2063-2070.
            • Signy Chow, Rena Buckstein, David E. Spaner. (2016) A link between hypercholesterolemia and chronic lymphocytic leukemia. Leukemia & Lymphoma 57:4, 797-802.
            • Uri Rozovski, Inbal Hazan-Halevy, Merav Barzilai, Michael J. Keating, Zeev Estrov. (2016) Metabolism pathways in chronic lymphocytic leukemia. Leukemia & Lymphoma 57:4, 758-765.
            • Steven C. Greenway, Ryan Butts, David C. Naftel, Elizabeth Pruitt, James K. Kirklin, Ingrid Larsen, Simon Urschel, Kenneth Knecht, Yuk Law. (2016) Statin therapy is not associated with improved outcomes after heart transplantation in children and adolescents. The Journal of Heart and Lung Transplantation 35:4, 457-465.
            • Leo Alexandre, Allan B. Clark, Hina Y. Bhutta, Simon S.M. Chan, Michael P.N. Lewis, Andrew R. Hart. (2016) Association Between Statin Use After Diagnosis of Esophageal Cancer and Survival: A Population-Based Cohort Study. Gastroenterology 150:4, 854-865.e1.
            • Ryan J. Koene, Anna E. Prizment, Anne Blaes, Suma H. Konety. (2016) Shared Risk Factors in Cardiovascular Disease and Cancer. Circulation 133:11, 1104-1114.
            • Udo Walther, Kristin Emmrich, Robert Ramer, Nadine Mittag, Burkhard Hinz. (2016) Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPARγ-dependent pathway. Oncotarget 7:9, 10345-10362.
            • Chi-Kang Lin, Meng-Yi Bai, Teh-Min Hu, Yu-Chi Wang, Tai-Kuang Chao, Shao-Ju Weng, Rui-Lan Huang, Po-Hsuan Su, Hung-Cheng Lai. (2016) Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer. Oncotarget 7:8, 8993-9006.
            • Beth Binnington, Long Nguyen, Mustafa Kamani, Delowar Hossain, David L Marks, Monique Budani, Clifford A Lingwood. (2016) Inhibition of Rab prenylation by statins induces cellular glycosphingolipid remodeling. Glycobiology 26:2, 166-180.
            • Robert P. Young, Raewyn J. Hopkins, Benjamin Marsland. (2016) The Gut–Liver–Lung Axis. Modulation of the Innate Immune Response and Its Possible Role in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology 54:2, 161-169.
            • Tingting Wang, Serena Seah, Xinyi Loh, Ching-Wan Chan, Mikael Hartman, Boon-Cher Goh, Soo-Chin Lee. (2016) Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget 7:3, 2532-2544.
            • Christopher P. Cannon. (2016) Should all surgery patients get statins pre-operatively? Clear or blurry VISION?. European Heart Journal 37:2, 186-188.
            • Emily J. Gallagher, Brian A. Neel, Irini M. Antoniou, Derek LeRoith. 2016. The Increased Risk of Cancer in Obesity and Type 2 Diabetes: Potential Mechanisms. Principles of Diabetes Mellitus, 1-23.
            • Mark A. Moyad. 2016. S.A.M. and Breast Cancer—Focus on Statins, Red Yeast Rice, Sterols, and Other Integrative Cholesterol Medicines: The Real “Natural” Options. Integrative Medicine for Breast Cancer, 141-171.
            • Bihter Atil, Evelyn Berger-Sieczkowski, Johanna Bardy, Martin Werner, Martin Hohenegger. (2016) In vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatin. Naunyn-Schmiedeberg’s Archives of Pharmacology 389:1, 17-32.
            • Jonathan Kiechle, Simon P. Kim. 2016. Prostate Cancer Prevention: Strategies and Realities. Prostate Cancer, 103-109.
            • Rana R. McKay, Xun Lin, Laurence Albiges, Andre P. Fay, Marina D. Kaymakcalan, Suzanne S. Mickey, Paiman P. Ghoroghchian, Rupal S. Bhatt, Samuel D. Kaffenberger, Ronit Simantov, Toni K. Choueiri, Daniel Y.C. Heng. (2016) Statins and survival outcomes in patients with metastatic renal cell carcinoma. European Journal of Cancer 52, 155-162.
            • K. Shiva Kumar, Bandari Rajesham, Meesa Siddi Ramulu, Boyapally Bhaskar, Surjya Narayan Dash, Mohd Ashraf Ashfaq, Raju Nagarapu, Aleem Ahmed Khan, Sanna Lehtonen, Manojit Pal. (2016) Cu-Catalyzed ligand-free synthesis of rosuvastatin based novel indole derivatives as potential anticancer agents. RSC Advances 6:102, 100487-100493.
            • Do Chang Moon, Hee Seung Lee, Yong Il Lee, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Si Young Song, Jae Bock Chung, Seungmin Bang. (2016) Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer. Yonsei Medical Journal 57:5, 1124.
            • Jonathan T. Davies, Spencer F. Delfino, Chad E. Feinberg, Meghan F. Johnson, Veronica L. Nappi, Joshua T. Olinger, Anthony P. Schwab, Hollie I. Swanson. (2016) Current and Emerging Uses of Statins in Clinical Therapeutics: A Review. Lipid Insights 9, LPI.S37450.
            • Gallelli Luca, Falcone Daniela, Perri Mariarita, Erika Cione, Pelaia Girolamo, Mesuraca Maria, Terracciano Rosa, Spaziano Giuseppe, D’Agostino Bruno, Navarra Michele, Savino Rocco. (2016) Simvastatin Action Is Not Related to HDAC2 Expression in Non-Small Cell Lung Cancer (NSCLC). Journal of Cancer Therapy 07:12, 939-952.
            • Aaron P. Thrift. (2015) Esophageal Adenocarcinoma: The Influence of Medications Used to Treat Comorbidities on Cancer Prognosis. Clinical Gastroenterology and Hepatology 13:13, 2225-2232.
            • Ahmed Q. Haddad, Lai Jiang, Jeffrey A. Cadeddu, Yair Lotan, Jeffrey C. Gahan, Linda S. Hynan, Neil Gupta, Ganesh V. Raj, Arthur I. Sagalowsky, Vitaly Margulis. (2015) Statin Use and Serum Lipid Levels Are Associated With Survival Outcomes After Surgery for Renal Cell Carcinoma. Urology 86:6, 1146-1152.
            • Caroline Fairhurst, Ian Watt, Fabiola Martin, Martin Bland, William J. Brackenbury. (2015) Sodium channel-inhibiting drugs and survival of breast, colon and prostate cancer: a population-based study. Scientific Reports 5:1.
            • Yoshito Takeda, Mayumi Suzuki, Yingji Jin, Isao Tachibana. (2015) Preventive Role of Tetraspanin CD9 in Systemic Inflammation of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology 53:6, 751-760.
            • Ida Skarping, Judith S. Brand, Per Hall, Signe Borgquist. (2015) Effects of statin use on volumetric mammographic density: results from the KARMA study. BMC Cancer 15:1.
            • Emma Gustbée, Helga Tryggvadottir, Andrea Markkula, Maria Simonsson, Björn Nodin, Karin Jirström, Carsten Rose, Christian Ingvar, Signe Borgquist, Helena Jernström. (2015) Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients. BMC Clinical Pathology 15:1.
            • Maria Feldt, Olöf Bjarnadottir, Siker Kimbung, Karin Jirström, Pär-Ola Bendahl, Srinivas Veerla, Dorthe Grabau, Ingrid Hedenfalk, Signe Borgquist. (2015) Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial. Journal of Translational Medicine 13:1.
            • Emma H Allott, Stephen D Hursting. (2015) Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocrine-Related Cancer 22:6, R365-R386.
            • Jérôme Lane, Stephan F. van Eeden, Ma’en Obeidat, Don D. Sin, Scott J. Tebbutt, Wim Timens, Dirkje S. Postma, Michel Laviolette, Peter D. Paré, Yohan Bossé, Marco Idzko. (2015) Impact of Statins on Gene Expression in Human Lung Tissues. PLOS ONE 10:11, e0142037.
            • Jennifer C. Melvin, Hans Garmo, Rhian Daniel, Thurkaa Shanmugalingam, Pär Stattin, Christel Häggström, Sarah Rudman, Lars Holmberg, Mieke Van Hemelrijck. (2015) An investigation into the relationship between statins and cancer using population-based data. BJU International 116:5, 681-683.
            • Signe Vedel-Krogh, Sune F. Nielsen, Børge G. Nordestgaard, Oliver Eickelberg. (2015) Statin Use Is Associated with Reduced Mortality in Patients with Interstitial Lung Disease. PLOS ONE 10:10, e0140571.
            • Yusuke Kobayashi, Hiroyasu Kashima, Ren-Chin Wu, Jin-Gyoung Jung, Jen-Chun Kuan, Jinghua Gu, Jianhua Xuan, Lori Sokoll, Kala Visvanathan, Ie-Ming Shih, Tian-Li Wang. (2015) Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models. Clinical Cancer Research 21:20, 4652-4662.
            • Taekyu Lim, Inkyoung Lee, Jungmin Kim, Won Ki Kang. (2015) Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor. International Journal of Radiation Oncology*Biology*Physics 93:2, 316-325.
            • Yu-Yun Shao, Chih-Hung Hsu, Kun-Huei Yeh, Ho-Min Chen, Yi-Chun Yeh, Chiu-Lin Lai, Zhong-Zhe Lin, Ann-Lii Cheng, Mei-Shu Lai. (2015) Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan. Clinical Colorectal Cancer 14:3, 177-184.e4.
            • Boyd R. Viers, R. Houston Thompson, Sarah P. Psutka, Christine M. Lohse, John C. Cheville, Bradley C. Leibovich, Matthew K. Tollefson, Stephen A. Boorjian. (2015) The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy. Urologic Oncology: Seminars and Original Investigations 33:9, 388.e11-388.e18.
            • Chen-Ying Hung, Yu-Cheng Hsieh, Cheng-Hung Li, Jin-Long Huang, Ching-Heng Lin, Tsu-Juey Wu. (2015) Age and CHADS2 Score Predict the Effectiveness of Renin-Angiotensin System Blockers on Primary Prevention of Atrial Fibrillation. Scientific Reports 5:1.
            • Li-Min Sun, Ming-Chia Lin, Cheng-Li Lin, Shih-Ni Chang, Ji-An Liang, I-Ching Lin, Chia-Hung Kao. (2015) Statin Use Reduces Prostate Cancer All-Cause Mortality. Medicine 94:39, e1644.
            • Koji Matsuo, Kosei Hasegawa, Kiyoshi Yoshino, Ryusuke Murakami, Takeshi Hisamatsu, Rebecca L. Stone, Rebecca A. Previs, Jean M. Hansen, Yuji Ikeda, Akiko Miyara, Kosuke Hiramatsu, Takayuki Enomoto, Keiichi Fujiwara, Noriomi Matsumura, Ikuo Konishi, Lynda D. Roman, Hani Gabra, Christina Fotopoulou, Anil K. Sood. (2015) Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. European Journal of Cancer 51:14, 1978-1988.
            • Jacqueline E. Reilly, Jeffrey D. Neighbors, Huaxiang Tong, Michael D. Henry, Raymond J. Hohl. (2015) Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis. Clinical & Experimental Metastasis 32:6, 555-566.
            • Mostafa A. Borahay, Kathleen Vincent, Massoud Motamedi, Elena Sbrana, Gokhan S. Kilic, Ayman Al-Hendy, Darren Boehning. (2015) Novel effects of simvastatin on uterine fibroid tumors: in vitro and patient-derived xenograft mouse model study. American Journal of Obstetrics and Gynecology 213:2, 196.e1-196.e8.
            • Alexandre Arcaro. (2015) Targeted therapies for small cell lung cancer: Where do we stand?. Critical Reviews in Oncology/Hematology 95:2, 154-164.
            • Bechien U Wu, Jonathan Chang, Christie Y Jeon, Stephen J Pandol, Brian Huang, Eunis W Ngor, Andrew L Difronzo, Robert M Cooper. (2015) Impact of Statin Use on Survival in Patients Undergoing Resection for Early-Stage Pancreatic Cancer. American Journal of Gastroenterology 110:8, 1233-1239.
            • Christoph Minichsdorfer, Christine Wasinger, Evelyn Sieczkowski, Bihter Atil, Martin Hohenegger. (2015) Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells. Melanoma Research 25:4, 284-294.
            • Olöf Bjarnadottir, Siker Kimbung, Ida Johansson, Srinivas Veerla, Mats Jönsson, Pär-Ola Bendahl, Dorthe Grabau, Ingrid Hedenfalk, Signe Borgquist. (2015) Global Transcriptional Changes Following Statin Treatment in Breast Cancer. Clinical Cancer Research 21:15, 3402-3411.
            • Ashish Saxena, Daniel Becker, Isabel Preeshagul, Karen Lee, Elena Katz, Benjamin Levy. (2015) Therapeutic Effects of Repurposed Therapies in Non‐Small Cell Lung Cancer: What Is Old Is New Again. The Oncologist 20:8, 934-945.
            • Jing-Yang Huang, Zhi-Hong Jian, Oswald Ndi Nfor, Kai-Ming Jhang, Wen-Yuan Ku, Pei-Chieh Ko, Shiou-Rung Jan, Chien-Chang Ho, Chia-Chi Lung, Hui-Hsien Pan, Yu-Chiu Liang, Yung-Po Liaw, Yuanpu Peter Di. (2015) The Impact of Coexisting Asthma, Chronic Obstructive Pulmonary Disease and Tuberculosis on Survival in Patients with Lung Squamous Cell Carcinoma. PLOS ONE 10:7, e0133367.
            • Nicole S. Nevadunsky, Anne Van Arsdale, Howard D. Strickler, Lori A. Spoozak, Alyson Moadel, Gurpreet Kaur, Eugenia Girda, Gary L. Goldberg, Mark H. Einstein. (2015) Association Between Statin Use and Endometrial Cancer Survival. Obstetrics & Gynecology 126:1, 144-150.
            • Emily Jane Gallagher, Derek LeRoith. (2015) Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. Physiological Reviews 95:3, 727-748.
            • Eiman Jahangir, Nichole M Polin, Carl J Lavie, Sergio Fazio. (2015) The link between lipids, statins and cancer: is there a role for cardio-oncology?. Future Cardiology 11:4, 389-393.
            • YUANYUAN SHEN, YINGYING DU, YING ZHANG, YUEYIN PAN. (2015) Synergistic effects of combined treatment with simvastatin and exemestane on MCF-7 human breast cancer cells. Molecular Medicine Reports 12:1, 456-462.
            • Linnea A. Polgreen, Elizabeth A. Cook, John M. Brooks, Yuexin Tang, Philip M. Polgreen. (2015) Increased Statin Prescribing Does Not Lower Pneumonia Risk. Clinical Infectious Diseases 60:12, 1760-1766.
            • Shanliang Zhong, Xiaohui Zhang, Lin Chen, Tengfei Ma, Jinhai Tang, Jianhua Zhao. (2015) Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies. Cancer Treatment Reviews 41:6, 554-567.
            • Michael Hoffmeister, Lina Jansen, Anja Rudolph, Csaba Toth, Matthias Kloor, Wilfried Roth, Hendrik Bläker, Jenny Chang-Claude, Hermann Brenner. (2015) Statin Use and Survival After Colorectal Cancer: The Importance of Comprehensive Confounder Adjustment. JNCI: Journal of the National Cancer Institute 107:6.
            • Ying Ling, Li Yang, Huiqiao Huang, Xiaohua Hu, Cuisong Zhao, Hongyan Huang, Yanping Ying. (2015) Prognostic Significance of Statin Use in Colorectal Cancer. Medicine 94:25, e908.
            • Heping Cai, Gongwu Zhang, Zhuo Wang, Zhihong Luo, Xiaochun Zhou, Yu-Jia Chang. (2015) Relationship Between the Use of Statins and Patient Survival in Colorectal Cancer: A Systematic Review and Meta-Analysis. PLOS ONE 10:6, e0126944.
            • Chun-Jung Lin, Cheng-Kuo Lai, Min-Chuan Kao, Lii-Tzu Wu, U-Ging Lo, Li-Chiung Lin, Yu-An Chen, Ho Lin, Jer-Tsong Hsieh, Chih-Ho Lai, Chia-Der Lin. (2015) Impact of cholesterol on disease progression. BioMedicine 5:2.
            • Lionel H. Opie, Gary D. Lopaschuk. (2015) What is good for the circulation also lessens cancer risk. European Heart Journal 36:19, 1157-1162.
            • Heidrun Karlic, Roman Thaler, Christopher Gerner, Thomas Grunt, Katharina Proestling, Florian Haider, Franz Varga. (2015) Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells. Cancer Genetics 208:5, 241-252.
            • Katsuhiko Warita, Tomoko Warita, Colin H. Beckwitt, Mark E. Schurdak, Alexei Vazquez, Alan Wells, Zoltán N. Oltvai. (2015) Statin-induced mevalonate pathway inhibition attenuates the growth of mesenchymal-like cancer cells that lack functional E-cadherin mediated cell cohesion. Scientific Reports 4:1.
            • Erik S. Stroes, Paul D. Thompson, Alberto Corsini, Georgirene D. Vladutiu, Frederick J. Raal, Kausik K. Ray, Michael Roden, Evan Stein, Lale Tokgözoğlu, Børge G. Nordestgaard, Eric Bruckert, Guy De Backer, Ronald M. Krauss, Ulrich Laufs, Raul D. Santos, Robert A. Hegele, G. Kees Hovingh, Lawrence A. Leiter, Francois Mach, Winfried März, Connie B. Newman, Olov Wiklund, Terry A. Jacobson, Alberico L. Catapano, M. John Chapman, Henry N. Ginsberg, , Erik Stroes, Paul D. Thompson, Alberto Corsini, Georgirene D. Vladutiu, Frederick J. Raal, Kausik K. Ray, Michael Roden, Evan Stein, Lale Tokgözoğlu, Børge G. Nordestgaard, Eric Bruckert, Ronald M. Krauss, Ulrich Laufs, Raul D. Santos, Winfried März, Connie B. Newman, M. John Chapman, Henry N. Ginsberg, M. John Chapman, Henry N. Ginsberg, Guy de Backer, Alberico L. Catapano, Robert A. Hegele, G. Kees Hovingh, Terry A. Jacobson, Lawrence Leiter, Francois Mach, Olov Wiklund. (2015) Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal 36:17, 1012-1022.
            • Chris R. Cardwell, Úna Mc Menamin, Carmel M. Hughes, Liam J. Murray. (2015) Statin Use and Survival from Lung Cancer: A Population-Based Cohort Study. Cancer Epidemiology Biomarkers & Prevention 24:5, 833-841.
            • XU ZHANG, YANG TENG, FANG YANG, MENG WANG, XUAN HONG, LEI-GUANG YE, YI-NA GAO, GONG-YAN CHEN. (2015) MCM2 is a therapeutic target of lovastatin in human non-small cell lung carcinomas. Oncology Reports 33:5, 2599-2605.
            • Shenying Fang, Yuling Wang, Dawen Sui, Huey Liu, Merrick I. Ross, Jeffrey E. Gershenwald, Janice N. Cormier, Richard E. Royal, Anthony Lucci, Christopher W. Schacherer, Julie M. Gardner, John D. Reveille, Roland L. Bassett, Li-E Wang, Qingyi Wei, Christopher I. Amos, Jeffrey E. Lee. (2015) C-Reactive Protein As a Marker of Melanoma Progression. Journal of Clinical Oncology 33:12, 1389-1396.
            • Evan J. Walker, Andrew H. Ko, Elizabeth A. Holly, Paige M. Bracci. (2015) Statin use and risk of pancreatic cancer: Results from a large, clinic-based case-control study. Cancer 121:8, 1287-1294.
            • Hyeongsun Moon, Jayde E. Ruelcke, Eunju Choi, Laura J. Sharpe, Zeyad D. Nassar, Helle Bielefeldt-Ohmann, Marie-Odile Parat, Anup Shah, Mathias Francois, Kerry L. Inder, Andrew J. Brown, Pamela J. Russell, Robert G. Parton, Michelle M. Hill. (2015) Diet-induced hypercholesterolemia promotes androgen-independent prostate cancer metastasis via IQGAP1 and caveolin-1. Oncotarget 6:10, 7438-7453.
            • Pinkal Desai, Amy Lehman, Rowan T. Chlebowski, Marilyn L. Kwan, Monica Arun, JoAnn E. Manson, Sayeh Lavasani, Sylvia Wasswertheil-Smoller, Gloria E. Sarto, Meryl LeBoff, Jane Cauley, Michele Cote, Jennifer Beebe-Dimmer, Allison Jay, Michael S. Simon. (2015) Statins and breast cancer stage and mortality in the Women’s Health Initiative. Cancer Causes & Control 26:4, 529-539.
            • Tobias Nordström, Mark Clements, Robert Karlsson, Jan Adolfsson, Henrik Grönberg. (2015) The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. European Journal of Cancer 51:6, 725-733.
            • Lionel H. Opie. (2015) Present status of statin therapy. Trends in Cardiovascular Medicine 25:3, 216-225.
            • Maya Horowitz, Elad Neeman, Eran Sharon, Shamgar Ben-Eliyahu. (2015) Exploiting the critical perioperative period to improve long-term cancer outcomes. Nature Reviews Clinical Oncology 12:4, 213-226.
            • Emily Jane Gallagher, Ruslan Novosyadlyy, Derek LeRoith. 2015. Type 2 diabetes and cancer. International Textbook of Diabetes Mellitus, 306-315.
            • Harumi Okuyama, Peter H Langsjoen, Tomohito Hamazaki, Yoichi Ogushi, Rokuro Hama, Tetsuyuki Kobayashi, Hajime Uchino. (2015) Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Review of Clinical Pharmacology 8:2, 189-199.
            • H. Okuyama. 2015. 6. Benefits of high cholesterol levels for all-cause mortality: biochemical bases. Handbook of eggs in human function, 93-108.
            • M. A. O’Rorke, L. J. Murray, C. M. Hughes, M. M. Cantwell, C. R. Cardwell. (2015) The effect of warfarin therapy on breast, colorectal, lung, and prostate cancer survival: a population-based cohort study using the Clinical Practice Research Datalink. Cancer Causes & Control 26:3, 355-366.
            • John Cuaron, Xin Pei, Gil’ad N. Cohen, Brett W. Cox, Yoshiya Yamada, Michael J. Zelefsky, Marisa A. Kollmeier. (2015) Statin use not associated with improved outcomes in patients treated with brachytherapy for prostate cancer. Brachytherapy 14:2, 179-184.
            • M R Danzig, S Kotamarti, R A Ghandour, M B Rothberg, B P Dubow, M C Benson, K K Badani, J M McKiernan. (2015) Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes. Prostate Cancer and Prostatic Diseases 18:1, 63-68.
            • Uffe Ravnskov, Paul J. Rosch, Kilmer S. McCully. (2015) Statins Do Not Protect Against Cancer: Quite the Opposite. Journal of Clinical Oncology 33:7, 810-811.
            • Chris R. Cardwell, Blanaid M. Hicks, Carmel Hughes, Liam J. Murray. (2015) Reply to U. Ravnskov et al, D. Tural et al, and M.A.N. Şendur et al. Journal of Clinical Oncology 33:7, 812-812.
            • ABDULLAH K. ALTWAIRGI. (2015) Statins are potential anticancerous agents (Review). Oncology Reports 33:3, 1019-1039.
            • Theresa Pluth Yeo. (2015) Demographics, Epidemiology, and Inheritance of Pancreatic Ductal Adenocarcinoma. Seminars in Oncology 42:1, 8-18.
            • Usman Iqbal, Phung-Anh Nguyen, Shabbir Syed-Abdul, Hsuan-Chia Yang, Chih-Wei Huang, Wen-Shan Jian, Min-Huei Hsu, Yun Yen, Yu-Chuan (Jack) Li. (2015) Is Long-term Use of Benzodiazepine a Risk for Cancer?. Medicine 94:6, e483.
            • Sarit Ben-Shmuel, Ran Rostoker, Eyal J. Scheinman, Derek LeRoith. 2015. Metabolic Syndrome, Type 2 Diabetes, and Cancer: Epidemiology and Potential Mechanisms. Metabolic Control, 355-372.
            • Daniel S. Oh, Bridget Koontz, Stephen J. Freedland, Leah Gerber, Pretesh Patel, Stephen Lewis, David S. Yoo, James Oleson, Joseph K. Salama. (2015) Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy. World Journal of Urology 33:1, 93-97.
            • Francesco Negro. (2015) Are statins a remedy for all seasons?. Journal of Hepatology 62:1, 8-10.
            • Samuel D. Kaffenberger, Opal Lin-Tsai, Kelly L. Stratton, Todd M. Morgan, Daniel A. Barocas, Sam S. Chang, Michael S. Cookson, S. Duke Herrell, Joseph A. Smith, Peter E. Clark. (2015) Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 33:1, 21.e11-21.e17.
            • A. Hirasawa, K. Makita, T. Akahane, W. Yamagami, T. Makabe, M. Yokota, Y. Horiba, M. Ogawa, S. Yanamoto, R. Deshimaru, E. Tominaga, K. Banno, N. Susumu, D. Aoki. (2015) Osteoporosis is less frequent in endometrial cancer survivors with hypertriglyceridemia. Japanese Journal of Clinical Oncology 45:1, 127-131.
            • Chris R. Cardwell, Blanaid M. Hicks, Carmel Hughes, Liam J. Murray. (2015) Statin Use After Diagnosis of Breast Cancer and Survival. Epidemiology 26:1, 68-78.
            • Hans Carl Hasselbalch, Mads Emil Bjørn. (2015) MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives. Mediators of Inflammation 2015, 1-16.
            • Vassiliki Benetou, Areti Lagiou, Pagona Lagiou. (2015) Chemoprevention of cancer: current evidence and future prospects. F1000Research 4, 916.
            • Tracey G Simon. (2015) Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes. World Journal of Gastroenterology 21:27, 8293.
            • Muhammad Shahzeb Khan, Kaneez Fatima, Rameez. (2015) Impact of statins on risk and survival of ovarian cancer. Journal of Gynecologic Oncology 26:3, 240.
            • Ju Hyun Lim, In Gab Jeong, Jong Yeon Park, Dalsan You, Bumsik Hong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim. (2015) Prognostic impact of preoperative statin use after radical nephroureterectomy for upper urinary tract urothelial carcinoma. Korean Journal of Urology 56:7, 498.
            • Jaeyoon Jung, Chunwoo Lee, Chanwoo Lee, Taekmin Kwon, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim. (2015) Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer. Korean Journal of Urology 56:9, 630.
            • J. Arroyo-Acevedo, R.J. Chávez-Asmat, A. Anampa-Guzmán, R. Donaires, Josέ Ráez-Gonzáles. (2015) Protective Effect of Piper aduncum Capsule on DMBA-induced Breast Cancer in Rats. Breast Cancer: Basic and Clinical Research 9, BCBCR.S24420.
            • David Gaist, Jesper Hallas, Søren Friis, Steinbjørn Hansen, Henrik Toft Sørensen. (2014) Statin use and survival following glioblastoma multiforme. Cancer Epidemiology 38:6, 722-727.
            • Peter Kubatka, Peter Kruzliak, Vladimir Rotrekl, Sarka Jelinkova, Beata Mladosievicova. (2014) Statins in oncological research: From experimental studies to clinical practice. Critical Reviews in Oncology/Hematology 92:3, 296-311.
            • Erik R. Nelson, Ching-yi Chang, Donald P. McDonnell. (2014) Cholesterol and breast cancer pathophysiology. Trends in Endocrinology & Metabolism 25:12, 649-655.
            • Christine Wasinger, Martin Künzl, Christoph Minichsdorfer, Christoph Höller, Maria Zellner, Martin Hohenegger. (2014) Autocrine secretion of 15d-PGJ 2 mediates simvastatin-induced apoptotic burst in human metastatic melanoma cells. British Journal of Pharmacology 171:24, 5708-5727.
            • Robert P. Young, Raewyn J. Hopkins. (2014) A review of the Hispanic paradox: time to spill the beans?. European Respiratory Review 23:134, 439-449.
            • Catarina Rodrigues dos Santos, Isabel Fonseca, Sérgio Dias, JC Mendes de Almeida. (2014) Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression. BMC Cancer 14:1.
            • , Haruo Nakamura, Kyoichi Mizuno. (2014) Cardiovascular and cancer events in hyper-high-density lipoprotein cholesterolemic patients: a post hoc analysis of the MEGA study. Lipids in Health and Disease 13:1.
            • Luca Gallelli, Daniela Falcone, Monica Scaramuzzino, Girolamo Pelaia, Bruno D’Agostino, Maria Mesuraca, Rosa Terracciano, Giuseppe Spaziano, Rosario Maselli, Michele Navarra, Rocco Savino. (2014) Effects of simvastatin on cell viability and proinflammatory pathways in lung adenocarcinoma cells exposed to hydrogen peroxide. BMC Pharmacology and Toxicology 15:1.
            • D. P. McDonnell, C.-Y. Chang, E. R. Nelson. (2014) The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer. Climacteric 17:sup2, 60-65.
            • Lisanne L. Krens, Lieke H. J. Simkens, Jara M. Baas, Els R. Koomen, Hans Gelderblom, Cornelis J. A. Punt, Henk-Jan Guchelaar, Anthony W.I. Lo. (2014) Statin Use Is Not Associated with Improved Progression Free Survival in Cetuximab Treated KRAS Mutant Metastatic Colorectal Cancer Patients: Results from the CAIRO2 Study. PLoS ONE 9:11, e112201.
            • Felix Lötsch, Oliver Königsbrügge, Florian Posch, Christoph Zielinski, Ingrid Pabinger, Cihan Ay. (2014) Statins are Associated with Low Risk of Venous Thromboembolism in Patients with Cancer: A Prospective and Observational Cohort Study. Thrombosis Research 134:5, 1008-1013.
            • Cinzia Casella, Daniel H. Miller, Kerry Lynch, Alexander S. Brodsky. (2014) Oxysterols synergize with statins by inhibiting SREBP-2 in ovarian cancer cells. Gynecologic Oncology 135:2, 333-341.
            • Amelia McFarland, Shailendra Anoopkumar-Dukie, Devinder Arora, Gary Grant, Catherine McDermott, Anthony Perkins, Andrew Davey. (2014) Molecular Mechanisms Underlying the Effects of Statins in the Central Nervous System. International Journal of Molecular Sciences 15:11, 20607-20637.
            • TOSHIHIKO FUKAMACHI, SHUNSUKE IKEDA, HIROMI SAITO, MASATOSHI TAGAWA, HIROSHI KOBAYASHI. (2014) Expression of acidosis-dependent genes in human cancer nests. Molecular and Clinical Oncology 2:6, 1160-1166.
            • Laura Galli, Vincenzo Spagnuolo, Andrea Poli, Stefania Salpietro, Nicola Gianotti, Francesca Cossarini, Alessia Carbone, Silvia Nozza, Simona Bossolasco, Alba Bigoloni, Adriano Lazzarin, Antonella Castagna. (2014) Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy. AIDS 28:16, 2407-2415.
            • Teemu J. Murtola, Kala Visvanathan, Miia Artama, Harri Vainio, Eero Pukkala, James M. Wright. (2014) Statin Use and Breast Cancer Survival: A Nationwide Cohort Study from Finland. PLoS ONE 9:10, e110231.
            • Elisabeth Livingstone, Loes M. Hollestein, Myrthe P. P. Herk‐Sukel, Lonneke Poll‐Franse, Arjen Joosse, Bastian Schilling, Tamar Nijsten, Dirk Schadendorf, Esther Vries. (2014) Statin use and its effect on all‐cause mortality of melanoma patients: a population‐based Dutch cohort study. Cancer Medicine 3:5, 1284-1293.
            • Stefanos Bonovas. (2014) Statins: Do They Have a Potential Role in Cancer Prevention and Modifying Cancer-Related Outcomes?. Drugs 74:16, 1841-1848.
            • Simona Pisanti, Paola Picardi, Elena Ciaglia, Alba D’Alessandro, Maurizio Bifulco. (2014) Novel prospects of statins as therapeutic agents in cancer. Pharmacological Research 88, 84-98.
            • P Jiang, R Mukthavaram, Y Chao, N Nomura, I S Bharati, V Fogal, S Pastorino, D Teng, X Cong, S C Pingle, S Kapoor, K Shetty, A Aggrawal, S Vali, T Abbasi, S Chien, S Kesari. (2014) In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. British Journal of Cancer 111:8, 1562-1571.
            • T Cohen, D Widdows, C Stephan, R Zinner, J Kim, T Rindflesch, P Davies. (2014) Predicting High-Throughput Screening Results With Scalable Literature-Based Discovery Methods. CPT: Pharmacometrics & Systems Pharmacology 3:10, 140.
            • Chris R. Cardwell, Blanaid M. Hicks, Carmel Hughes, Liam J. Murray. (2014) Statin Use After Colorectal Cancer Diagnosis and Survival: A Population-Based Cohort Study. Journal of Clinical Oncology 32:28, 3177-3183.
            • Yi-Fang Yang, Yi-Hua Jan, Yu-Peng Liu, Chih-Jen Yang, Chia-Yi Su, Yu-Chan Chang, Tsung-Ching Lai, Jean Chiou, Hong-Yuan Tsai, Jean Lu, Chia-Ning Shen, Jin-Yuh Shew, Pei-Jung Lu, Yuan-Feng Lin, Ming-Shyan Huang, Michael Hsiao. (2014) Squalene Synthase Induces Tumor Necrosis Factor Receptor 1 Enrichment in Lipid Rafts to Promote Lung Cancer Metastasis. American Journal of Respiratory and Critical Care Medicine 190:6, 675-687.
            • Luca Mascitelli, Mark R. Goldstein. (2014) Do the immunosuppressive effects of statins increase Merkel cell carcinoma risk?. International Journal of Dermatology 53:9, e406-e409.
            • Junichi Akiyama, Leo Alexandre, Anushka Baruah, Navtej Buttar, Raghav Chandra, Allan B. Clark, Andrew R. Hart, Ernest Hawk, Daniela Kandioler, Sonja Kappel, Sheila K. Krishnadath, Anamay Sharma, Ishtpreet Singh, Danielle Straub, George Triadafilopoulos, Asad Umar, Brigitte Wolf. (2014) Strategy for prevention of cancers of the esophagus. Annals of the New York Academy of Sciences 1325:1, 108-126.
            • Aleksandra Pandyra, Peter J. Mullen, Manpreet Kalkat, Rosemary Yu, Janice T. Pong, Zhihua Li, Suzanne Trudel, Karl S. Lang, Mark D. Minden, Aaron D. Schimmer, Linda Z. Penn. (2014) Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop. Cancer Research 74:17, 4772-4782.
            • Mohammed Habis, Kristen Wroblewski, Michael Bradaric, Nadia Ismail, S. Diane Yamada, Lacey Litchfield, Ernst Lengyel, Iris L. Romero, Shannon M. Hawkins. (2014) Statin Therapy Is Associated with Improved Survival in Patients with Non-Serous-Papillary Epithelial Ovarian Cancer: A Retrospective Cohort Analysis. PLoS ONE 9:8, e104521.
            • Cleo Robinson, Helman Alfonso, Samantha Woo, Amy Walsh, Nola Olsen, Arthur W. Musk, Bruce W. S. Robinson, Anna K. Nowak, Richard A. Lake, Sumitra Deb. (2014) Statins Do Not Alter the Incidence of Mesothelioma in Asbestos Exposed Mice or Humans. PLoS ONE 9:8, e103025.
            • Soo Lim, Pyung Chun Oh, Ichiro Sakuma, Kwang Kon Koh. (2014) How to balance cardiorenometabolic benefits and risks of statins. Atherosclerosis 235:2, 644-648.
            • Lara I. de Llobet, Marta Baro, Ricard Mesia, Josep Balart. (2014) Simvastatin Enhances the Effects of Radiotherapy and Cetuximab on a Cell Line (FaDu) Derived from a Squamous Cell Carcinoma of Head and Neck. Translational Oncology 7:4, 513-522.
            • Jennifer W Wu, Denise M Boudreau, Yikyung Park, Naoko I Simonds, Andrew N Freedman. (2014) Commonly used diabetes and cardiovascular medications and cancer recurrence and cancer-specific mortality: a review of the literature. Expert Opinion on Drug Safety 13:8, 1071-1099.
            • Ayelet Shai, Hedy S. Rennert, Ofer Lavie, Muona Ballan-Haj, Arie Bitterman, Mariana Steiner, Shoshana Keren, Gad Rennert. (2014) Statins, aspirin and risk of venous thromboembolic events in breast cancer patients. Journal of Thrombosis and Thrombolysis 38:1, 32-38.
            • Behzad Yeganeh, Emilia Wiechec, Sudharsana R. Ande, Pawan Sharma, Adel Rezaei Moghadam, Martin Post, Darren H. Freed, Mohammad Hashemi, Shahla Shojaei, Amir A. Zeki, Saeid Ghavami. (2014) Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacology & Therapeutics 143:1, 87-110.
            • Aram Ghalali, Fredrik Wiklund, Huiyuan Zheng, Ulla Stenius, Johan Högberg. (2014) Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells. Carcinogenesis 35:7, 1547-1555.
            • Ellen L. Hedditch, Bo Gao, Amanda J. Russell, Yi Lu, Catherine Emmanuel, Jonathan Beesley, Sharon E. Johnatty, Xiaoqing Chen, Paul Harnett, Joshy George, Rebekka T. Williams, Claudia Flemming, Diether Lambrechts, Evelyn Despierre, Sandrina Lambrechts, Ignace Vergote, Beth Karlan, Jenny Lester, Sandra Orsulic, Christine Walsh, Peter Fasching, Matthias W. Beckmann, Arif B. Ekici, Alexander Hein, Keitaro Matsuo, Satoyo Hosono, Toru Nakanishi, Yasushi Yatabe, Tanja Pejovic, Yukie Bean, Florian Heitz, Philipp Harter, Andreas du Bois, Ira Schwaab, Estrid Hogdall, Susan K. Kjaer, Allan Jensen, Claus Hogdall, Lene Lundvall, Svend Aage Engelholm, Bob Brown, James Flanagan, Michelle D Metcalf, Nadeem Siddiqui, Thomas Sellers, Brooke Fridley, Julie Cunningham, Joellen Schildkraut, Ed Iversen, Rachel P. Weber, Andrew Berchuck, Ellen Goode, David D. Bowtell, Georgia Chenevix-Trench, Anna deFazio, Murray D. Norris, Stuart MacGregor, Michelle Haber, Michelle J. Henderson. (2014) ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer. JNCI: Journal of the National Cancer Institute 106:7.
            • Ronac Mamtani, Nick Pfanzelter, Kevin Haynes, Brian S. Finkelman, Xingmei Wang, Stephen M. Keefe, Naomi B. Haas, David J. Vaughn, James D. Lewis. (2014) Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas. Diabetes Care 37:7, 1910-1917.
            • Lara Lacerda, Jay P. Reddy, Diane Liu, Richard Larson, Li Li, Hiroko Masuda, Takae Brewer, Bisrat G. Debeb, Wei Xu, Gabriel N. Hortobágyi, Thomas A. Buchholz, Naoto T. Ueno, Wendy A. Woodward. (2014) Simvastatin Radiosensitizes Differentiated and Stem-Like Breast Cancer Cell Lines and Is Associated With Improved Local Control in Inflammatory Breast Cancer Patients Treated With Postmastectomy Radiation. STEM CELLS Translational Medicine 3:7, 849-856.
            • Naveed A. Sattar, Henry Ginsberg, Kausik Ray, M. John Chapman, Marcello Arca, Maurizio Averna, D. John Betteridge, Deepak Bhatnagar, Elena Bilianou, Rafael Carmena, Richard Češka, Alberto Corsini, Raimund Erbel, Paul D. Flynn, Xavier Garcia-Moll, Janusz Gumprecht, Shun Ishibashi, Selim Jambart, John J.P. Kastelein, Vincent Maher, Pedro Marques da Silva, Luis Masana, Masato Odawara, Terje R. Pedersen, Carlo Maria Rotella, Ibrahim Salti, Tamio Teramoto, Lale Tokgozoglu, Peter P. Toth, Paul Valensi, Bruno Vergès. (2014) The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. Atherosclerosis Supplements 15:1, 1-15.
            • Yanqiong Liu, Aiping Qin, Taijie Li, Xue Qin, Shan Li. (2014) Effect of statin on risk of gynecologic cancers: A meta-analysis of observational studies and randomized controlled trials. Gynecologic Oncology 133:3, 647-655.
            • Stephanie M. J. Fliedner, Tobias Engel, Nikoletta K. Lendvai, Uma Shankavaram, Svenja Nölting, Robert Wesley, Abdel G. Elkahloun, Hendrik Ungefroren, Angela Oldoerp, Gary Lampert, Hendrik Lehnert, Henri Timmers, Karel Pacak, Benjamin Edward Rich. (2014) Anti-Cancer Potential of MAPK Pathway Inhibition in Paragangliomas–Effect of Different Statins on Mouse Pheochromocytoma Cells. PLoS ONE 9:5, e97712.
            • Sarah C.W. Marott, Sune F. Nielsen, Marianne Benn, Børge G. Nordestgaard. (2014) Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. European Heart Journal 35:18, 1205-1214.
            • Xiang Song, Bing-Chen Liu, Xiao-Yu Lu, Li-Li Yang, Yu-Jia Zhai, Amity F. Eaton, Tiffany L. Thai, Douglas C. Eaton, He-Ping Ma, Bao-Zhong Shen. (2014) Lovastatin inhibits human B lymphoma cell proliferation by reducing intracellular ROS and TRPC6 expression. Biochimica et Biophysica Acta (BBA) – Molecular Cell Research 1843:5, 894-901.
            • Ayelet Shai, Hedy S. Rennert, Gad Rennert, Shlomi Sagi, Michelle Leviov, Ofer Lavie. (2014) Statins, aspirin and risk of thromboembolic events in ovarian cancer patients. Gynecologic Oncology 133:2, 304-308.
            • Kenneth G. Linden, Sancy A. Leachman, Jonathan S. Zager, James G. Jakowatz, Jaye L. Viner, Christine E. McLaren, Ronald J. Barr, Philip M. Carpenter, Wen-Pin Chen, Craig A. Elmets, Joseph A. Tangrea, Sung-Jig Lim, Alistair J. Cochran, Frank L. Meyskens. (2014) A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology. Cancer Prevention Research 7:5, 496-504.
            • Matthaeus Stoehr, Christian Mozet, Andreas Boehm, Achim Aigner, Andreas Dietz, Gunnar Wichmann. (2014) Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics. Cancer Chemotherapy and Pharmacology 73:4, 827-837.
            • Vinay Prasad, Nancy Ho. (2014) Why do we continue to adopt medical practices based on pathophysiology alone when we should be insisting on clinical trials?. Journal of Clinical Epidemiology 67:4, 361-363.
            • Robert J. Hamilton, Daniel Morilla, Fernando Cabrera, Michael Leapman, Ling Y. Chen, Melanie Bernstein, A. Ari Hakimi, Victor E. Reuter, Paul Russo. (2014) The Association between Statin Medication and Progression after Surgery for Localized Renal Cell Carcinoma. The Journal of Urology 191:4, 914-919.
            • Teemu J. Murtola. (2014) Impact of Statins on Genitourinary Cancer Outcomes: the Promise and the Challenge. The Journal of Urology 191:4, 889-890.
            • Nathan A. Berger. (2014) Obesity and cancer pathogenesis. Annals of the New York Academy of Sciences 1311:1, 57-76.
            • Harumi Okuyama, Tomohito Hamazaki, Yoichi Ogushi, Rokuro Hama. (2014) Risks of diabetes mellitus and cancer caused by cholesterol lowering medications. Lipid Technology 26:3, 55-58.
            • Jill Wright, Brandt L. Schneider. (2014) Cell Growth: When Less Means More. Current Biology 24:7, R283-R285.
            • Maria Wilke, Andy Göbel, Martina Rauner, Peggy Benad-Mehner, Norbert Schütze, Susanne Füssel, Peyman Hadji, Lorenz C. Hofbauer, Tilman D. Rachner. (2014) Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells. Journal of Bone Oncology 3:1, 10-17.
            • Eleftherios Sachlos, Amber Kerstetter-Fogle. (2014) Research Highlights: Highlights from the latest articles in regenerative medicine. Regenerative Medicine 9:2, 145-147.
            • Young Kwang Chae, Long Trinh, Preetesh Jain, Xuemei Wang, Uri Rozovski, William G. Wierda, Michael J. Keating, Zeev Estrov. (2014) Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia. Blood 123:9, 1424-1426.
            • D. Lissa, L. Senovilla, S. Rello-Varona, I. Vitale, M. Michaud, F. Pietrocola, A. Boileve, F. Obrist, C. Bordenave, P. Garcia, J. Michels, M. Jemaa, O. Kepp, M. Castedo, G. Kroemer. (2014) Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention. Proceedings of the National Academy of Sciences 111:8, 3020-3025.
            • Kui-Kai Lau, Yuen-Kwun Wong, Kay-Cheong Teo, Richard Shek-Kwan Chang, Sonny Fong-Kwong Hon, Koon-Ho Chan, Raymond Tak-Fai Cheung, Leonard Sheung-Wai Li, Hung-Fat Tse, Shu-Leong Ho, Chung-Wah Siu, Alice Y. W. Chang. (2014) Stroke Patients with a Past History of Cancer Are at Increased Risk of Recurrent Stroke and Cardiovascular Mortality. PLoS ONE 9:2, e88283.
            • Xiao Yi, Wei Jia, Yin Jin, Shang Zhen, Balraj Mittal. (2014) Statin Use Is Associated with Reduced Risk of Haematological Malignancies: Evidence from a Meta-Analysis. PLoS ONE 9:1, e87019.
            • Senthil Selvaraj, Durga S. Borkar, Vinay Prasad, Yan Gong. (2014) Media Coverage of Medical Journals: Do the Best Articles Make the News?. PLoS ONE 9:1, e85355.
            • Fathia Zaky El Sharkawi, Hany Abdelaziz El Shemy, Hussein Moustafa Khaled. (2014) Possible Anticancer Activity of Rosuvastatine, Doxazosin, Repaglinide and Oxcarbazepin. Asian Pacific Journal of Cancer Prevention 15:1, 199-203.
            • Tamer M. Fouad, Takahiro Kogawa, James M. Reuben, Naoto T. Ueno. 2014. The Role of Inflammation in Inflammatory Breast Cancer. Inflammation and Cancer, 53-73.
            • Jung Yong Hong, Eun Mi Nam, Jeeyun Lee, Joon Oh Park, Sang-Cheol Lee, Seo-Young Song, Seong Ho Choi, Jin Seok Heo, Se Hoon Park, Ho Yeong Lim, Won Ki Kang, Young Suk Park. (2014) Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. Cancer Chemotherapy and Pharmacology 73:1, 125-130.
            • Michel Record, Marc Poirot, Sandrine Silvente-Poirot. (2014) Emerging concepts on the role of exosomes in lipid metabolic diseases. Biochimie 96, 67-74.
            • Si Jin, Yongzhong Wu, Shiwei Deng, Jinxiang Zhang, Xiao Qian Chen. (2014) Oxidants and Antioxidants in Metabolic Syndrome and Cancer. Oxidative Medicine and Cellular Longevity 2014, 1-3.
            • Catarina Rodrigues dos Santos, Germana Domingues, Inês Matias, João Matos, Isabel Fonseca, José de Almeida, Sérgio Dias. (2014) LDL-cholesterol signaling induces breast cancer proliferation and invasion. Lipids in Health and Disease 13:1, 16.
            • Pengfei Jiang, Rajesh Mukthavavam, Ying Chao, Ila Bharati, Valentina Fogal, Sandra Pastorino, Xiuli Cong, Natsuko Nomura, Matt Gallagher, Taher Abbasi, Shireen Vali, Sandeep C Pingle, Milan Makale, Santosh Kesari. (2014) Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. Journal of Translational Medicine 12:1, 13.
            • Oriana Yu, Maria Eberg, Serge Benayoun, Armen Aprikian, Gerald Batist, Samy Suissa, Laurent Azoulay. (2014) Use of Statins and the Risk of Death in Patients With Prostate Cancer. Journal of Clinical Oncology 32:1, 5-11.
            • Lorelei A. Mucci, Meir J. Stampfer. (2014) Mounting Evidence for Prediagnostic Use of Statins in Reducing Risk of Lethal Prostate Cancer. Journal of Clinical Oncology 32:1, 1-2.
            • Masato KATO. (2014) Anesthesia and Perioperative Management Affecting Long Term Outcome : an Overview. THE JOURNAL OF JAPAN SOCIETY FOR CLINICAL ANESTHESIA 34:3, 377-381.
            • Lili Qu, Jiandong Jiang, Weijia Kong. (2014) Pharmacological Effects of Statins Related to Gap Junction Modulation. Pharmacology & Pharmacy 05:04, 319-331.
            • Stefano Tiziani, Yunyi Kang, Ricky Harjanto, Joshua Axelrod, Carlo Piermarocchi, William Roberts, Giovanni Paternostro, Linda Bendall. (2013) Metabolomics of the Tumor Microenvironment in Pediatric Acute Lymphoblastic Leukemia. PLoS ONE 8:12, e82859.
            • Jonathan Hiller, Gerhard Brodner, Antje Gottschalk. (2013) Understanding clinical strategies that may impact tumour growth and metastatic spread at the time of cancer surgery. Best Practice & Research Clinical Anaesthesiology 27:4, 427-439.
            • Chin-Hsiao Tseng. (2013) Higher risk of mortality from lung cancer in Taiwanese people with diabetes. Diabetes Research and Clinical Practice 102:3, 193-201.
            • Jeremy M. Jacobs, Aaron Cohen, Eliana Ein-Mor, Jochanan Stessman. (2013) Cholesterol, Statins, and Longevity From Age 70 to 90 Years. Journal of the American Medical Directors Association 14:12, 883-888.
            • Kimberly A Hartwell, Peter G Miller, Siddhartha Mukherjee, Alissa R Kahn, Alison L Stewart, David J Logan, Joseph M Negri, Mildred Duvet, Marcus Järås, Rishi Puram, Vlado Dancik, Fatima Al-Shahrour, Thomas Kindler, Zuzana Tothova, Shrikanta Chattopadhyay, Thomas Hasaka, Rajiv Narayan, Mingji Dai, Christina Huang, Sebastian Shterental, Lisa P Chu, J Erika Haydu, Jae Hung Shieh, David P Steensma, Benito Munoz, Joshua A Bittker, Alykhan F Shamji, Paul A Clemons, Nicola J Tolliday, Anne E Carpenter, D Gary Gilliland, Andrew M Stern, Malcolm A S Moore, David T Scadden, Stuart L Schreiber, Benjamin L Ebert, Todd R Golub. (2013) Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nature Chemical Biology 9:12, 840-848.
            • M Rieken, L A Kluth, E Xylinas, C Seitz, H Fajkovic, P I Karakiewicz, Y Lotan, A Briganti, W Loidl, T Faison, J J Crivelli, D S Scherr, A Bachmann, A K Tewari, A Kautzky-Willer, K Pummer, S F Shariat. (2013) Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. Prostate Cancer and Prostatic Diseases 16:4, 367-371.
            • Herman van Besien, Antonella Sassano, Jessica K. Altman, Leonidas C. Platanias. (2013) Antileukemic properties of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Leukemia & Lymphoma 54:12, 2601-2605.
            • E. R. Nelson, S. E. Wardell, J. S. Jasper, S. Park, S. Suchindran, M. K. Howe, N. J. Carver, R. V. Pillai, P. M. Sullivan, V. Sondhi, M. Umetani, J. Geradts, D. P. McDonnell. (2013) 27-Hydroxycholesterol Links Hypercholesterolemia and Breast Cancer Pathophysiology. Science 342:6162, 1094-1098.
            • Sophie Clément, Marion Peyrou, Michelangelo Foti, Francesco Negro. (2013) Statins May Protect Against Hepatocellular Carcinoma Development in Patients Infected With Hepatitis C Virus, but What Are the Mechanisms?. Journal of Clinical Oncology 31:32, 4160-4161.
            • Belal AL-Husein, Anna Goc, Payaningal R. Somanath. (2013) Suppression of interactions between prostate tumor cell-surface integrin and endothelial ICAM-1 by simvastatin inhibits micrometastasis. Journal of Cellular Physiology 228:11, 2139-2148.
            • Naomi Gronich, Gad Rennert. (2013) Beyond aspirin—cancer prevention with statins, metformin and bisphosphonates. Nature Reviews Clinical Oncology 10:11, 625-642.
            • Lorenzo Galluzzi, Oliver Kepp, Matthew G. Vander Heiden, Guido Kroemer. (2013) Metabolic targets for cancer therapy. Nature Reviews Drug Discovery 12:11, 829-846.
            • Adam G. Mace, Gerald A. Gantt, Marek Skacel, Rish Pai, Jeff P. Hammel, Matthew F. Kalady. (2013) Statin Therapy Is Associated With Improved Pathologic Response to Neoadjuvant Chemoradiation in Rectal Cancer. Diseases of the Colon & Rectum 56:11, 1217-1227.
            • Elena N. Atochina-Vasserman, Dmitry A. Goncharov, Alla V. Volgina, Megan Milavec, Melane L. James, Vera P. Krymskaya. (2013) Statins in Lymphangioleiomyomatosis. Simvastatin and Atorvastatin Induce Differential Effects on tuberous sclerosis complex 2 –Null Cell Growth and Signaling. American Journal of Respiratory Cell and Molecular Biology 49:5, 704-709.
            • Purvesh Khatri, Silke Roedder, Naoyuki Kimura, Katrien De Vusser, Alexander A. Morgan, Yongquan Gong, Michael P. Fischbein, Robert C. Robbins, Maarten Naesens, Atul J. Butte, Minnie M. Sarwal. (2013) A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation. Journal of Experimental Medicine 210:11, 2205-2221.
            • Xiao-Dan Wu, Kai Zeng, Fang-Qin Xue, Jin-Hua Chen, Yan-Qing Chen. (2013) Statins are associated with reduced risk of gastric cancer: A meta-analysis. European Journal of Clinical Pharmacology 69:10, 1855-1860.
            • K. Vermaelen, G. Brusselle. (2013) Exposing a deadly alliance: Novel insights into the biological links between COPD and lung cancer. Pulmonary Pharmacology & Therapeutics 26:5, 544-554.
            • Derek J. Erstad, James C. Cusack. (2013) Targeting the NF-κB Pathway in Cancer Therapy. Surgical Oncology Clinics of North America 22:4, 705-746.
            • Lingzhi Wang, Yanni Fu, Jianxin Peng, Dengpan Wu, Meiling Yu, Chengfang Xu, Qin Wang, Liang Tao. (2013) Simvastatin-induced up-regulation of gap junctions composed of connexin 43 sensitize Leydig tumor cells to etoposide: An involvement of PKC pathway. Toxicology 312, 149-157.
            • Emily J. Gallagher, Derek LeRoith. (2013) Diabetes, antihyperglycemic medications and cancer risk. Current Opinion in Endocrinology & Diabetes and Obesity 20:5, 485-494.
            • Robert P Young, Raewyn J Hopkins. (2013) Update on the potential role of statins in chronic obstructive pulmonary disease and its co-morbidities. Expert Review of Respiratory Medicine 7:5, 533-544.
            • Stefan Nickels, Alina Vrieling, Petra Seibold, Judith Heinz, Nadia Obi, Dieter Flesch-Janys, Jenny Chang-Claude, Tone Frost Bathen. (2013) Mortality and Recurrence Risk in Relation to the Use of Lipid-Lowering Drugs in a Prospective Breast Cancer Patient Cohort. PLoS ONE 8:9, e75088.
            • Cesar A. Santa-Maria, Vered Stearns. (2013) Statins and Breast Cancer: Future Directions in Chemoprevention. Current Breast Cancer Reports 5:3, 161-169.
            • David Margel, David R. Urbach, Lorraine L. Lipscombe, Chaim M. Bell, Girish Kulkarni, Peter C. Austin, Neil Fleshner. (2013) Metformin Use and All-Cause and Prostate Cancer–Specific Mortality Among Men With Diabetes. Journal of Clinical Oncology 31:25, 3069-3075.
            • Fredrick Onono, Thangaiah Subramanian, Manjula Sunkara, Karunai Leela Subramanian, H. Peter Spielmann, Andrew J. Morris. (2013) Efficient Use of Exogenous Isoprenols for Protein Isoprenylation by MDA-MB-231 Cells Is Regulated Independently of the Mevalonate Pathway. Journal of Biological Chemistry 288:38, 27444-27455.
            • Milan S. Geybels, Jonathan L. Wright, Sarah K. Holt, Suzanne Kolb, Ziding Feng, Janet L. Stanford. (2013) Statin Use in Relation to Prostate Cancer Outcomes in a Population-based Patient Cohort Study. The Prostate 73:11, 1214-1222.
            • Željko Reiner. (2013) Statins in the primary prevention of cardiovascular disease. Nature Reviews Cardiology 10:8, 453-464.
            • Jessica J. Howell, Stéphane J.H. Ricoult, Issam Ben-Sahra, Brendan D. Manning. (2013) A growing role for mTOR in promoting anabolic metabolism. Biochemical Society Transactions 41:4, 906-912.
            • Patrizia Gazzerro, Elena Ciaglia, Maurizio Bifulco. (2013) Statins and Cancer-Related Mortality: An Open Question. Basic & Clinical Pharmacology & Toxicology 113:2, 73-74.
            • Abby B Siegel, Hashem B El-Serag. (2013) Statins for chemoprevention of hepatocellular carcinoma: assessing the evidence. Expert Review of Gastroenterology & Hepatology 7:6, 493-495.
            • C. Tsigos, R. Bitzur, Y. Kleinman, H. Cohen, A. Cahn, G. Brambilla, G. Mancia, G. Grassi. (2013) Targets for Body Fat, Blood Pressure, Lipids, and Glucose-Lowering Interventions in Healthy Older People. Diabetes Care 36:Supplement_2, S292-S300.
            • Martin Werner, Bihter Atil, Evelyn Sieczkowski, Peter Chiba, Martin Hohenegger. (2013) Simvastatin-induced compartmentalisation of doxorubicin sharpens up nuclear topoisomerase II inhibition in human rhabdomyosarcoma cells. Naunyn-Schmiedeberg’s Archives of Pharmacology 386:7, 605-617.
            • T M Brewer, H Masuda, D D Liu, Y Shen, P Liu, T Iwamoto, K Kai, C M Barnett, W A Woodward, J M Reuben, P Yang, G N Hortobagyi, N T Ueno. (2013) Statin use in primary inflammatory breast cancer: a cohort study. British Journal of Cancer 109:2, 318-324.
            • Noora Sjösten, Hermann Nabi, Hugo Westerlund, Paula Salo, Tuula Oksanen, Jaana Pentti, Marianna Virtanen, Mika Kivimäki, Jussi Vahtera. (2013) Effect of depression onset on adherence to medication among hypertensive patients. Journal of Hypertension 31:7, 1477-1484.
            • Joseph J. Crivelli, Evanguelos Xylinas, Luis A. Kluth, Rodrigo Donalisio da Silva, James Chrystal, Giacomo Novara, Pierre I. Karakiewicz, Scott G. David, Douglas S. Scherr, Yair Lotan, Shahrokh F. Shariat. (2013) Effect of statin use on outcomes of non-muscle-invasive bladder cancer. BJU International 112:2, E4-E12.
            • Robert P. Young, Raewyn J. Hopkins. (2013) Statins Reduce Lung Inflammation by Promoting the Clearance of Particulate Matter From Lung Tissues. Chest 144:1, 358-359.
            • P.P. Singh, S. Singh. (2013) Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Annals of Oncology 24:7, 1721-1730.
            • Evanguelos Xylinas, Luis A. Kluth, Joseph J. Crivelli, Malte Rieken, Vitaly Margulis, Christian Seitz, Shahrokh F. Shariat. (2013) Impact of Statin Use on Oncologic Outcomes of Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. European Urology 63:6, 1134-1135.
            • Patrizia Gazzerro, Maurizio Bifulco. (2013) Statins and Cancer in Gastroenterology: New Insight?. Gastroenterology 144:7, 1572-1573.
            • Fotis Barkas, Manfredi Rizzo, James J DiNicolantonio, Evangelos Liberopoulos. (2013) Beyond cholesterol reduction, the pleiotropic effects of statins: is their use in cancer prevention hype or hope?. Clinical Lipidology 8:3, 273-277.
            • H.S. Park, J.D. Schoenfeld, R.B. Mailhot, M. Shive, R.I. Hartman, R. Ogembo, L.A. Mucci. (2013) Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Annals of Oncology 24:6, 1427-1434.
            • Martin Huth Ruwald, Anne-Christine Ruwald, Christian Jons, Morten Lamberts, Morten Lock Hansen, Michael Vinther, Lars Køber, Christian Torp-Pedersen, Jim Hansen, Gunnar Hilmar Gislason. (2013) Evaluation of the CHADS 2 Risk Score on Short- and Long-Term All-Cause and Cardiovascular Mortality After Syncope. Clinical Cardiology 36:5, 262-268.
            • Geoffrey C. Farrell, Vincent Wai-Sun Wong, Shiv Chitturi. (2013) NAFLD in Asia—as common and important as in the West. Nature Reviews Gastroenterology & Hepatology 10:5, 307-318.
            • Wales WN Chan, Gordon TC Wong, Michael G Irwin. (2013) Perioperative statin therapy. Expert Opinion on Pharmacotherapy 14:7, 831-842.
            • Yu-Tse Tsan, Chang-Hsing Lee, Wen-Chao Ho, Meng-Hung Lin, Jung-Der Wang, Pau-Chung Chen. (2013) Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection. Journal of Clinical Oncology 31:12, 1514-1521.
            • Abby B. Siegel. (2013) An Ounce of Prevention Is Better Than a Pound of Cure: A Patient-Centered Approach to Hepatocellular Carcinoma. Journal of Clinical Oncology 31:12, 1499-1501.
            • Olöf Bjarnadottir, Quinci Romero, Pär-Ola Bendahl, Karin Jirström, Lisa Rydén, Niklas Loman, Mathias Uhlén, Henrik Johannesson, Carsten Rose, Dorthe Grabau, Signe Borgquist. (2013) Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Research and Treatment 138:2, 499-508.
            • Joshua Liao, John A. Farmer. (2013) Aggressive Statin Therapy and the Risk of Malignancy. Current Atherosclerosis Reports 15:4.
            • James Robert Krycer, Andrew John Brown. (2013) Cholesterol accumulation in prostate cancer: A classic observation from a modern perspective. Biochimica et Biophysica Acta (BBA) – Reviews on Cancer 1835:2, 219-229.
            • Rafael Tabarés-Seisdedos, John L. Rubenstein. (2013) Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders. Nature Reviews Neuroscience 14:4, 293-304.
            • John C. LaRosa, Terje R. Pedersen, Ransi Somaratne, Scott M. Wasserman. (2013) Safety and Effect of Very Low Levels of Low-Density Lipoprotein Cholesterol on Cardiovascular Events. The American Journal of Cardiology 111:8, 1221-1229.
            • Koji Matsuo, Annie A. Yessaian, Yvonne G. Lin, Huyen Q. Pham, Laila I. Muderspach, Howard A. Liebman, C. Paul Morrow, Lynda D. Roman. (2013) Predictive model of venous thromboembolism in endometrial cancer. Gynecologic Oncology 128:3, 544-551.
            • (2013) Statin Use and Reduced Cancer-Related Mortality. N Engl J Med 368:6, 574-577.
              • Georg Marcus Fröhlich, Frank Enseleit, Mathias Wolfrum, Michelle von Babo, Michelle Frank, Reto Berli, Mathias Hermann, Johannes Holzmeister, Georg Noll, Thomas F. Lüscher, Frank Ruschitzka, Kaspar Rufibach, Markus Wilhelm, Volkmar Falk. (2013) Response to Letters Regarding Article, “Statins and the Risk of Cancer After Heart Transplantation”. Circulation 127:5.
              • Stephanie K. Doerner, Nathan A. Berger. 2013. Dietary Fats as Mediators of Obesity, Inflammation, and Colon Cancer. Obesity, Inflammation and Cancer, 99-132.
              • David A. Forero-Peña, Fredy R. S. Gutierrez. (2013) Statins as Modulators of Regulatory T-Cell Biology. Mediators of Inflammation 2013, 1-10.
              • Robert P Young, Raewyn J Hopkins. (2013) Interleukin-6 and statin therapy: potential role in the management of COPD. Respiratory Research 14:1, 74.
              • Sonia C Dolfi, Leo Li-Ying Chan, Jean Qiu, Philip M Tedeschi, Joseph R Bertino, Kim M Hirshfield, Zoltán N Oltvai, Alexei Vazquez. (2013) The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer & Metabolism 1:1, 20.
              • Emily J. Gallagher, Derek LeRoith. (2013) Diabetes, Antihyperglycemic Medications and Cancer Risk: Smoke or Fire?. Endocrine Practice 1:-1, 1-28.
              • Siddharth Singh. (2013) Statin a day keeps cancer at bay. World Journal of Clinical Oncology 4:2, 43.
              • Caporaso Neil E.. (2012) Statins and Cancer-Related Mortality — Let’s Work Together. N Engl J Med 367:19, 1848-1850.
                • Robert Bublak. (2012) Senken Statine die Krebssterblichkeit?. Info Onkologie 15:7, 48-48.
                • RB. (2012) Senken Statine die Krebssterblichkeit?. MMW – Fortschritte der Medizin 154:21, 7-7.
                • Juan P. de-Torres, Javier J. Zulueta. The association with COPD. Lung Cancer, 38-49.

                Un gând despre „Consumul de statine și reducerea mortalității legate de cancer

                1. Nielsen și colegii (ediția din 8 noiembrie) 1 raportează că utilizarea statinelor la pacienții danezi cu cancer corelată cu mortalitatea redusă legată de cancer într-un studiu observațional. Cu toate acestea, o meta-analiză recentă a 22 de studii randomizate, controlate bine efectuate, cu date de la 66.582 de pacienți care au primit statine și 66.604 care au primit placebo, a arătat că 5 ani de terapie cu statine nu au avut niciun efect asupra riscului de deces legat de cancer (risc relativ , 1,00; interval de încredere 95%, 0,93-0,08) .2 Studiile observaționale arată efectele benefice ale statinelor asupra diferitelor rezultate asupra sănătății, surprinzător de des, în timp ce studiile randomizate și controlate nu. Astfel de discrepanțe între studiile observaționale și studiile randomizate, controlate, au fost observate și pentru studiile privind fracturile3 și pneumonia.4. Un sondaj efectuat în rândul medicilor generaliști britanici a arătat că aceștia sub-prescriu în mod selectiv statine fumătorilor, din cauza stilului lor de viață nesănătos.5 Fumatul este un factor de risc puternic pentru fracturi, pneumonie și deces cauzat de cancer. Acest lucru ar fi putut duce la o asociere inversă între utilizarea statinelor și riscul de deces legat de cancer în studiul observațional realizat de Nielsen și colegii săi. Lipsa unui efect doză-răspuns în studiul lor susține în continuare această ipoteză.

                  Corinne Klop, Pharm.D.
                  Institutul de Științe Farmaceutice din Utrecht, Utrecht, Olanda

                  Johanna H.M. Driessen, M.Sc.
                  Școala CAPHRI pentru sănătate publică și asistență primară, Maastricht, Olanda

                  Frank de Vries, Ph.D., Pharm.D.
                  Institutul de Științe Farmaceutice din Utrecht, Utrecht, Olanda
                  f.devries@uu.nl

                Exprimati-va pararea!

                Completează mai jos detaliile tale sau dă clic pe un icon pentru a te autentifica:

                Logo WordPress.com

                Comentezi folosind contul tău WordPress.com. Dezautentificare /  Schimbă )

                Fotografie Google

                Comentezi folosind contul tău Google. Dezautentificare /  Schimbă )

                Poză Twitter

                Comentezi folosind contul tău Twitter. Dezautentificare /  Schimbă )

                Fotografie Facebook

                Comentezi folosind contul tău Facebook. Dezautentificare /  Schimbă )

                Conectare la %s

                Acest site folosește Akismet pentru a reduce spamul. Află cum sunt procesate datele comentariilor tale.